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Biosynthesis of Fatty Acid Amides 
 
Emma K. Farrell 
ABSTRACT 
 
Primary fatty acid amides (PFAMs) and N-acylglycines (NAGs) are important 
signaling molecules in the mammalian nervous system, binding to many drug receptors 
and demonstrating control over sleep, locomotor activity, angiogenesis, vasodilatation, 
gap junction communication, and many other processes. Oleamide is the best-studied of 
the PFAMs, while the in vivo activity of the others is largely unstudied. Even less is 
known about the NAGs, as their discovery as novel compounds is much more recent due 
to low endogenous levels. Herein is described extraction and quantification techniques 
for PFAMs and NAGs in cultured cells and media using solvent extraction combined 
with solid phase extraction (PFAM) or thin layer chromatography (NAG), followed by 
gas chromatography-mass spectroscopy to isolate and quantify these lipid metabolites. 
The assays were used to examine the endogenous amounts of a panel of PFAMs as well 
as the conversion of corresponding free fatty acids (FFAs) to PFAMs over time in several 
cell lines. The cell lines demonstrated the ability to convert all FFAs, including a non-
natural FFA, and an ethanolamine to the corresponding PFAM. Different patterns of 
relative amounts of endogenous and FFA-derived PFAMs were observed in the cell lines 
tested. 
Essential to identifying therapeutic targets for the many disorders associated with 
PFAM signaling is understanding the mechanism(s) of PFAM and NAG biosynthesis. 
Enzyme expression studies were conducted to determine potential metabolic enzymes in 
the model cell lines in an attempt to understand the mechanism(s) of PFAM biosynthesis. 
It was found that two of the cell lines which show distinct metabolisms of PFAMs also 
demonstrate unique enzyme expression patterns, and candidate enzymes proposed to 
xxi 
 
 
perform PFAM and NAG metabolism are described. RNAi knockdown studies revealed 
further information about the metabolism of PFAMs and calls into question the recently 
proposed involvement of cytochrome c. Isotopic labeling studies showed there are two 
pathways for PFAM formation. A novel enzyme is likely to be involved in formation of 
NAGs from acyl-CoA intermediates.  
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1 Literature Review: Fatty Acid Amides – Biosynthesis, 
Degradation, and Pharmacological Significance 
 
 
The identification of two 
biologically active fatty acid amides, 
N-arachidonoylethanolamine 
(anandamide) and oleamide, has 
generated a great deal of excitement 
and stimulated considerable research. 
However, anandamide and oleamide 
are merely the best-known and best-
understood members of a much larger 
family of biologically-occurring fatty 
acid amides. In this review, the fatty 
acid amides that have been isolated 
from mammalian sources will be 
outlined, what is known about how 
these molecules are made and 
degraded in vivo will be discussed, 
and their potential for the development of novel therapeutics will be highlighted. Relative 
to NAEs, much less is currently known about the NAAs, the NADAs and the PFAMs, 
except that they are found in biological systems (see refs. 
6,61,62
 for earlier reviews). 
 The fatty acid amide bond has long been recognized in nature, being important in 
the structure of the ceramides
65
 and the sphingolipids.
71
 The first non-sphingosine based 
fatty acid amide isolated from a natural source was N-palmitoylethanolamine from egg 
yolk in 1957.
90
 Interest in the N-acylethanolamines (NAEs) dramatically increased upon 
Table 1-1: The Structures of the Fatty Acid Amides 
Fatty Acid 
Amide 
Structure 
NAE 
N
H
R1
O
OH
 
NADA 
R1
O
N
H
OH
OH
 
NAA
a 
R1
O
N
H
COOH
R2
 
PFAM 
R1
O
NH2  
aR2 represents the functional groups that define 
the different amino acids. R1 represents various 
acyl chains (see Table 2). 
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the identification of N-arachidonoylethanolamine (anandamide) as an endogenous ligand 
for the cannabinoid receptors in the mammalian brain.
94
 It is now known that a family of 
NAEs is found in the brain and in other tissues.
8,95
 In addition to the NAEs, other classes 
of fatty acid amides have been characterized, including the N-acylamino acids (NAAs),
96
 
the N-acyldopamines (NADAs)
103
 and the primary fatty acid amides (PFAMs).
104,105
 
Table 1-1 shows the structure of the amides, and Table 1-2 shows some of the commonly 
found acyl groups.  
 
a 
 
Table 1-2: Acyl Chains Found on the Fatty Acid Amides 
Name Carbon 
skeleton 
Structure of R1 
Arachidonic 20:4(5,8,11,14) 
 
Erucic 22:1(13) 
 
Palmitoleic 16:1(9) 
 
Linoleic 18:2(9,12) 
 
Linolenic 18:3(9,12,15) 
 
Oleic 18:1(9) 
 
Elaidic
a 
18:1(trans-9) 
 
Palmitic 16:0 
 
Stearic 18:0 
 
The arrow points to carbon-2 in the fatty acid chain. R1 is the acyl group  
from Table 1-1. 
a
This acyl chain originates from a dietary source. 
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1.1 N-Acylethanolamines  
 
A series of long-chain NAEs have been identified in the mammalian brain, the 
most abundant being N-palmitoyl-, N-stearoyl- and N-oleoylethanolamine,
61,95
 each 
compromising ≥25% of total brain NAEs. Other less abundant NAEs found in the brain 
are anandamide, N-linoleoyl-, N-linolenoyl-, N-dihomo-γ-linolenoyl- and N-
docosatetraenoylethanolamine.
61
  In addition to the brain, the NAEs are widespread in the 
peripheral tissues.
95,109
  
Aanandamide is the best-understood NAE. The function of anandamide in 
mammals is mediated largely by its binding to the CB1 receptors (Kd = ~80 nM).
4,110
 
Anandamide is also known to bind to CB2 receptors (Kd = ~500 nM),
4
 peroxisome 
proliferator-activated receptors (PPARα, Kd=20 µM and PPARγ, Kd=10 µM),
5
 to the 
transient receptor potential (TRP) vanilloid type 1 (TRPV1) channels (Kd ~ 2 µM),
6
 and 
the transient receptor potential channels of melastatin type 8 (TRPM8) (Kd ~ 1 µM).
7
 It is 
unclear how much the binding of anandamide to the non-CB1 receptors contributes to its 
total activity in vivo. 
Anandamide is involved in the regulation of body temperature, locomotion, 
feeding and the perception of pain, anxiety and fear.
29,30,122-124
 The functions of the other 
known mammalian NAEs are not as well-established as anandamide, even though 
ananadamide represents only 1-10% of brain NAEs.
61,95
 With the exception of N-dihomo-
γ-linolenoyl-, and N-docosatetraenoylethanolamine, the other NAEs do not bind to the 
CB1 and CB2 receptors.
6,125,126
 N-Oleoylethanolamine binds to PPARα and PPARβ, 
functioning to inhibit feeding behavior,
5,126
 as well as the TRPV1 receptor,
8
 and the G-
protein-coupled receptor, GPR119.
46
 Stearoylethanolamine binds to specific, non-CB1 
and CB2 receptors and yet exhibits activities similar to anandamide.
127
 N-
Palmitoylethanolamine is neuroprotective and also modulates pain and inflammation.
128
 
The anti-inflammatory effect of N-palmitoylethanolamine is mediated by its binding to 
PPARα.128 Ryberg et al. 54 recently found that N-palmitoylethanolamine is a ligand for 
the orphan GPR55 receptor.  It has been suggested that at least some of the activities of 
N-palmitoylethanolamine, N-oleoylethanolamine and N-stearoylethanolamine result from 
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the “entourage effect”: cellular levels of anandamide are stabilized or increased because 
the other NAEs compete with anandamide for enzymatic degradation.
125
 
The most widely-accepted biosynthetic pathway for NAEs involves the cleavage 
of N-acylphosphatidylethanolamine (NAPE) to the corresponding NAE and phosphatidic 
acid (PA) by NAPE-specific phospholipase D (NAPE-PLD) (reaction 1 in Figure 
1-1).
130,131
 NAPE is produced by the N-acylation of phosphatidylethanolamine in a 
reaction catalyzed by a calcium-activated transacylase (Figure 1-2).
130
 Recent evidence 
suggests that there are other PLD-independent pathways for NAE biosynthesis.
10,67
 One 
alternative pathway involves the phospholipase C-mediated cleavage of NAPE to yield a 
phospho-NAE (pNAE) which is then cleaved by a phosphatase to yield the NAE and 
inorganic phosphate (reactions 6 and 7 in Figure 1-1).  Another alternative pathway 
involves sequential hydrolysis of the O-acyl chains of NAPE to produce free fatty acids 
and glycerophospho-NAE (GP-NAE) (reactions 2 and 4 in Figure 1-1).  Simon and 
Cravatt
10
 have found that a serine hydrolase, α/β-hydrolase 4 (Abh4), can catalyze both 
O-deacylation steps required to convert NAPE to GP-NAE.  Phosphodiesterase cleavage 
of GP-NAE will yield the NAE and glycerol 3-phosphate (reaction 5 in Figure 1-1). 
Other possible routes to the NAEs are direct hydrolysis of lysoNAPE (reaction 3 in 
Figure 1-1) or the 2-step conversion of GP-NAE to the NAE via phospho-NAE (reactions 
8 and 7 in Figure 1-1). The PLD-independent pathways for NAE biosynthesis are 
exciting discoveries, suggesting that the body has redundant “back-up” methods to 
produce these important bioactive lipid amides that are made “on demand.”62,67 Future 
work will determine how these three pathways function to supply the required NAE 
levels. 
For completeness, one last NAE synthetic strategy must be mentioned. There is 
data going back more than 40 years, showing that the NAEs can be produced in vitro 
from ethanolamine and free fatty acids (FFAs) in brain microsomes to form NAPEs, in a 
reaction that did not require ATP or CoA-SH.
132
 The authors hypothesize that the FFAs 
are taken into proteins and then exchanged to acceptor molecules (ethanolamines or 
phosphatidylethanolamines, in this case). However, in vivo significance of this chemistry 
is unclear.   
5 
 
 
 
 
 
 Figure 1-1: Biosynthetic Pathways for N-Acylethanolamines  
The enzymes catalyzing the individual reactions are in the shaded boxes and the numbers that 
refer to reactions in the text are in bold blue. The reader is referred to Simon and Cravatt10 
and Liu et al.67 for greater details on NAE biosynthesis. Abdh4, α,β-hydrolase 4; G3P, 
glyercol 3-phosphate; GP-NAE, glycerophospho-NAE; LPA, lysophosphatic acid; 
LysoNAPE, lyso N-acylphosphatidylethanolamine; LysoPLC/D, lysophospholipase C/D; 
NAE, N-acylethanolamine; NAPE, N-acylphosphatidylethanolamine; NAPE-PLD, NAPE-
specific phospholipase D; PA, phosphatidic acid; PDEase, phosphodiesterase; Pi, phosphate; 
PLA2, phopholipase A2; PLC, phopholipase C; pNAE, phospho-NAE; PTase, phosphatase 
(most probably tyrosine phosphatase, PTPN22 or inositol-5′-phosphatase, SHIP1, in vivo). 
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NAE degradation is by hydrolysis to fatty acid and ethanolamine (see Equation 
1-1). Three enzymes are known to catalyze this reaction: two fatty acid amide hydrolases 
(FAAH-1 and FAAH-2)
133
 and N-acylethanolamine-hydrolyzing acid amidase 
(NAAA).
134
 FAAH-1 and FAAH-2 both hydrolyze NAEs, but have different acyl group 
specificities (see Chapter 4 for more information). Note that FAAH inhibitors have been 
targeted as potential analgesics.
135-137
 
 
Figure 1-2: Biosynthesis of N-Acylphosphatidylethanolamine 
Biosynthesis of N-acylphosphatidylethanolamine (NAPE). See text for more details. 
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1.2 N-Acyldopamines  
 
 A relatively small number of long-chain N-fatty acyldopamines (NADAs) have 
been isolated and characterized from mammalian systems, including N-palmitoyl-, N-
stearoyl-, N-oleoyl- and N-arachidonoyldopamine.
1,63
 All of these NADAs are found in 
the mammalian brain, with the highest concentrations in the striatum, hippocampus and 
cerebellum.
1
  
 N-Arachidonoyldopamine and N-oleoyldopamine were first identified as 
capsaicin-like endovanilloids that bound tightly to the TRPV1 receptor.
1,6,63
 As a 
consequence of their binding to the TRPV1 receptors, both of these N-fatty 
acyldopamines stimulated calcium influx in HEK-293 cells over-expressing either rat or 
human TRPV1 and produced hyperalgesia in rats.
1,63
 N-Arachidonoyldopamine also 
binds tightly to the CB1 receptor (Kd = 250-500 nM)
63,138
 and a non-CB1/CB2 G-protein 
receptor (GPR) in the aorta.
64
 Other endogenous N-fatty acyldopamines include N-
palmitoyldopamine and N-stearoyldopamine, both of which bind with to the TRPV1 or 
CB1 receptors with relatively low affinity (Kd values >5 µM).
63
 The biological role(s) 
fulfilled by N-palmitoyldopamine and N-stearoyldopamine are unclear, but there is 
evidence that both enhance the activity of N-arachidonoyldopamine via the entourage 
effect.
139
  
 In addition to the long-chain N-fatty acyldopamines, N-acetyldopamine is a 
known metabolite in mammals. The function of N-acetyldopamine is unclear, but it has 
been shown to inhibit mammalian sepiapterin reductase (an enzyme in the 
tetrahydrobiopterin biosynthetic pathway) with a Ki = 400 nM.
140
 
 There has been little work on the pathways for the biosynthesis and degradation 
of the N-acyldopamines. N-Acetyldopamine is produced by the acetyl-CoA-dependent N-
acetylation of dopamine
141
 and has been found in the urine, kidney and liver.
141,142
 It has 
 
Equation 1-1: Hydrolysis of an N-Acylethanolamine 
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been proposed that the long-chain N-acyldopamines are made in vivo in a similar fashion, 
with the acyl donors being the corresponding acyl-CoA thioesters.
1
 Alternatively, the N-
acyldopamines could be produced by the tyrosine hydroxylase-mediated oxidation of N-
acyltyrosines, metabolites that were identified in mammals just this year (see Table 1-4).  
Huang et al.
1
 provide data in support of both biosynthetic pathways, as inhibition of 
tyrosine β-hydroxylase reduced formation of a NADA-like compound from tyrosine. 
Skimob et al. also show the increased formation of N-arachidonoyldopamine during the 
incubation of arachidonic acid and tyrosine as compared to the incubation of arachidonic 
acid and dopamine.
143
 Evidence suggests a decarboxylation preceding oxidation (Figure 
1-3). 
 
 
 
 Degradation of the NADAs is thought to occur by FAAH-catalyzed hydrolysis to 
the fatty acid and dopamine
1
 or O-methylation by catechol-O-methyltransferase 
(COMT).
1
 N-Acetyldopamine can serve as a substrate for tyrosinase; thus, the long-chain 
N-acyldopamines could also be oxidized to a quinone by this enzyme.
32
 N-
Acetylnoradrenaline is a known human metabolite
66
 suggesting that N-acetyldopamine 
and the longer-chain N-acyldopamines could serve as substrates for dopamine β-
monooxygenase (DBM) (Table 1-3). 
 
 
 Figure 1-3: Biosynthesis of N-Acyldopamine 
Proposed biosynthesis of NADAs. Enzyme 1 is unknown. Enzyme 2 is tyrosine hydroxylase 
(a.k.a. monophenol monooxygenase). 
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1.3 N-Acylamino acids  
 
 Mammalian N-acylamino acids have a long history, tracing their discovery to the 
conjugation of glycine to benzoate to form N-benzoylglycine (hippurate) in the 1840s 
(see Caldwell et al.
96
 and reference cited therein). N
α
-Acetyl conjugates for all 20 of the 
common amino acids have been identified in mammals.  In addition, the N
α
-acetyl 
conjugates of other amino acids, including β-alanine, allo-isoleucine, α-aminobutyric 
acid, GABA, 2-aminooctanoic acid, citrulline and Nε-acetyllysine have also been 
characterized from mammalian sources.
3,92,93,98,129,144-153
 With the exception of N-
acetylglutamate, which serves as an allosteric activator of carbamoyl phosphate 
synthetase I,
68
 the N-acetylamino acid conjugates are trace metabolites that function in 
the excretion/detoxification of abnormally high levels of a particular amino acid. 
Similarly, a set of N-isovaleroylamino acids have been identified from patients suffering 
from isovaleric acidemia, with N-isovaleroylglycine being the most abundant 
metabolite.
93,100,152,154,155
 The function of these N-isovaleroylamino acids is also in 
excretion; one patient suffering from isovaleric academia was excreting 1.7 grams of N-
isovaleroylglycine per day.
156
   
 Glycination is essential in the synthesis of bile acids
157,158
 and metabolism of short 
chain fatty acids
159
 and small molecule xenobiotics.
107,160
 N-Conjugation of fatty acids to 
amino acids forming the long-chain N-fatty acylglycines is known, but is relatively 
uncommon in mammals, and a comprehensive listing of the known long-chain NAGs 
isolated from mammalian sources can be found in Chapter 4. The most common 
Table 1-3: Degradation of N-Acyldopamines 
Enzyme Reaction Ref 
FAAH NADA + H2O  FFA + dopamine 
1
 
COMT NADA + S-adenosyl-L-methionine   
S-adenosyl-L-homocysteine  + N-acyl-3-methoxytyramine 
1
 
tyrosinase NADA + ½ O2  H2O + N-acyldopamine quinone 
32
 
DBM NADA + ascorbate + O2   
dehydroascorbate + H2O + N-acylnoradrenaline 
66
 
Abbreviations: COMT, catechol-O-methyltransferase; DBM, dopamine β-monooxygenase; 
FAAH, fatty acid amide hydrolase; FFA, free fatty acid; NADA, N-acyldopamine 
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mammalian N-fatty acylamino acids are conjugates of glycine, glutamine and taurine 
(Table 1-4). Many of the N-acylamino acids were discovered in the last 1-3 years, thanks 
to improvements in separation techniques and more sensitive mass spectrometry 
equipment. (See Chapter 2 for a discussion of these innovations and more details on 
metabolite analysis.) 
Like the shorter chain N-acetyl and N-isovaleroyl amino acids, the major function 
of these longer chain amino acid conjugates appears to be in the detoxification and 
excretion of xenobiotic carboxylates.
96
 Glycine conjugation is particularly important in 
detoxification and elimination, as a careful analysis of the metabolism of most xenobiotic 
carboxylates reveals at least a trace of the corresponding N-acylglycine conjugate.
161
  In 
fact, the list of N-acylglycines shown in Table 1-4 is incomplete as glycine conjugates of 
many other carboxylates also have been reported.
159,161
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Table 1-4: Mammalian N-Fatty Acylamino Acids
a 
Amino Acid
b
 N-Acyl Group Refs 
Alanine Arachidonoyl, Oleoyl, Palmitoyl, Stearoyl 2,3 
γ-Aminobutyric 
acid 
Arachidonoyl, Docosahexaenoyl, Oleoyl, Palmitoyl, 
Stearoyl 
2,3 
Arginine Stearoyl 3 
Asparagine Oleoyl 3 
Glutamic Acid Arachidonoyl, Docosahexaenoyl, Oleoyl, Palmitoyl, 
Stearoyl, β-Citryl, Phenylacetyl  
3,91-93
 
Glutamine Arachidonoyl, Docosahexaenoyl, Oleoyl, Palmitoyl, 
Phenylacetyl and other arylacetyls, 4-Phenylbutyryl, 
Stearoyl 
3,91,93
 
Glycine
c
 Arachidonoyl, Benzoyl, Butyryl, Bile acids, Decanoyl, 
Hexanoyl, Isobutyryl, 2-Methylbutyryl, 3-
Methylcrotonyl, Octanoyl, Phenylacetyl and other 
arylacetyls, Palmitoyl, Propionyl, Suberyl, Tiglyl 
2,74,93,96-
101
 
Histidine Arachidonoyl, Docosahexaenoyl, Oleoyl, Palmitoyl 3 
(Iso)leucine Arachidonoyl, Lactyl, Oleoyl, Palmitoyl 
3,106
 
Leucine Lactyl 
106
 
Methionine Oleoyl, Palmitoyl, Stearoyl 3 
Phenylalanine Docosahexaenoyl, Oleoyl, Palmitoyl, Stearoyl, 
Succinoyl 
3,112
 
Proline Oleoyl, Palmitoyl, Stearoyl 3 
Pyroglutamic acid Phenylacetyl 
98
 
Serine Arachidonoyl, Palmitoyl, Stearoyl 
3,120
 
Taurine Bile acids, Phenylacetyl and other arylacetyls, long 
chain, saturaturated acyl groups from C16:0-C26:0,
d
 
long-chain, monounsaturated acyl groups from C18:1-
C24:1,
d
 Linoleoyl  
3,96,99,121
 
Threonine Oleoyl, Palmitoyl 3 
Tryptophan Oleoyl, Palmitoyl, Stearoyl 3 
Tyrosine Oleoyl, Palmitoyl, Stearoyl 3 
Valine Lactyl, Linoleoyl, Palmitoyl, Stearoyl 
106
 
aN-Acetyl and N-isovaleroylamino acids were not included in this table. 
bAmino acids not commonly found in proteins are italicized. 
cIncluded here most of the more common N-acylglycine conjugates known.  Many others have 
been identified as metabolites in various organic acid acidemias or in the detoxification of a 
xenobiotic carboxylate. 
dIncluded in the family of long-chain fatty acyl groups found N-conjugated to taurine were odd-
numbered acyl chains including C21:0, C21:1, C23:0, C23:1, C25:0, and C25:1. N-
Tricosanoyltaurine was found to be one of the more abundant N-acyltaurines in mouse brain.129 
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Amino acid N-fatty acyl conjugation may function primarily in 
excretion/detoxification; however, this chemistry does serve other roles in mammals. Bile 
acid conjugation to glycine or taurine increases bile acid solubility, renders the bile acids 
impermeable to cell membranes and is essential to proper liver function.
162
 In addition, β-
citrylglutamate may have a role in spermatogenesis
92
 and in the differentiation of lens 
epithelial cells into fiber cells.
163
 
 Most intriguing are the emerging roles of the long-chain N-fatty acylamino acids. 
Milman et al.
120
 isolated and characterized N-arachidonoyl-L-serine from bovine brain 
and showed that this novel N-fatty acylserine had vasodilatory properties.  The Merkler 
lab has proposed that the N-fatty acylglycines are biosynthetic precursors to the PFAMs, 
being oxidatively cleaved to the corresponding PFAM and glyoxylate in a reaction 
catalyzed by peptidylglycine α-amidating monooxygenase (PAM).
164
 Recent evidence 
suggests that the N-fatty acylglycines may serve as more than simple PFAM pathway 
intermediates and may have independent functions as lipid messengers: N-oleoylglycine 
regulates body temperature and locomotion,
165
 N-arachidonoyltaurine activates TRPV1 
and TRPV4 calcium channels of the kidney,
72
 N-arachidonoylglycine is an endogenous 
ligand for the orphan GPR18 receptor,
73
 and N-palmitoylglycine inhibits nociception and 
induces transient calcium influx.
74
 Similar to prostaglandins
166
 and endocannabinoids,
22
 
the actions of fatty acyl glycines are likely to be mediated through G-protein-coupled 
receptors, as has been recently reported for N-arachidonoyl glycine.
73
 For a more 
thorough list of endogenous long-chain mammalian signaling NAGs and their known 
function, see Chapter 4.  
N-Arachidonoyl-γ-aminobutyric acid is analgesic,
2
 and N-arachidonoylglycine is 
analgesic, and inhibits FAAH
167
 and the GLYT2a glycine transporter.
102
 The function(s) 
served by N-arachidonoylalanine is currently not understood. Another set of N-acyl 
amino acid conjugates that warrant some discussion are related to the conjugation of fatty 
acids to either the α-amino group of an N-terminal glycine residue or to the ε-amino 
group of internal lysine residue.  The most common N-terminal acyl group found in 
eukaryotes is myristic acid, but other fatty acids, including lauric, (cis-
5
)-tetradecaenoic 
(physeteric), (cis,cis-
5
,
8
)-tetradecadienic, and palmitic acids, have been identified as N-
terminal fatty acids.
113,168,169
 Mammalian proteins decorated via an amide linkage 
13 
 
 
between the ε-amino group of an internal lysine and myristic acid
170
 or palmitic acid
171
 
have been identified.  Proteolytic degradation of N-terminal or ε-acyllysyl lipidated 
proteins could release the corresponding N-acylglycine or Nε-acyllysine, but there are no 
reports showing that such metabolites have been detected in mammals.   
 One biosynthetic route to the N-acylamino acids utilizes an acyl-CoA thioester as 
the acyl group donor (Table 1-5).  Enzymes known to catalyze this reaction include N-
acetylglutamate synthase (a.k.a. amino acid N-acetyltransferase),
68
 bile acid coenzyme 
A:amino acid N-acyltransferase (BAAT),
99
 acyl-CoA:glycine N-acyltransferase 
(ACGNAT),
107
 a peroxisomal acyl-CoA:amino acid N-acyltransferase (ACNAT1),
108
 and 
acyl-CoA:L-glutamine N-acyltransferase.
111
 These enzymatic reactions are summarized 
in Table 1-5. N-Terminal acylation is catalyzed by N-myristoyl transferase (NMT), an 
enzyme which strongly prefers myristoyl-CoA as a substrate, and only transfers the acyl 
group to the α-amino moiety of an N-terminal glycine.  Glycine and the α-amino moiety 
of other N-terminal amino acids are not NMT substrates.
113
  Evidence suggests that 
myristoyl-CoA or palmitoyl-CoA are also the acyl donors for the acylation of ε-amino 
group of internal lysine residues.
169
   
 
 
Table 1-5: Formation of N-Acylamino Acids 
Enzyme Product Ref 
𝐴𝑐𝑦𝑙˗𝐶𝑜𝐴 + 𝑎𝑚𝑖𝑛𝑜 𝑎𝑐𝑖𝑑 → N˗𝑎𝑐𝑦𝑙𝑎𝑚𝑖𝑛𝑜 𝑎𝑐𝑖𝑑 + 𝐶𝑜𝐴˗𝑆𝐻 
N-Acetylglutamate synthase N-Acetylglutamate 
68
 
Bile acid coenzyme A:amino acid N-
acyltransferase 
Bile acyl-glycine and -taurine 
99
 
Acyl-CoA:glycine N-acyltransferase Short- and brainched-chain N-
acylglycines 
107
 
Peroxisomal acyl-CoA:amino acid N-
acyltransferase 
N-Acyltaurines 
108
 
Acyl-CoA:L-glutamine N-acyltransferase N-Acylglutamines 
111
 
N-Myristoyltransferase N- Myristoylated proteins 
113
 
Cytochrome C Long chain N-acylamino acids 
114-116
 
𝑁𝐴𝐸 + 2𝑁𝐴𝐷+ → N˗𝑎𝑐𝑦𝑙𝑎𝑚𝑖𝑛𝑜 𝑎𝑐𝑖𝑑 + 2𝑁𝐴𝐷𝐻 + 2𝐻+ 
Alcohol/aldehyde dehydrogenase
 
Short- and medium-chain N-
acylglycines 
110,117-
119
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 The data regarding the biosynthesis of the long-chain N-fatty acylglycines is not 
clear.  N-conjugation of fatty acids to glycine via a fatty acyl-CoA thioester is an 
attractive possibility. The available evidence strongly suggests that ACGNAT does not 
catalyze this reaction in vivo:  long-chain acyl-CoA thioesters are not ACGNAT 
substrates,
107
 and ACGNAT is found primarily in the liver and kidney
107
 while the 
PFAMs have been isolated from the brain.
105
 ACGNAT is not likely involved in the 
biosynthesis of other N-fatty acylamino acids, as amino acids other than glycine are very 
poor ACGNAT substrates.
172
 Other possible candidates that might catalyze this reaction 
in vivo include BAAT, which will produce N-fatty acylglycines at a low rate relative to 
the bile acid conjugates,
173
 or cytochrome c.
115,174
 The recent report that cytochrome c 
can catalyze the formation of N-oleoylglycine and N-arachidonoyl -glycine, -serine, -
alanine and –γ-aminobutyric acid from the corresponding CoA thioester in a reaction 
stimulated by H2O2 is very intriguing,
114-116,174
  but the in vitro significance is unclear. 
There is also evidence for lcNAG formation via the NAD
+
-dependent oxidation of the 
NAEs by the sequential actions of a fatty alcohol dehydrogenase (ADH) or an ADH 
followed by a fatty aldehyde dehydrogenase (AlDH) (Table 1-5, bottom). Deuterium-
labeled N-arachidonoylethanolamine (D4 on the ethanolamine) incubated in RAW264.7 
and C6 glioma cells is converted to D2-labeled N-arachidonoylglycine (see Chapter 4 for 
more in-depth discussion).
110,117,175
   
 The catabolic fates of the N-acylamino acids are not well-defined. FAAH will 
hydrolyze the N-acyltaurines and N-arachidonoylglycine to the corresponding fatty acid 
and amino acid,
2,133
 but the other N-acylamino acids are not degraded by FAAH.
167
  N-
palmitoylglycine is up-regulated in FAAH knockout mice,
74
 and increased levels of N-
oleoylglycine and N-stearoylglycine were observed after injection with a FAAH 
inhibitor,
176
 but N-docosahexaenoylglycine and N-linoleoylglycine were not increased 
under these conditions. The Merkler lab has shown that N-acylglycines are biosynthetic 
precursors to the PFAMs using purified PAM
164
 and in PAM-expressing neuroblastoma 
N18TG2 cells.
177
 Marnett and co-workers have found that the N-arachidonoylamino acids 
are substrates for lipoxygenase (LO) and cyclooxygenase-2 (COX-2) in vitro,
178,179
 
pointing either to a mechanism for the inactivation of the N-arachidonoylamino acids or 
for the formation of other bioactive, oxidized amino acid conjugates. Some NAAs, 
15 
 
 
including long chain NAGs, have also been shown to be substrates for cytochrome 
P450BM-3, a bacterial monooxygenase similar to eukaryotic P450s, resulting in 
production of ω-1, ω-2, and ω-3 hydroxylated NAAs.180,181 Much work is needed to better 
define the pathways of biosynthesis and degradation for the N-acylamino acids. 
1.4 Primary Fatty Acid Amides  
 
Arafat et al.
104
 first isolated and characterized five PFAMs (palmitamide, 
palmitoleamide, oleamide, elaidamide and linoleamide) from luteal phase plasma in 
1989.  Because the function of the PFAMs was initially unknown, interest in these 
molecules was modest until Cravatt et al.
105
 isolated oleamide and erucamide from the 
cerebrospinal fluid (CSF) of cat, rat and human and further demonstrated that the 
intraperitoneal injection of nanomole quantities of oleamide induced physiological sleep 
in rats. Research concerning oleamide has progressed rapidly since this first report and, in 
addition to its role in regulating the sleep/wake cycle, this PFAM has been shown to 
block gap junction communication in glial cells and between dendritic and T-cells,  to 
regulate memory processes, to decrease body temperature and locomotor activity, to 
stimulate Ca
2+
 release, to modulate depressant drug receptors in the CNS, and to 
allosterically activate the GABAA receptors and specific serotonin receptor subtypes (see 
refs.
87,182,183
 and Chapter 3 for reviews). The mode of action of the hypothermic response 
may be by modulation of the 5-HT receptors since they modulate thermoregulation in the 
hypothalamus and GABAA receptors, which also regulate thermal control in the 
hypothalamus. GABAA knockout mice are no longer induced to sleep but retain 
hypothermia after oleamide injection.
85
 Thus, oleamide produces these activities through 
separate systems. 
Like oleamide, other members of the PFAM are bioactive: linoleamide increases 
Ca
2+
 flux
184
 and inhibits the erg (ether-à-go-go related gene) current in pituitary cells,
185
 
erucamide stimulates angiogenesis
186
 and regulates fluid imbalance,
187
 and elaidamide 
may function as an endogenous inhibitor of epoxide hydrolase.
188
 For a more thorough 
and detailed description of the functions of endogenous PFAMs, see Chapter 3. 
16 
 
 
 
The PFAMs are degraded by fatty acid amide hydrolase, being hydrolyzed to the 
fatty acid and ammonia (Equation 1-2).
8,167
 One of the key unanswered questions 
regarding the PFAMs is how these novel brain lipid amides are produced in the body.  A 
number of reactions have been proposed to account for PFAM production. Sugiura et 
al.
189
 found that FAAH catalyzed the in vitro production of oleamide from oleic acid and 
NH3 (Equation 1-2 backwards).  This reaction is unlikely to occur in vivo because the KM 
for ammonia was high (65 mM), and the pH optimum for oleamide synthesis was > 9.  
Mouse neuroblastoma N18TG2 cells secrete [1-
14
C]-oleamide when cultured in the 
presence of [1-
14
C]-oleic acid.
177,190
 Thus, these cells must contain the enzymatic 
machinery required for oleamide biosynthesis. Oleamide production in the N18TG2 cells 
increases upon the inhibition of FAAH, providing further evidence against a role for this 
enzyme in PFAM production in vivo.  Bisogno et al.
190
 proposed that PFAMs were 
produced by phospholipid aminolysis. However, incubation of [
14
C]-oleic acid-containing 
phospholipids with NH4OH in the presence of N18TG2 cell homogenates did not result in 
the formation of [
14
C]-oleamide.   
  
 
Equation 1-2:  Hydrolysis of a PFAM by FAAH 
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Currently, there are two proposed pathways for the biosynthesis of the long chain 
PFAMs that have some experimental support (Figure 1-4). One is the direct amidation of 
fatty acyl-CoA thioesters by ammonia as catalyzed by cytochrome c.
191,192
 The PFAM-
synthesizing activity of cyt c yields a number of PFAMs, exhibits Michealis-Menton 
kinetics with a KM value for oleoyl-CoA of 21 µM and a pH optimum of 7.5, and is 
stimulated by H2O2. The optimal concentrations for H2O2 (2 mM) and NH3 (125 mM) 
have led to the proposal of an “oleamide synthesome” in which several proteins are 
aggregated to provide the necessary ingredients for oleamide synthesis
192
 (see Chapter 4 
for more details). 
A second proposed pathway for PFAM biosynthesis involves the PAM-mediated 
cleavage of N-fatty acylglycines.
165,178
 The Merkler laboratory has shown that PAM is 
expressed in the oleamide-synthesizing N18TG2 cells and further demonstrated that 
pharmacological inhibition of PAM in N18TG2 cells results in the accumulation of N-
oleoylglycine.
177,193
 A melding of the two proposed pathways could also lead to PFAMs:  
 
Figure 1-4: Proposed PFAM Biosynthetic Reactions 
Synthesis of primary fatty acid amides through the actions of 
cytochrome c and PAM. 
ASC, ascorbate; SDA, semidehydroascorbic acid 
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first the cytochrome c-mediated production of the N-fatty acylglycine (Figure 1-4 cyt c 
reaction with glycine instead of ammonia) followed by PAM oxidation to the 
corresponding PFAM. As discussed by Mueller and Driscoll,
174
 there may be more than 
one pathway for the in vivo production of the PFAMs, consistent with the fact that there 
are a number of pathways known for the in vivo production of the NAEs (Figure 1-1). 
These are the most likely routes for PFAM biosynthesis, but a more detailed analysis can 
be found in Chapter 4.  Outlined below in Figure 1-5 are potential pathways for the 
biosynthesis of the PFAMs that metabolically link together the PFAMs to the N-fatty 
acylglycines and the NAEs. The potential conversion of one class of fatty acid amide to 
another only adds another fascinating dimension to this family of bioactive compounds.   
19 
 
 
 
1.5 Pharmacological Importance of the Fatty Acid Amides 
 
Because of the broad functions exhibited by the various members of the fatty acid 
amide family, a wide range of indications could benefit from a fatty acid amide-targeted 
 
 Figure 1-5: Proposed Biosynthetic and Degradative Pathways for PFAMs, NAGs, and NAEs 
The enzymes catalyzing the individual reactions are in the boxes and the fatty acyl group is 
represented by the bold blue „R‟. The reader is referred to Chapter 4 for greater details on 
PFAM and NAG biosynthesis. ACGNAT, acyl-CoA:glycine N-acyltransferase; ACS, acyl-
CoA synthetase; ADH, alcohol dehydrogenase; AlDH, aldehyde dehydrogenase; ASC, 
ascorbic acid; BAAT, bile acid:amino acid transferase; Cyt c, cytochrome c; CYP45F, 
cytochrome P450BM3; FAAH, fatty acid amide hydrolase; NAE, N-acylethanolamine; NAG, 
N-acylglycine; PAM, peptidylglycine α-amidating monooxygenase; PFAM, primary fatty 
acid amide; SDA, semidehydroascorbic acid. 
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drug, including cancer, cardiovascular disease, inflammation, pain, drug addiction, eating 
disorders, anxiety, ganglial motor disorders, and depression (see refs. 
6,24,62,194,195
 for 
recent reviews). Potential drug targets include the enzymes involved in fatty acid amide 
biosynthesis and degradation,
196,197
 transporters responsible for moving the fatty acid 
amides across the cell membranes,
195
 and analogs of the fatty acid amides themselves as 
agonists or antagonists for their respective receptors (Table 1-6).
6,24,198
   
Although the role of oleamide as an endocannabinoid is a topic of debate,
88
 the 
vasodilatory actions of oleamide were attenuated in the presence of certain cannabinoid 
and TRPV1 receptor antagonists,
199
 indicating that oleamide-induced vasorelaxation is 
mediated, in part, by CB1 and non-CB1 cannabinoid receptors, as well as TRPV1 
receptors. Endocannabinoids such as anandamide and 2-arachidonoyl glycerol (2-AG) are 
released in response to pathogenic events and activate cannabinoid receptors that in turn 
activate signaling pathways linked to neuronal repair and maintenance as well as 
neuroprotective responses.
24
 Indeed, the endocannabinoid system is currently being 
investigated as potential targets in treating inflammatory neurodegenerative diseases, 
including Parkinson‟s,14,18,20 Huntington‟s,14 Alzheimer‟s,17,20 multiple sclerosis20 and 
amyotrophic lateral sclerosis.
20
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Table 1-6: Receptors Identified for the Mammalian Bioactive Fatty Acid Amides
a
 
A.  N-Acylethanolamines 
NAE Receptors(s) Reference 
Anandamide CB1, CB2, PPARα, PPARγ, TRPV1, 
and TRPM8
 
4-8 
N-Dihomo-γ-
linolenoylethanolamine 
CB1 and CB2 9 
5Z,8Z,11Z-
Eicosatrienoylethanolamine 
CB1 and CB2 9 
N-Oleoylethanolamine PPARα, PPARγ, TRPV1, and GPR119 5,8,46 
N-Palmitoylethanolamine PPARα, GPR55 5,54  
N-Linolenoylethanolamine TRPV1 {Movahed, 
2005 
#29}8 
N-Linoleoylethanolamine TRPV1 8 
B.  N-Acyldopamines 
NDA Receptors(s) Reference 
N-Arachidonoyldopamine CB1, TRPV1, and non-CB1/CB2 GPCR
 1,63,64
 
N-Oleoyldopamine PPARα, PPARγ, and TRPV1 1,63 
C.  N-Acylamino acids
b,c
 
NAA Receptors(s) Reference 
N-Arachidonoyltaurine TRPV1 and TRPV4
 72
 
N-Arachidonoylglycine
c
 GPR18, GPR92 
73-75
 
D.  Primary Fatty Aid Amides 
PFAM Receptors(s) Reference 
Oleamide GABAA, 5-HT1A 5-HT2A, 5-HT2C, and 
5-HT7, CB1
d 
76-89
 
aIn some cases, the indicated fatty acid amide has not been demonstrated to bind to the listed 
target by direct binding, but instead has been shown to be an agonist or antagonist to the 
target using a reporter assay. Details are in the citations listed. 
bWhile N-acetylglutamate is not formally a fatty acid amide, this N-acylamino acid binds a 
protein target as it is an allosteric activator of carbamoylphosphate synthetase I. 
cFatty acid conjugation to amino acids serves largely in the detoxification and excretion of 
xenobiotic carboxylates.  Thus, many of the N-acylamino acids are likely to bind to a 
membrane-bound transporter.  For example, Wiles et al. 102 have recently shown that N-
arachidonoylglycine inhibits the GLYT2a glycine transporter. 
dThe role of oleamide as an endocannabinoid is under debate, as the amount necessary for 
CB1 binding is high. Oleamide is known to inhibit antagonist and agonist binding to these 
receptors, however.88 
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Inhibiting the de-activation of endocannabinoids by FAAH, monoacylglycerol 
lipase (MGL) and the anandamide transport system have been the subject of studies 
designed to enhance endogenous repair signaling (see ref 12,19 for recent reviews). 
FAAH inhibition might serve as a therapeutic strategy for treatment of pain, 
inflammation, spasticity, some types of cancer, and cardiovascular and psychiatric 
diseases,
19
 and the most widely used FAAH inhibitor, URB597, is demonstrated to 
function without toxicity in preclinical safety studies in rats and monkeys.
200
 It has been 
suggested that unlike receptor agonists, which activate receptors everywhere at 
approximately the same time and might cause opposing effects on the progress or 
symptoms of certain disorders, selective FAAH (and MGL) inhibitors prolong the 
activity of cannabinoid receptors only where they‟re being produced and degraded, 
thereby exhibiting higher therapeutic efficacy with less unwanted effects.
12
 It is also 
pointed out, however, than non-endocannabinoid FAAH substrates would similarly have 
prolonged activity, which may or may not produce the desired effect. 
Anandamide and 2-AG have been shown to inhibit cancer cell proliferation by 
acting at CB receptors, as these receptors mediate cell proliferation.
201
 FAAH inhibitors 
are therefore potentially useful as anticancer agents as well. As discussed in earlier 
sections, some FAAH substrates such as oleamide, palmitoleamide, N-
palmitoleoylethanolamine, and N-oleoylethanolamine are thought to increase the action 
of other endocannabinoids (i.e. anandamide) by the entourage effect.
125
 
Because the role of MGL as a 2-AG hydrolyzing enzyme was only recently 
established, the therapeutic significance of this enzyme remains to be clarified, and 
specific inhibitors remain to be designed.
19
 As detailed by Felder et al.,
195
 the potential 
existence of specific transporters for anandamide and the other fatty acid amides is 
controversial, but accumulating evidence suggests that the simple passive diffusion of the 
these hydrophobic compounds across the membrane driven by FAAH-hydrolysis is 
insufficient to account for published anandamide uptake data. The inhibition of PFAM-
producing PAM is shown to have anti-inflammatory effects to prevent edema and during 
the three phases of adjuvant-induced polyarthritis in rats.
202
 The mechanism is thought to 
act by way of reducing endogenous levels of substance P and calcitonin gene-related 
23 
 
 
peptide, although several endogenous PFAMs have recently been shown to influence 
inflammation as well (see Chapter 3). 
Recent evidence has indicated that cannabinoid receptor antagonists can reduce 
the self-administration of several commonly addictive drugs. The mechanism of this is 
currently unknown but proposed to be based on such antagonists blocking the effects of 
endocannabinoids.
203
 The recruitment of such cannabinoid antagonists during increased 
dopamine neural activity has been shown to ameliorate cravings of several addictive 
drugs, including marijuana,
204
 opiates,
28,205
 alcohol,
206,207
 and tobacco.
26,208
 
In addition to reports of PFAMs binding to well known receptor systems such as 
serotonin and GABA receptors (Table 1-6), some of the first reports of oleamide function 
were in the inhibition of gap junction communication.
209-212
 Although this ability of 
oleamide to interfere with intercellular communication via gap junctions has been 
demonstrated in a variety of cell systems,
210,213-222
 it is unknown whether the PFAM acts 
as an allosteric effector of the gap junction proteins or via specific oleamide/PFAM 
receptors. Regardless, this modulation of gap junction communication has important 
implications in cell death. Normal gap junction communication is essential for electrical 
and chemical syncytium and provides for the delivery of nutrients and growth factors, 
and for removal of excess metabolites and toxins.
223-226
 Inhibition of this communication 
by oleamide may preserve cells during apoptotic waves and prevent “bystander killing” 
such as occurs during ischemia and stroke,
227-229
 and myocardial infarction.
230
 In primary 
hippocampal cultures, oleamide was shown to reduce the spread of apoptosis in response 
to metabolic depression,
231
 and in cerebellar granule cells it acted similarly during K
+
 
depravation.
232
 
The number of diseases (and thus pharmacological targets) associated with acyl 
amides and their receptors is large. Some of these disorders are outlined in Table 1-7.  
The fatty acid amides represent an exciting opportunity for the development of new drugs 
for the treatment of disease.  The potential for fatty acid amide-targeted therapeutics is 
high. 
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1.6 Conclusion 
 
Fatty acid amides are a large family of structurally-diverse molecules found in 
humans and other organisms. Because many of these molecules have been shown to be 
bioactive, particularly in cell signaling, analogs of the fatty acid amides could prove 
useful as agonists or antagonists for their respective receptors, and a better understanding 
of how they are synthesized and metabolized will lead to better treatments. The enzymes 
involved in the biosynthesis and degradation of the various fatty acid amides, many of 
which are still poorly defined, provide an exciting opportunity for the development of 
new drugs to treat sleep disorders, anxiety, depression, cardiovascular disease, and 
neurodegenerative diseases.  
 
 
 
 
 
 
Table 1-7: Disorders Associated with Amide-Binding Receptors 
Receptor 
Category P
a
in
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Refs 
CB √ √ √ √ √ √ √ √ √ √ 11-31 
PPAR √ √ √ √   
 
√ 
 
√ 15,33-42 
TRPV √ √ √ √  √ √ 
  
 13,15,43-45 
GABA √ 
 
√ 
 
√  √ √ √ √ 47-53 
5-HT √ a √ 
 
√ b √ √ √ √ 16,55-60 
5-HT, 5-hydroxytryptamine (serotonin) receptor, CB, cannabinoid receptor; GABA, γ-
aminobutyric acid receptor; PPAR, peroxisome proliferator-activated receptor; TRPV, transient 
receptor potential vanilloid type. 
aThere is a possible connection between serotonin and valvular heart disease.69 
bTrial data has been inconsistent regarding 5-HT agonists‟ effect on Parkinson‟s disease.70 
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2 Development of Quantitative Assays for Long Chain Acyl 
Amides 
 
2.1 Background of N-Acylglycine and Primary Fatty Acid Amide 
Isolation  
 In 1957, the first (non-sphingosine-based) fatty acid amide was isolated as N-
palmitoylethanolamine, a natural anti-inflammatory agent,  from egg yolk, soybeans and 
peanuts.
2
 Interest in the N-acylethanolamines (NAEs) grew after evidence showed that N-
arachidonoylethanolamine (anandamide) was an endogenous ligand for cannabinoid 
receptors after they were shown to attenuate the electrically evoked twitch response in 
Mus musculus vas deferens.
3
  
Although N-arachidonoylethanolamine has been studied at length, the 
identification and characterization of other lipid signaling molecules has lagged behind 
peptides and polar signaling molecules due to the nonpolar nature of lipids. Not only are 
they hydrophobic, thus making isolation by traditional methods difficult, but they are in 
low abundance and in constant chemical flux, often quickly being metabolized to other 
species. Relative to the NAEs, less is known about long chain primary fatty acid amides 
(PFAMs), and even less about the N-acylglycines (NAGs), more recently discovered 
members of this group of mammalian signaling molecules. The current literature for 
extraction and identification of NAGs and PFAMs from mammalian sources is 
summarized in Table 2-1 and Table 2-2. 
Aside from a surge of interest in the 1990’s in short chain NAGs as excretion 
products  that accumulate due to acidurias and other inborn errors of metabolism, little 
work has been done toward extracting NAGs as mammalian metabolites until very 
recently (Table 2-1). The signaling NAGs are present in much lower abundance than 
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found as excretion products in aciduria patients, making their isolation difficult until the 
advent of sensitive analytical instrumentation combined with efficient extraction 
techniques. For completeness, a few of the urinary NAG studies have been included in 
Table 2-1.  
Renewed interest in isolating PFAMs from mammalian sources arose in the 
1990’s after the discovery that nanomole quantities of oleamide induced physiological 
sleep in rats.
12
 A survey of the techniques used to isolate PFAMs is presented in Table 
2-2. Much of the PFAM research has focused on oleamide, likely because it has a known 
physiological function (see Chapters 3 for a review of PFAM function). 
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Table 2-1: Summary of N-Acylglycine Analysis from Mammalian Sources 
 Initial 
purification 
method 
Detection 
method 
Detection 
limit 
Endogenous 
amount 
NAG 
source 
NAG(s) 
identified Ref 
 
L
C
-M
S
 
none LC/MS 6 nmol 
1-9 
mmol/mol 
creatinine 
Human 
urine 
various short 
chain NAGs 
5 
none 
ESI-
MS/MS 
Not 
reported 
0.2-4760 
mmol/mol 
creatininec 
Human 
urine 
various short 
chain NAGs 
6 
S
P
E
 
SPE 
(IE, RP, NP) 
LC-
QqTOF, 
MRM 
150 fmol, 
 100 
attomol 
0.26 to 333 
pmol/gb 
Rat 
tissues 
N-palmitoyl, 
N -stearoyl, 
N -oleoyl, 
N -linoleoyl, 
N -docosa-
hexaenoyl 
7-9 
SPE (IE, 
RP) 
LC-
QqTOF, 
MRM 
Not 
reported; 
<500fmol 
6-1612 
pmol/ga 
Rat 
tissues 
N -palmitoyl 10 
SPE (IE, 
RP) 
LC-
QqTOF 
Not 
reported 
1-140 
pmol/gb 
Rat 
tissues 
and 
bovine 
brain 
N -arach-
idonoyl 
11 
P
re
p
- 
T
L
C
 NP TLC LC/MS 
Not 
reported 
~50 pmol/gb 
Rat 
brain 
G
C
-M
S
 
NP TLC GC-MS 1.5 nmol 
~45pmol/107 
cells 
N18TG2 
cells 
N -oleoyl 
this 
disser-
tation 
NP HPTLC GC-MS Not quantified 
N18TG2 
cells 
not 
identified 
14 
 
None GC-MS 0.2 nmol15 
0.024-299 
mmol/mol 
creatininec 
Human 
urine 
various short 
chain NAGs 
15-22 
Abbreviations: ESI-MS/MS, electrospray ionization tandem MS; GC-MS, gas chromatography-mass 
spectrometry; HPTLC, high performance TLC; IE, ion exchange; LC/MS, liquid chromatography/MS; 
LC-QqTOF, liquid chromatography-hybrid quadrupole time of flight MS; MRM, multiple-reaction 
monitoring on a HPLC-triple quadrupole MS; MS, mass spectrometry; MS/MS, tandem mass 
spectrometry; NP, normal phase; prep-TLC, preparatory TLC; RP, reversed phase; SPE, solid phase 
extraction; TLC, thin layer chromatography  
The left hand columns summarize the purification (far left) and detection methods (right) across the 
studies shown. 
aQuantity is amount per gram dry tissue. 
bQuantity is amount per gram wet tissue. 
cAmount varied based on type of inborn error of metabolism or normal phenotype. 
 
37 
 
 
 
 
Table 2-2: Summary of Primary Fatty Acid Amide Analysis from Mammalian Sources 
 
Initial 
purification 
method 
Detection 
method 
Detection 
limit 
Endogen
-ous 
amount 
PFAM 
source 
PFAM(s) 
identified Ref 
 
L
C
-M
S
 
HPLC (HPLC) 
~3.5 
nmol 
255-660 
ng/ga 
Squirrel 
brain 
ole 1 
HPLC 
ESI-MS, 
MS/MS, 
and MS3 
Not 
reported; 
<0.2 
pmol 
0.1-5 
pmol/100 
µl 
Cat 
CSF 
ole 4 
S
P
E
/T
L
C
 
HPLC, SPE 
and TLC 
ESI-MS, 
MS/MS, 
MS3, IR, 
NMR, 
GC-MS, 
and 
ozonolysis 
Not 
reported 
Not 
reported 
Cat 
CSF 
ole, eruc 12 
 
Solvent 
extraction 
only 
ESI-MS 
Not 
reported 
Not 
reported 
N18TG2 
cells 
ole 13  (HPLC) 
G
C
-M
S
 
GC-MS 
T
L
C
 TLC, HPLC GC-MS 0.1 nmol 
55 
pmol/107 
cells 
N18TG2 
cells 
ole 23 
 
SPE, 
HPTLC 
GC-MS 1.8 nmol 
1.4-28 
µg/g 
Rabit 
brain, 
heart 
palmit, 
stear,ole 
14 
S
P
E
 SPE GC-MS 
Not 
reported 
0.5-12 
ng/g 
pig eruc 28 
SPE GC-MS 0.5 nmol 
112-6042 
pmol/107 
cells 
N18TG2 
and 
SCP 
cells 
palmitole, 
palmit, 
ole, linole 
This 
disser-
tation 
 
Solvent 
extraction 
only 
GC-MS 0.28 fmol 
9.9-44 
ng/ml 
Rat 
CSF 
and 
serum 
ole 29 
Solvent 
extraction 
only 
GC-MS 
Not 
reported 
2-32 
µg/ml 
Human 
leutal 
phase 
plasma 
palmitole, 
palmit, 
ole, elaid, 
linole 
45 
Abbreviations: GC-MS, gas chromatography-mass spectrometry; ESI-MS, electrospray ionization 
MS; HPLC, high performance liquid chromatography; HPTLC, high performance TLC; IR, infrared 
analysis; LC/MS, liquid chromatography/MS; MS, mass spectrometry; MS/MS and MS3, tandem 
mass spectrometry; NMR, nuclear magnetic resonance; SPE, solid phase extraction; TLC, thin layer 
chromatography 
The left hand columns summarize the purification (far left) and detection methods (right) across the 
studies shown. 
aQuantity is amount per gram dry tissue. 
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2.1.1 Lipid Extraction 
 
Although short-chain NAGs are present in certain urine samples and can be 
analyzed without extraction, the long-chain NAGs and PFAMs are generally in much 
lower abundance and require more extensive extraction techniques to remove them from 
the tissues and cells in which they are found. Commonly used extractions are based on 
those of Folch
24
 and Bligh,
25
 and variations thereof. Usually a 20-fold volume of 
chloroform:methanol (2:1) or methanol is added to the tissue or cell pellet prior to  
homogenization, and a small volume of water or brine is added to the supernatant to 
separate lipids from remaining non-lipid contaminants that remain in the upper, aqueous 
phase. The lower phase, which contains lipid molecules, including NAGs and PFAMs, is 
then reduced in volume before initial sample preparation. 
2.1.2 Sample Preparation 
 
Older methods of long chain fatty acid-related molecules required purification to 
homogeneity prior to structural analysis by MS or NMR,
26,27
 a problem which is 
compounded by the low abundance of lipid signaling molecules such as PFAMs and 
NAGs. Modern instrumentation can characterize individual lipid components in a more 
complex, less purified sample. Initial purification is typically done using either 
preparatory thin layer chromatography (TLC) or solid phase extraction (SPE) after 
solvent extraction (see Table 2-1 and Table 2-2 for examples). Greater specificity can be 
achieved using column chromatography (ion exchange or normal phase) or TLC, as the 
characteristic functional groups (i.e. glycine and primary amide) interact with the solid 
matrix, and samples can be separated based on those functional groups. Reverse phases 
are useful for separating compounds based on their acyl chain lengths. 
2.1.2.1 Solid Phase Extraction 
 
Normal phase (NP), reversed phase (RP) and ion exchange (IE) chromatography 
columns have all been used for initial sample purification before MS analysis of NAGs, 
PFAMs, and other related lipids (see Table 2-1 and Table 2-2). There are several things 
to consider when attempting to purify a lipid sample by SPE. The different solid matrices 
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can be used to separate the PFAMs and NAGs from different metabolites depending on 
the desired outcome. Crude extracts can often contain cholesterols, triacylglycerols, 
squalenes and other nonpolar lipids, which can be removed by using an ion exchange or 
normal phase column. When put in acidic conditions, PFAMs gain a positive charge (-
NH3
+
) and NAGs gain one (-NH2
+
-) or two (=O
+
-H) positive charges and become good 
candidates for ion exchange. Reverse phase columns are useful for separating compounds 
of different acyl chain length. Silica matrix material varies from manufacturer-to-
manufacturer and even from lot-to-lot, and the sample purification by SPE should be 
optimized with a solution of standards. The analytes can become difficult to recover if 
they bind too tightly with the column material or are in low abundance. 
 All of these SPE techniques have been put to use by the Bradshaw/Walker group 
for partial purification of NAGs
7-11
 as well as by many others for selective extraction of 
different lipid classes.
30-36
 Compounds that contain similar polarities such as PFAMs, 
NAGs monoacyl glycerols, and N-acylethanolamines can be difficult to separate on SPE. 
This may be overcome in the later MS analyses if sufficiently sensitive instruments are 
available, but TLC is another option that may offer a better pre-analysis separation in 
these cases. 
2.1.2.2 Thin Layer Chromatography 
 
TLC has long been used to separate lipid samples from crude extract
37-44
 (see ref. 
41
 for a review). TLC can purify samples to a greater extent in one step relative to SPE, 
although amine-based diffusion of the PFAMs and NAGs spreads the amide TLC spot 
more widely than for other lipid classes. High performance thin layer chromatography 
(HPTLC) plates use smaller particle size (~15µm), which gives rise to less spot spread 
and higher resolution, ameliorating the diffusion caused by the amino group. Because NP 
silica gel is polar, PFAMs and, particularly, the NAGs will not move far from the 
baseline of the TLC plate and, as plates are developed, the more non-polar lipids will 
travel away from these amides.   
While providing a means to rapidly remove most contaminants at once, TLC can 
also provide a quick profile of all the types of compounds present in a sample. Larger 
amounts of lipids can be visualized under UV light, while smaller quantities can be 
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visualized using a dye such as potassium permanganate (KMnO4), which is used to 
visualize as little as 1nmol NAG or PFAM. KMnO4 is oxidative, so standards are run in 
tandem with test plates, and position of the target spot is estimated based on the dyed 
standard before scraping into desorption solvent.  
It is important to remove silica and binding agent(s) before the next analytical 
step to avoid clogging the analytical instrumentation or dampening the signal with excess 
background noise. A fine syringe filter can remove most of the silica, and careful use of 
dry solvents can minimize silica solubility. The Merkler and Johnson groups have had 
some success with desorbing into anhydrous isopropanol (this dissertation and ref. 
14
); 
however, certain binding agents can deteriorate GC column material over time. Careful 
selection of TLC plates or in-house production of the plates will avoid this problem.
 
2.1.3 Sample Detection 
 
Nuclear magnetic resonance (NMR), although useful for complete atom 
assignment, is not useful for most PFAM and NAG analyses because of the limited 
quantities of purified materials obtain from mammalian sources and inability to purify 
samples to homogeneity. Even when using large animals and large tissue samples, the 
pmol/g tissue quantities do not provide enough material for 13C-NMR, which requires 
mg quantities.
3
 More sensitive techniques are required. Analysis via mass spectroscopy 
provides excellent sensitivity, and unambiguous assignment of compound can be 
achieved by mass fragmentation pattern and retention time comparisons to known 
standards. The two main methods used are GC-MS and LC-MS. 
2.1.3.1 Gas Chromatography-Mass Spectrometry 
 
 Gas chromatography-mass spectrometry (GC-MS) is an excellent system for the 
rapid separation and detection of metabolites. Even with crude preparations, the GC-MS 
spectrum can be mined for characteristic fragment ions to be quantified, or only those 
mass to charge ratios (m/z) of interest can be monitored (see section 2.2.12). One 
advantage of GC over LC is its higher peak capacity due to longer column length. 
Nonpolar (95-100% dimethylpolysiloxane) columns provide a separation by chain length. 
Because the typical ionization potential used in most electron ionization systems is 70 
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eV, much higher than the potential required to ionize organic molecules, fragment ions 
are observed in much greater abundance than M
+•
 ions. However, identification by 
retention time and fragmentation pattern still allows unambiguous assignment of 
structure. If a standard is unavailable and determination of molecular weight is desired, 
chemical ionization (CI) can be used. A protonated molecular ion is formed through a 
two-step reaction in which a reagent gas is bombarded with electrons to ionize it and then 
the activated gas is allowed to react with the analyte molecule, forming an intact, ionized 
compound for mass detection. 
  Although underivitized NAGs and PFAMs can be seen when in abundance in GC 
analysis, the amounts of NAGs and PFAMs extracted from a natural source are not 
sufficiently abundant to allow production of robust standard curves within useful ranges 
for metabolite analysis without derivitization. Typically, N,O-
bis(trimethylsilyl)trifluoroacetamide (BSTFA),
19,46-48
 tert-butyl dimethylsilyl ether (t-
BDMS),
49
 or methylation
50,51
 are used for volatilization, which greatly increases 
sensitivity over non-volatilized compounds.  
2.1.3.2 High Pressure Liquid Chromatography-Mass Spectrometry 
 
HPLC-MS/MS has been the method of choice for identifying long chain NAGs 
and PFAMs over the last 3-5 years. Both HPLC-MS/MS and GC-MS allow for virtually 
unambiguous structure assignment (when synthetic standards are available) due to both 
fragmentation pattern analysis and retention times. HPLC-MS/MS often can provide 
more accurate masses (<10 ppm) than GC-MS (~100 ppm), allowing identification to a 
higher degree of confidence and with fewer fragment peaks. These methods, in addition 
to requiring less material, also eliminate the need for pure sample. A modestly purified 
sample (via SPE) can be further separated on the LC column, and tandem MS can further 
isolate compounds of interest if their intact molecular weights are known. Tandem mass 
spectrometers can include triple quadrupole, ion trap, and quadrupole/time-of-flight to 
isolate fragments of specific mass to charge ratio (m/z) prior to final fragmentation for 
unambiguous identification.
26
 Sensitivity can be increased further by using a smaller LC 
column, as the increase in sensitivity is the square of the proportion of the column 
diameters.
26
 Although Tan et al. do not report a 1600-fold increase in sensitivity when 
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moving from a 4.1 mm to a 75 µm diameter column as theoretically predicted, they did 
find novel compounds with less than 250 fmol of a fatty acyl amide when using a nano-
HPLC QqTOF, and 100 attomol in the multiple-reaction monitoring (MRM) scan on a 
triple quadrupole MS for quantification of known compounds.
9
  
Tan et. al. have developed an algorithm designed to assist with the intensive data 
analysis required to process the roughly 1000 spectra generated from each MS/MS run 
from crude brain extract. The algorithm searches each MS scan for predicted ions from 
the masses of acyl groups plus amino acids and other small endogenous amines. 
Candidate MS/MS must also contain the masses of the acyl and the amino fragments. 
They recently have used this method to identify 11 novel acyl amino acids in rat tissue 
homogenates.
8
 
2.1.4 Other Considerations 
 
Unambiguous assignment of unsaturated acyl chains can pose a problem in some 
samples. Separation of cis/trans isomers is not ideal on a nonpolar matrix such as the 
dimethylpolysiloxane GC column that is commonly used for lipid analysis, but a highly 
polar bis(cyanopropyl) polysiloxane phase has been shown to provide this separation.
52
  
A recent review article describes Ag
+
-HPLC, Ag
+
-TLC, RP HPLC and high-speed 
counter current chromatography methods for separating cis/trans isomers of fatty acid 
methyl esters before MS analysis,
53
 and could be adopted to fatty acid amides. 
Retention times of metabolites can vary due to co-eluting compounds, general 
sample purity, column deterioration, and changes and general maintenance in 
chromatography apparatus for both LC- and GC-MS.
8
 Retention times are therefore best 
estimated by running extracts spiked with putative target compounds directly after 
analysis of unspiked sample rather than running pure NAGs or standards at a later time. 
This is not always possible when searching for novel metabolites but putative metabolites 
can be synthesized after the fact. The synthesis of NAGs both for analyte validation and 
for use as an internal standard is typically done by the reaction of glycine ethyl ester with 
the desired acid chloride, followed by deprotection of the glycine in base.
54
 Primary fatty 
acid amides are synthesized by amidation of the acyl chloride.
55
 (See section 2.2.2) 
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Internal standards should be added before sample analysis at different steps. A 
deuterated lipid of similar chain length to the analyte(s) of interest is preferred as it will 
give similar standard curves for quantitative analysis and have similar retention times but 
remain distinct from any endogenously found amides. An internal standard should be 
added before sample extraction, purification, and analysis to determine efficiency of 
metabolite recovery. Additionally, instrument performance can vary from day to day and 
from run to run and, therefore, an internal standard of known amount should be included 
with each GC-MS or LC-MS/MS run if quantitative analysis is desired. 
The advent of modern analytical tandem MS/MS instruments has greatly 
increased our ability to quickly analyze metabolites of low abundance and to search for 
novel NAGs and PFAMs (as well as other related lipids).  Careful selection of extraction 
solvents, purification matrices, and analytical separation columns allow for the 
identification and quantification of low-abundant NAGs and PFAMs from complex lipid 
mixtures. In this chapter, quantitative assays for PFAMs and NAGs are presented, along 
with some metabolism data for the conversion of oleic acid to oleamide. PFAM 
purification on NP SPE and identification by GC-MS proved to be a robust method for 
the quantification of these metabolites. NAGs were found to be more easily separated and 
recovered on TLC before identification by GC-MS. These methods were put to use in 
standard solutions, spiked cell and media extracts, and in some model cell lines after 
incubation with free fatty acids (FFAs). 
2.1.5 Oleamide-Producing Cell Selection 
The successful isolation of fatty acid amides from mammalian sources, to date, is 
summarized in Table 2-2. In selecting a cell line for isolation of oleamide, mouse 
neuroblastoma N18TG2 was an ideal choice because these cells express PAM,
56
 and are 
known to produce oleamide and N-oleoylglycine.
13,23
 These cells could, therefore, serve 
as a model for validation of extraction methods. 
In order to gain a more thorough perspective about long chain PFAM metabolism, 
two additional cell lines were examined for the production of oleamide from exogenously 
added oleic acid: sheep choroid plexus (SCP) and human epithelial kidney (HEK-293) 
cells. These cell lines were chosen because of their potential to synthesize oleamide. 
44 
 
 
Liver and kidney cells have the highest expression of the short-and medium-chain acyl 
CoA processing enzyme ACGNAT
57-62
 and, therefore, may have a greater potential to 
process long chain acyl CoAs, NAGs and PFAMs as well. SCP cells were chosen 
because this tissue type is known to secrete molecules into CSF where PFAMs have been 
found.
63-65
 
2.2 Materials and Methods 
2.2.1 Materials 
Fetal bovine serum (FBS) was from Atlanta Biologicals (Lawrenceville, GA). 
Donor equine serum was from Thermo Scientific (Waltham, MA). DMEM, EMEM and 
penicillin/streptomycin were from Mediatech Cellgro (Manassas, VA). Mouse 
neuroblastoma N18TG2 cells were from DSMZ (Deutsche Sammlung von Mikrooganism 
und Zellkuturen GmBH). SCP and HEK-293 cells were from American Type Culture 
Collection (Manassas, VA). Primers were from IDT DNA. MicroPoly(A) Pure
TM
 mRNA 
purification kit and RETROscript® Reverse Transcription kit were from Ambion 
(Austin, TX). QIAQuick gel extraction kit was from Qiagen (Valencia, CA). PVDF 
membrane was from Millipore (Billerica, MA). Tween-20, oleic acid and 
13
C18-oleic acid 
were from Sigma-Aldrich (St. Louis, MO). PAM (S-16) and FAAH (V-17) antibodies 
were from Santa Cruz Biotech, Inc (Santa Cruz, CA). FACL5 (N-term), FACL3 (center), 
FACL6 (center) antibodies were from Abgent (San Diego, CA). Goat anti-rabbit and 
donkey anti-goat secondary antibodies conjugated with horse radish peroxidase were 
from ICN Biomedical (Solon, OH). SuperSignal chemiluminescent detection system was 
from Pierce (Rockford, IL). BSTFA and silica were from Supelco (St. Louis, MO). 
Deuterated D33-heptadecanoic acid was from C/D/N isotopes (Pointe-Claire, Quebec). 
All other reagents and cell culture supplies were of the highest quality available from 
commercial suppliers. 
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2.2.2 Standard Synthesis 
2.2.2.1 Acyl Chloride Synthesis 
The free fatty acid (FFA) and thionyl chloride were combined in a 1:2 molar ratio 
neat under nitrogen while stirring (Equation 2-1). The reaction was allowed to proceed 
under reflux for 30 minutes at 50
o
C in a heating mantle. Excess unreacted thionyl 
chloride was removed by heating or under vacuum until the solution no longer produced 
gas. 
 
2.2.2.2 13C18-Oleamide Synthesis 
13
C18-Oleamide was synthesized for use as a standard following a procedure 
similar to Fong et. al.
55
 Undistilled acyl chloride was added dropwise to ice cold 
concentrated NH4OH (29% NH3) in a ratio of 1:6 acyl chloride:NH4OH (v/v) (see 
Equation 2-2). The reaction was allowed to continue until the precipitation of 
13
C18-
oleamide visibly ceased. Excess NH4OH was removed from the oleamide crystals by 
washing with H2O in a Büchner funnel. The sample was allowed to dry and stored at -
20
o
C flushed under nitrogen. 
 
 
 
 Equation 2-2: Synthesis of 
13
C18-Oleamide from the Acyl Chloride 
 
 
 
Equation 2-1: Synthesis of Acyl Chloride from a Fatty Acid 
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2.2.2.3 Acylglycine Synthesis 
Heptadecanoylglycine, D33 (HdG) and 
13
C18-N-oleoylglycine were synthesized for 
use as standards using the procedure slightly modified from Goujard et.al
54
 (Equation 
2-3). Glycine ethyl ester hydrochloride and triethylamine were slurried together in a 1:2 
molar ratio in a small volume of dichloromethane (DCM). The acyl chloride was taken 
up in a small volume of DCM and added dropwise to the slurry in a ratio of 1 mmol 
chloride:10 mmol glycine ethyl ester. The reaction was allowed to proceed, with stirring, 
at room temperature for 24 hours. 
Acidified water (pH ~2) was added to the reaction (1:1 ratio of acidified water to 
reaction solvent), along with additional DCM (2:1 ratio of new DCM to reaction solvent).  
The solution was taken into a separatory funnel and washed twice with H2O and once 
with saturated NaCl solution. The organic phase was dried over anhydrous sodium sulfate 
and then taken to an oil in vacuuo. 
The glycine ethyl ester was deprotected by stirring with excess NaOH (~2:1 molar 
ratio of amide:NaOH) in methanol/water 90:10 (v/v) for 24 hours. The reaction was 
quenched with HCl (pH ~2) and placed in a separatory funnel with ethyl acetate. The 
reaction was washed twice with H2O and once with saturated NaCl solution. The organic 
phase was dried over anhydrous sodium sulfate and taken to a white powder in vacuuo. 
The product was allowed to dry, flushed with nitrogen and stored at -20
o
C. 
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2.2.3  Isotope Metabolism Studies 
Prior to development of a quantitative PFAM assay, N18TG2 cells were incubated 
with 
13
C18-oleic acid (OA) to determine whether these cells would produce 
13
C18-
oleamide from the exogenously added 
13
C18-OA. In these preliminary incubations, 0.2 
mM fatty acid was added directly to the cell media without a BSA carrier. Cells were 
incubated for 48 hours with 
13
C18-oleic acid and then collected for PFAM analysis. 
Metabolite extraction was performed as described in Section 2.2.6, but no solid phase 
extraction (SPE) was performed. Samples were injected directly onto the GC-MS after 
derivitization with BSTFA and analyzed for 
13
C18-oleamide and –oleonitrile by 
comparing with chemically synthesized standards. 
2.2.4 Oleic Acid-BSA mixture 
BSA was used as a carrier for OA in aqueous media because of the low solubility 
of the long-chain fatty acid in water. OA was dissolved in ethanol, converted to the 
sodium salt with excess NaOH, dried under vacuum, and dissolved in Dulbecco’s 
phosphate-buffered saline (PBS) to make a 25 mM solution.  The sample was then heated 
 
 
 Equation 2-3: Synthesis of HdG from Acyl Chloride 
Synthesis of HdG from heptadecanoyl chloride. The chloride is glycinated with glycine ethyl 
ester, followed by base-hydrolysis of the ethyl group and quenching with HCl. 
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in 49
o
C water bath for 5 minutes before adding 2.5 mM BSA. The sample was stirred at 
room temperature for 4 hours, sterile-filtered, and stored at -20
o
C. 
2.2.5 Cell Culture and Fatty Acid Incubation 
 
All cells were grown in 225 cm
2
 culture dishes. N18TG2 cells were grown in 
DMEM supplemented with 100 µM 6-thioguanine. SCP and HEK-293 cells were grown 
in EMEM (SCP were supplemented with 100 µM sodium pyruvate).  SCP and N18TG2 
media had 10% FBS and HEK-293 had 10% horse serum. All cells were grown with 100 
I.U./ml penicillin, 1.0mg/ml streptomycin and incubated at 37
o
C with 5% CO2 according 
to supplier instructions. Cultures were grown to 80%-90% confluency, and culture 
medium removed and replaced with media containing 0.5% FBS or horse serum and 2.5 
mM fatty acid/0.25 mM BSA mixture. After 12, 24, or 48 hour incubation, media was 
collected, cells washed with PBS and trypsinized. An aliquot was taken for counting and 
determination of cell viability on a hemacytometer with trypan blue. Cells were 
centrifuged, the supernatant removed, and the pellet stored at -80
o
C. Spent media was 
centrifuged to remove any cells and the supernatant also stored at -80
o
C.  
2.2.6 Metabolite Extraction 
 
Metabolites were extracted from cells similar to Sultana and Johnson.
46
 Methanol 
(4 ml) was added to cell pellets and samples were sonicated for 15 minutes at room 
temperature. Samples were centrifuged at 5000 rpm for 10 min, and the supernatant 
separated from the pellet, dried under N2 in a warm water bath at 40
o
C. The pellet was re-
extracted with 4 ml 1:1:0.1 (v/v/v) chloroform:methanol:water, sonicated for 10 min, 
vortexed for 2 min and centrifuged 10 min at 5000 rpm. Supernatant from this step was 
added to the dried supernatant from the previous step and dried under N2 at 40
o
C. The 
pellet was re-extracted with 4.8 ml chloroform:methanol 2:1 (v/v) and 800 µL 0.5 M 
KCl/0.08 M H3PO4, sonicated 2 min, vortexed 2 min, and centrifuged 10 min at 5000 
rpm. The lower lipid phase was added to the dried supernatant from the previous steps 
and dried under N2 at 40
o
C. These steps are summarized in Figure 2-1. 
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Metabolite extraction from conditioned media was performed on all the media 
collected from the flasks (~45 ml per T-225 cm
2
 flask). Extractions were done with 15 ml 
chloroform:methanol 2:1 (two times) followed by two extractions with 15 ml 
chloroform:methanol 2:1 plus 2.4ml 0.5 M KCl/0.08 M H3PO4. No sonication was 
performed, and precipitated protein layers that resulted from sovlent addition were 
condensed by centrifugation for 30-45 min at 5000 rpm. Organic lipid phases were also 
combined and dried under N2 at 40
o
C. 
2.2.7 Solid Phase Extraction 
 
Solid phase extraction (SPE) was run for PFAM purification. Silica columns were 
run as described by Sultana and Johnson.
46
  Each column contained 0.5 g silica.  Dried 
lipid extract samples were taken up in 100 µL n-hexane and added to silica columns after 
rinsing with n-hexane. The mobile phase was run as follows: 4 ml n-hexane, 1 ml 99:1 
 
Figure 2-1: Extraction of PFAMs for Analysis by GC-MS. 
General schematic for the extraction and characterization of PFAMs from cells. 
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hexane:acetic acid, 1 ml 90:10 hexane:ethyl acetate, 1 ml 80:20 hexane:ethyl acetate, 1 
ml 70:30 hexane:ethyl acetate, 1.5 ml 2:1 chloroform:isopropanol, 0.5 ml methanol. The 
last two fractions were combined and dried down under N2 at 45
o
C. An internal standard, 
3 nmol D33-heptadecanoic acid, was added and dried before derivitization. 
2.2.8 Thin Layer Chromatography 
 
TLC was used for NAG purification. Dried lipid extracts were applied to a 10 cm 
EMD (Gibbstown, NJ) analytical NP TLC plate that had been prewashed with 
chloroform:acetone 1:1. After spotting the sample onto the TLC plate with both ethyl 
acetate and ethanol, chloroform:methanol:acetic acid 95:5:1 was used to run up to 5.5 cm. 
The plate was dried and placed in the second running solvent, hexanes:diethyl 
ether:acetone 60:40:5 and run up to 8 cm. After drying, the final solvent, hexanes:diethyl 
ether 97:3, was run up to 9.5 cm. N-Oleolglycine and HdG standards were run alongside 
the cell extract on a separate plate and visualized using KMnO4 to test for position of the 
NAGs. The appropriate area was scraped from the experimental TLC plate containing 
cell extract and collected into anhydrous isopropanol before water bath sonication for 5 
minutes. After initial sonication, the sample was centrifuged to pellet the silica. The 
supernatant liquid was transferred into a syringe, filtered with a 0.22 µm syringe filter, 
and set to dry under nitrogen at 40-50
o
C.

 The silica was subjected to another round of 
sonication in anhydrous isopropanol, centrifugation and syringe filtering before adding to 
the previous supernatant. Sample preparation for analysis of NAGs is summarized in 
Figure 2-2. 
                                                 
The syringe filter has to be rinsed with isopropanol before running the sample through it to 
remove the slip additive oleamide. Although oleamide is not the metabolite of interest while 
performing the TLC purification, there was enough oleamide present to interfere with subsequent 
analyses. This finding of oleamide in such abundance in the syringe filter may help explain the 8 
order of magnitude difference between the endogenous amount of oleamide reported in N18TG2 
cells by this study (119 pmol/107 cells) and Bisogno (55pmol/107cells) (23) Bisogno, T.; 
Sepe, N.; De Petrocellis, L.; Mechoulam, R.; Di Marzo, V. Biochem Biophys Res Commun 1997, 
239, 473. and by Sultana (16.67 pmol/cell).  (14) Sultana, T. Doctoral Dissertation, 
Duquesne University, 2005.  
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2.2.9 Sample Derivitization 
 
Trimethylsilylation was achieved using BSTFA. Samples were flushed with dry 
N2, 100 µL BSTFA added, and the sample allowed to react at 55-60
o
C for 1 hour before 
analysis by GC-MS. The reaction scheme of BSTFA with amides to form trimethylsilyl 
derivatives, nitriles, and enyliminoacetate derivatives (from NAGs) is shown in Figure 
2-3. 
2.2.10 GC-MS 
 
All analyses were performed using a Shimadzu QP-5000 GC-MS. Separations 
were achieved on a J & W Scientific (Folsom, CA) DB-5 column (0.25 mm x 30 m). The 
GC temperature program was 55-150
o
C at 40
o
C/min, hold at 150
o
C for 3.6 min, ramp at 
10
o
C/min to 300
o
C, and hold for 1 min. The transfer line was held at 280
o
C and the 
 
Figure 2-2: Extraction of NAGs for Analysis by GC-MS 
General schematic for the extraction and characterization of NAGs from cells. For more details 
see text. 
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injection port at 250
o
C throughout the separation.  Helium was used as the carrier gas, at 
a flow rate of 0.9 ml/min.  The mass range was 35-700 amu. 
 After running two aliquots of the experimental sample through the GC-MS, the 
remaining sample was dried down, spiked with oleamide, re-derivitized with BSTFA, and 
re-run on the GC-MS to validate sample retention times  
2.2.11 Contamination Controls 
 
As controls, all glassware and plasticware were treated with solvents as described 
for the cell and media samples and were subjected to sonication, solid phase extraction, 
and derivitization to test for contaminating plasticizers.
66
 Integration of the GC trace was 
taken over the same time integral as standard amides and for the same set of ions. An 
averaged number of cells was used to calculate blank amount of amide per cell. Unspent 
media was also subjected to extraction to check for existing amides. No significant 
amount of oleamide was found in any of these samples compared to cells and conditioned 
media samples (data not shown). 
2.2.12 Data Analysis 
 
Total ion chromatograms (TIC) were taken to more clearly determine the 
identities of species present in the sample. Post-run, a set of selected ions unique to 
oleamide and oleonitrile was overlaid and integrated so that effects of any co-eluting 
compounds could be minimized. These unique ion sets were 83, 97, 110, 122, 136, 150, 
164, 190, 206, 220, 234 and 263 for oleonitrile, and 59, 86, 112, 116, 122, 126, 128, 131, 
136, 140, 144, 154, 158, 170, 184, 186, 198, 200, 226, 238, 264, 281, 338 and 353 for 
oleamide-TMS. Standards were integrated in the same way for production of a standard 
curve. 
Heptadecanoic Acid, D33 (HdA), was spiked into each sample as an internal 
standard to test for performance of the instrument. The amides and nitriles of interest 
were integrated along with the HdA, both compared to their standard curves, and a 
correction factor determined based on the integration of HdA compared to its standard 
curve was used to adjust the amount of amide. Each sample was run on the GC-MS 
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twice, and each incubation run at least twice to provide replicates. T-tests were performed 
using GraphPad. 
2.3 Results 
2.3.1 GC-MS of Standard Spectra 
 
Throughout these experiments BSTFA was used to volatilize the lipids, and the 
BSTFA derivitization is shown in Figure 2-3A. When derivitizing a primary amide with 
BSTFA, a side reaction is observed in which a nitrile is formed, as can be seen in the GC-
MS of oleamide in Figure 2-4. There is precedence for this type of reaction, and a 
suggested mechanism based on that proposed by Ichiyama involving L-chloropropionic 
acid as the electrophile
67
 is shown in Figure 2-3B. 
Upon derivitization of NAGs, an enyliminoacetate product was also found in 
addition to the mono- and bi- trimethylsilyl (TMS) products (Figure 2-5). The proposed 
formation of this enyliminoacetate can be found in Figure 2-3C, and more information 
regarding the elucidation of this structure is in Appendix A.   
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Figure 2-3: Mechanism for the Derivitization of Amides with BSTFA 
Panel A shows the addition of a trimethylsilyl group to an electronegative atom previously 
bound to a hydrogen. Panel B shows the competing reaction where a nitrile is formed from a 
primary amide. Panel C shows an enyliminoacetate product from derivitization with an NAG. 
For more details on enyliminoacetate identification see Appendix A. 
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Figure 2-4: GC-MS of Oleonitrile and Oleamide-TMS from Oleamide BSTFA reaction 
Panel A (top) shows the entire GC spectrum for this oleamide sample, with a zoom in of the 
oleonitrile and oleamide-TMS peaks (bottom). Panel B shows the annotated MS of the oleonitrile 
mass spectrum. Panel C shows the annotated MS of the oleamide-TMS mass spectrum. 
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Figure 2-5: GC-MS of N-Oleoylglycine Derivitized with BSTFA 
Y-axes are intensity. Panel A shows the whole GC chromatogram (top) and closeup of NOG 
peaks (bottom). Panel B shows the MS spectrum for the enyliminoacetate derivative. Panel B 
shows the MS of NOG with two TMS groups attached. Panel D shows mono-derivitized 
NOG. 
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 One of the most common reactions for carboxylated acyl chains is the McLafferty 
rearrangement. The McLafferty rearrangement and resulting fragments from oleamide 
and the mono- and bi-derivitized NOG molecules is shown in Figure 2-6. Additional 
fragmentation schemes for these compounds can be found in Appendices A and B. 
 
 
13
C18-Oleamide, 
13
C18-N-oleoylglycine, and deuterated D33-N-
heptadecanoylglycine were synthesized for use as standards for these analyses. The MS 
spectra for these samples are shown in Figure 2-7 and Figure 2-9. 
 
Figure 2-6: McLafferty Rearrangements for Acyl Amides 
The common McLafferty rearrangements for acyl amides are shown here for a primary amide 
(A), mono-derivitized NAG (B) and di-derivitized NAG (C). The m/z shown are for an oleoyl 
acyl chain. Additional fragmentation schemes are shown in Appendices A and B. 
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Figure 2-7: 
13
C18-Oleamide-TMS Mass Spectrum 
The top panel (A) shows 13C18-oleamide-TMS. Panel B shows 
13C18-oleonitrile. 
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Figure 2-8: N-
13
C18-Oleoylglycine Mass Sspectra 
The top panel (A) shows the enyliminoacetate derivative of 13C18-NOG (see Appendix A). Panel 
B shows 13C18-NOG-TMS. Panel C shows 
13C18-NOG-(TMS)2. 
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2.3.2 Isotope Metabolism Studies 
 
In order to determine whether exogenously added OA was directly converted to 
oleamide, incubations were performed with isotopically labeled 
13
C18-OA in N18TG2 
cells. These experiments would help determine whether OA is a direct metabolic 
precursor to NOG and oleamide depending on whether the carbon backbone remained 
intact. These initial extractions were performed similar to Merkler et. al.
13
 and did not 
include an initial sample purification before application to GC-MS.  
 The cells were incubated with 0.2 mM 
13
C18-oleic acid (sans BSA lipid carrier, 
see Section 2.2.4), the cells and conditioned media collected after 48 hours incubation 
before lipid analysis. The GC-MS of 
13
C18-oleamide extracted from the cells and 
derivitized with  BSTFA is shown in Figure 2-10 and the spectrum of underivitized 
13
C18-
oleamide from the conditioned media is included in Figure 2-11. The GC-MS spectrum 
 
Figure 2-9: GC-MS of  HdG 
Panel A shows the MS of the enyliminoacetate derivative of HdG.Panel B shows the MS of 
HdG-TMS. No HdG-(TMS)2 was observed. For more information on the enyliminoacetate 
derivative, see Appendix A. 
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of 
13
C18-NOG isolated from cells and conditioned media and derivitized with BSTFA are 
shown in Figure 2-12 Figure 2-13, respectively. These results strongly suggest that the 
chain of custody of the carbon atoms is directly from OA to NOG and oleamide. 
 
 
Figure 2-10: GC-MS of  N18TG2 Cells Incubated with 
13
C18-Oleic Acid Showing 
13
C18-Oleamide-
TMS 
Panel A shows the GC over the entire timecourse (top) and a closeup of the 13C18-oleamide-TMS 
spectrum (bottom). Panel B shows the annotated MS for 13C18-oleamide-TMS. 
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Figure 2-11: GC-MS of N18TG2 Conditioned Media Incubated with 
13
C18-Oleic Acid Showing 
13
C18-
Oleamide 
Panel A shows the GC over the entire timecourse (top) and a closeup of the 
13
C18-oleamide 
spectrum (bottom). Panel B shows the annotated MS for 13C18-oleamide. 
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Figure 2-12: GC-MS of N18TG2 Incubated with 
13
C18-Oleic Acid Showing 
13
C18-Oleoylglycine-
TMS 
Panel A shows the GC over the entire timecourse (top) and a closeup of the 13C18-NOG-TMS 
peak (bottom). The peak at 20.19 minutes is 13C18-NOG-(TMS)2 Panel B shows the annotated 
MS for 13C18-NOG-TMS. 
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2.3.3 Quantitative PFAM Assay Development 
 
Initial isotopic metabolism studies provided qualitative results, but not robust 
reproducible quantitative PFAM analysis. In order to improve the quantification of 
PFAMs, an extraction step was added prior to derivitization with BSTFA and analysis by 
GC-MS. This solid phase extraction on normal phase silica provided an excellent way to 
remove many interfering compounds such as cholesterols, triacylglycerols, squalenes and 
other nonpolar lipids. While this extraction was not able to remove all the fatty acids due 
to the large amount incubated with the cells (2.5 mM), sufficient quantities were removed 
 
Figure 2-13: GC-MS of N18TG2 Conditioned Media Incubated with 
13
C18-Oleic Acid Showing 
13
C18-
Oleoylglycine-TMS 
Panel A shows the GC over the entire timecourse (top) and a closeup of the 13C18-NOG-TMS 
peak (bottom). The peak at 20.18 minutes is 13C18-NOG-(TMS)2 Panel B shows the annotated 
MS for 13C18-NOG-TMS. 
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to prevent saturation of the detector on the GC-MS, essential to preserving the life of the 
detector system and in removing enough interference to allow the detection of smaller 
PFAM peaks. 
 Extraction efficiency experiments were run for oleamide and other PFAMs, and a 
detailed description of the analysis can be found in Chapter 3. Extraction efficiency for 
oleamide from cells was 81% ± 7% and in media was 94% ± 9% (average ± standard 
deviation). 
 
2.3.3.1 Oleic Acid Time Course Incubations 
 
Once it was established that the N18TG2 cell line is capable of converting OA 
directly to oleamide and the quantitative assay had been demonstrated with spiked 
samples (data not shown), the next step was to quantify the endogenous amount of 
oleamide in all three model cell lines and to demonstrate the rate of conversion from OA 
to oleamide over time in each of them. (For a discussion on the selection of model cell 
lines see section 2.1.5.) 
All three model cell lines were found to contain endogenous amounts of 
oleamide, where the “endogenous” amount refers to the amount of oleamide extracted 
and quantified in normally growing cells without incubation with OA. All three cell lines 
also showed an increase in oleamide level after incubation with OA over time. GC-MS 
spectra showing oleamide or oleonitrile can be found in Figure 2-14 through Figure 2-19.  
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Figure 2-14: GC-MS HEK-293 Cell Extract after Incubation with OA for 12h, Showing Oleonitrile 
 GC-MS of HEK-293 cell extract after incubation with OA for 12 hours. Panel A shows the 
whole GC and a close-up of the peak of interest. Panel B shows the MS of the indicated GC peak 
(oleonitrile). Panel C shows the library database MS for oleonitrile. Panel D shows the difference 
between panels B and C. The cells were extracted as described in the methods section. The cells 
had been incubated with 2.5 mM OA in 0.25 mM BSA for 12 hours in this case before extraction. 
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Figure 2-15: GC-MS of HEK-293 Conditioned Media Extract after Incubation with OA for 24h, 
Showing Oleonitrile.  
GC-MS of HEK-293 media extract after incubation with OA for 24 hours. Panel A shows the 
whole GC and zoom in of the peak of interest. Panel B shows the MS of the indicated GC 
peak (oleonitrile). Panel C shows the library database MS for oleonitrile. Panel D shows the 
difference between panels B and C. The cells were extracted as described in the methods 
section. The cells had been incubated with 2.5 mM OA in 0.25 mM BSA for 24 hours in this 
case before extraction. 
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Figure 2-16: GC-MS of N18TG2 Cell Extract after Incubation with OA for 12h, Showing 
Oleonitrile 
GC-MS of N18TG2 cell extract after incubation with OA for 12 hours. Panel A shows the 
whole GC and zoom in of the peak of interest. Panel B shows the MS of the indicated GC 
peak (oleonitrile). Panel C shows the library database MS for oleonitrile. Panel D shows the 
difference between panels B and C. The cells were extracted as described in the methods 
section. The cells had been incubated with 2.5 mM OA in 0.25 mM BSA for 12 hours in this 
case before extraction. 
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Figure 2-17: GC-MS of N18TG2 Conditioned Media Extract after Incubation with OA for 48h, 
Showing Oleonitrile 
GC-MS of N18TG2 media extract after incubation with OA for 48 hours. Panel A shows the 
whole GC and zoom in of the peak of interest. Panel B shows the MS of the indicated GC peak 
(oleonitrile). Panel C shows the library database MS for oleonitrile. Panel D shows the difference 
between panels B and C. The cells were extracted as described in the methods section. The cells 
had been incubated with 2.5 mM OA in 0.25 mM BSA for 48 hours in this case before 
extraction. 
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Figure 2-18: GC-MS of SCP cell Extract after Incubation with OA for 48h, Showing Oleamide-TMS 
GC-MS of SCP cell extract after incubation with OA for 48 hours. Panel A shows the whole GC 
and zoom in of the peak of interest. Panel B shows the MS of the indicated GC peak (oleamide-
TMS). Panel C shows the library database MS for oleamide-TMS. Panel D shows the difference 
between panels B and C. The cells were extracted as described in the methods section. The cells 
had been incubated with 2.5 mM OA in 0.25 mM BSA for 48 hours in this case before 
extraction. 
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Figure 2-19: GC-MS of SCP Conditioned Media Extract after Incubation with OA for 24h, Showing 
Oleonitrile 
GC-MS of SCP media extract after incubation with OA for 24 hours. Panel A shows the whole 
GC and zoom in of the peak of interest. Panel B shows the MS of the indicated GC peak 
(oleonitrile). Panel C shows the library database MS for oleonitrile. Panel D shows the difference 
between panels B and C. The cells were extracted as described in the methods section. The cells 
had been incubated with 2.5 mM OA in 0.25 mM BSA for 24 hours in this case before 
extraction. 
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The amount of oleamide found in the conditioned media was similar to that found 
in the cells for all three cell lines at all time points (Figure 2-20). This could mean that 
these molecules may be in equilibrium with no specific transport protein to move them 
against a concentration gradient. Due to the high incubation concentration of OA (2.5 
mM), there was no observed tailing off of oleamide production in the SCP and N18TG2 
cells. The HEK-293 cells, however, did not show a significant increase in oleamide 
production after the first 12 hours (Figure 2-20). Another finding was that the SCP cells 
showed significantly higher amounts of oleamide (p<0.001 vs both N18TG2 and HEK-293 
cell data).  
 
 
Figure 2-20: Oleamide Production in SCP, N18TG2, and HEK-293 Cells after Oleic Acid 
Incubation 
For incubation conditions, see materials and methods section. Top panel shows the amount of 
oleamide found in all three cell lines and media extracts. Bottom panel is close-up showing 
N18TG2 and HEK-293 only. Error bars shown are ± standard deviation. 
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N18TG2 cells had similar endogenous levels of oleamide as the HEK-293 cells, 
but showed much higher amounts of oleamide after incubation with oleic acid. It is 
possible that HEK-293 cells are either less capable of taking up oleic acid from its BSA 
carrier, is less able to convert OA to oleamide, or that these cells process oleamide back 
into OA through the action of FAAH more quickly than do N18TG2. 
 
2.3.4 N-Acylglycine Assay Development 
 
Initial experiments with separating NAGs via the same SPE method as was used for 
the primary amide resulted in recovery rates of approximately 35% in the 30 nmol NAG 
range, and samples below about 10 nmol were not recovered from the SPE columns at 
all. As a consequence of these findings, TLC was explored as a different method of NAG 
isolation. In addition, the BSTFA derivitization was optimized because the standard 
curve for NAGs had a lower slope than for PFAMs and FFAs. 
2.3.4.1 Optimization of NAG Derivitization 
 
Because NAGs form four different reaction products: NAG-O-TMS, NAG-N-
TMS, NAG-(TMS)2 and an enyliminoacetate derivative (see Figure 2-3 and Figure 2-5) 
that make up three distinct peaks on the GC spectrum (NAG-O-TMS and NAG-N-TMS 
co-elute), the lower limit of detection for these molecules is higher than for molecules 
that generate fewer products. This is due to a minimal amount of the compound necessary 
to overcome the background in order to form an integrable GC peak. Therefore, it was 
necessary to optimize the BSTFA derivitization of NAGs in order to reach the lowest 
limit of detection for these compounds. Optimization of the reaction of BSTFA with 
NOG is shown in Figure 2-21. The optimal reaction conditions of those tested were 60
o
C 
for one hour in neat BSTFA.

  
                                                 

 PFAMs were found to have the same amount of derivitized products after 30 and 60 
minutes of reaction time under these conditions (data not shown), but for consistency the 
reaction times were made the same for all species throughout all ensuing experiments. 
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 Once reaction conditions were optimized, running conditions on TLC were 
optimized. Different TLC plates were tested (Figure 2-22) and different prewashing 
solvents tried (Figure 2-23), among other conditions. The best combination was found to 
be NP analytical TLC plates from EMD (Preparatory plates showed too much 
background interference from binder; data not shown), prewashed with 
chloroform:acetone 1:1. Finally, these conditions were used to show separation of HdG in 
N18TG2 media (Figure 2-24) and SCP cell extracts (Figure 2-25) that were spiked with 
15nmol HdG prior to solvent extraction, TLC purification, and GC-MS analysis. 
  
Figure 2-21: Integration of NOG under Various Reaction Conditions 
Different reaction conditions were tested for NOG derivitization with BSTFA. Left panel shows 
the integration of each of the 3 NOG species. Right panel shows the species added together.  
The amount derivitized was 2 nmol NOG. Reaction conditions were in neat BSTFA, BSTFA in 
toluene, BSTFA spiked with TCMS, and BSTFA spiked with potassium acetate. Times and 
temperatures are indicated in the legends. 
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Figure 2-23: Determination of Best Prewashing Solvent for TLC 
GC chromatogram of HdG run on TLC plates prewashed with various solvents. The vertical 
line passes through HdG-TMS and the left peak at 20.25 minutes is the enyliminoacetate 
derivative. Prewashing solvents were isopropanol (black) ether:acetic acid 99:1 (pink), 
chloroform: acetone 1:1 (blue) and none (brown). The recovery was not significantly 
improved, but background levels were lowered. Chloroform:acetone 1:1 showed the greatest 
decrease in background while maintaining the highest signal. 
 
Figure 2-22: Recovery of NAGs on Various TLC Plates 
GC chromatogram of 5 nmol HdG run on different normal phase TLC plates. The vertical line 
passes through the enyliminoacetate derivative of HdG. The peaks around 21 minutes are 
HdG-TMS. Plates were EMD brand (black; good recovery and low background), Dynamic 
with a thin plastic backing (pink; decent recovery but higher background), Dynamic with a 
normal glass backing (below the y-axis of this graph; low background but poor recovery) and 
Watman (brown; low background but mediocre recovery). Percent recoveries are shown in the 
bar graph on the right. The EMD plate showed the best recovery with the lowest background. 
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Figure 2-24: Recovery of HdG from Spiked N18TG2 Media  
N18TG2 conditioned media was spiked with 15 nmol HdG before running the NAG extraction 
and quantification assay. For a scheme of the successful NAG assay, see section 2.1.2.2 of 
methods. Panel A shows the full GC (top) and closeup of HdG-TMS (bottom). Panel B shows 
the MS of the GC peak indicated with a vertical line. Panel C shows the database MS for 
HdG-TMS from the synthesized standard. Panel D shows the difference between panels B 
and C. 
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Figure 2-25: Recovery of HdG from Spiked SCP Cells 
SCP cells were spiked with 15 nmol HdG before running the NAG extraction and quantification 
assay. For a scheme of the successful NAG assay, see section 2.1.2.2 of methods. Panel A shows 
the full GC (top) and closeup of HdG-TMS (bottom). Panel B shows the MS of the GC peak 
indicated with a vertical line. Panel C shows the database MS for HdG-TMS from the 
synthesized standard. Panel D shows the difference between panels B and C. 
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2.3.4.2 Extraction Efficiency for NAGs 
To test the robustness of our NAG extraction method, NOG and HdG were 
subjected to the extraction procedure. Percent recoveries were 86% ± 18% and 91% ± 
16%, respectively (Figure 2-26). 
 
 
2.4 Discussion 
 
Metabolite analysis revealed the presence of endogenous oleamide in all three cell 
lines tested: HEK-293, N18TG2 and SCP. Oleamide was also detected in conditioned 
 
Figure 2-26: Extraction Efficiency of NAGs 
Extraction efficiency experiments were performed the same way as 
experimental samples (Figure 2-2). NAGs were dried down, extraction 
solvents added before sonication. Organic layers were combined and dried 
down. TLC was performed and a second plate run in tandem that was dyed 
to determine NAG position. Spots were scraped into anhydrous 
isopropanol, sonicated, centrifuged and the supernatant filtered in a 0.22µm 
syringe filter. The silica was re-sonicated, spun and filtered. Isopropanol 
supernatants were combined, spiked with HdA internal standard, and dried 
down before derivitization with BSTFA and analysis on GC-MS. The error 
bars are standard deviation from multiple extractions. 
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media (Table 2-3). Finding similar levels of oleamide in cell and conditioned media 
samples throughout all cell lines means that these molecules may be in equilibrium with 
no specific transport protein to move them against a concentration gradient. In addition, 
the production of oleamide increased after incubation with oleic acid. The previously 
reported amount of oleamide in N18TG2 cells (55 pmol/10
7
 cells)
23
 is in fair agreement 
with measurements reported here (119 pmol/10
7
 cells). However, the amount reported by 
Sultana was much higher (16.67 pmol/cell)
14
 and may be due to contamination to slip 
additives (see footnote on  p.34). We have taken precautions to minimize and test for 
these slip additives, and detailed procedures and discussion of this can be found in 
Chapter 3.  
 
SCP cells had approximately 45-50 times as much endogenous oleamide as the 
other two cell lines, and at least 10 times as much lines after incubation with OA. This is 
consistent with the knowledge that choroid plexus produces cerebrospinal fluid,
68
 and 
PFAMs have been found in CSF.
4,64,65
 In light of the expression results in which the 
oleamide-degrading FAAH was not found in SCP cells, the ability of the choroid plexus 
to harbor and excrete these molecules in higher concentration is commensurate with the 
lack of detectable FAAH expression (see Chapter 4 for expression results and further 
discussion). 
 N18TG2 cells had similar endogenous levels of oleamide as the HEK-293 cells, 
but showed much higher amounts of oleamide after incubation with OA (Figure 2-20). It 
is possible that HEK-293 express less fatty acid transport proteins,  but another 
possibility is that these cells might be able to process the amide back into its 
Table 2-3: Endogenous Levels of Oleamide in Cells and Media 
Cell line 
Endogenous 
oleamide 
SCP cells 6367 
media 4087 
N18TG2 cells 119 
media 208 
HEK cells 154 
media 122 
Values are average pmol/107 cells  
Endogenous amount refers to oleamide extracted, purified 
and quantified from cells and media under normal growing 
conditions without OA. 
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corresponding fatty acid through the action of FAAH more quickly than is N18TG2, a  
possibility made more likely based on the observed increase in oleamide from 0 to 12 
hours. A high level of hydrolysis would prevent accumulation of oleamide, as is seen in 
the HEK-293 samples. This is consistent with the role the kidney plays in detoxification.  
A TLC separation method for NAGs was developed because the SPE method 
successfully employed to identify PFAMs proved unsuitable for the small amounts of 
NAGs extracted from cultured cells. The TLC media performed well as a way to separate 
trace NAGs in spiked cell and media samples for identification, with recovery rates of 
79% (HdG) and 84% (NOG, data not shown). Although liquid chromatography-hybrid 
quadrupole time of flight MS has greater sensitivity and can handle a more complex 
sample, GC-MS is less expensive and more widely available than the LC-QqTOF and 
related instruments. No recoverable endogenous amounts were found with the number of 
cells that were tested for these experiments. For successful use of this assay on a cell 
sample, refer to Chapter 5. 
The extraction efficiencies of both the PFAM and NAG assays were fairly high 
(82-101%), and the limits of detection 1.5 nmol for NAGs and 0.5 nmol for oleamide. 
These assays were used to demonstrate the conversion of OA to oleamide in the three 
model cell lines and recover NAGs from spiked cell and conditioned media extracts. 
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3 Metabolic Profiling of Primary Fatty Acid Amides in SCP and 
N18TG2 cells 
3.1 Review: Primary Fatty Acid Amides as Signaling Molecules 
 
The first five primary fatty acid amides (PFAMs) to be isolated from a 
mammalian source were found 1989 in luteal phase plasma by Arafat et al: palmitamide, 
palmitoleamide, oleamide, elaidamide and linoleamide.
5
  At the time of their discovery, 
the biological function of the mammalian PFAMs was unknown.  Several years later, 
oleamide was discovered to accumulate in the CSF of sleep-deprived cats and was 
misnamed cerebrodiene.
17
 Soon after, oleamide was correctly identified in other studies 
where it was shown to accumulate in the CSF during sleep deprivation and induce 
physiological sleep and hypomotility in mammals.
15,18-22
 In addition, brain oleamide 
levels in the ground squirrel were found to be ~2.5-fold higher in hibernating animals 
relative to that found in non-hibernating animals.
23
 Since these initial reports, more than 
300 papers have been published about oleamide and other mammalian PFAMs. The 
purpose of this review is to summarize what is known about the mammalian endogenous 
PFAMs, including both in vitro and in vivo studies. An overview of PFAMs isolated from 
mammalian sources and endogenous amounts is given in Table 3-1. 
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Due to the early understanding oleamide’s neurological actions, it has become the 
model PFAM and has been studied far more extensively than any of the other PFAMs. 
Oleamide has been found to modulate gap junction communication in glial cells
15,27
 
tracheal epithelial cells,
45
 seminiferous tubule cells,
46
 and fibroblasts,
47
  modulate 
memory processes,
30
 increase food intake,
48
 depress body temperature and locomotor 
 
Table 3-1: Quantification and Location of Endogenous Mammalian PFAMs 
PFAM Organism Location in Organism Amount Ref 
Myristamide  
(C14:0) 
Human Meibomian secretiona Not reported 6 
Palmitamide 
(C16:0) 
Human Meibomian secretiona Not reported 6 
Plasma 13.8 nmol/ml 5 
Rabbit Brain 11.4-25.6 nmol/g 13 
Heart 5.7-6.8 nmol/g 13 
Palmitoleamide 
(C16:1 cis-9) 
Human Plasma 15.6 nmol/ml 5 
Stearamide 
(C18:0) 
Human Meibomian secretiona Not reported 6 
 Plasma Not reported 25 
Rabbit Brain 12.4-15.6 nmol/g 13 
 Heart 5.0-7.1 nmol/g 13 
Elaidamide 
(C18:1 trans-9) 
Human Plasma 13.1 nmol/ml 5 
Oleamide 
(C18:1 cis -9) 
Cat CSF 10-50 nmol/ml 17,18 
Human Plasma  5 
Mouse N18TG2 cells 55 nmol/10
10cells 68,69 
Rabbit Brain 82-99 nmol/g 13 
Heart 16-26.6 nmol/g 13 
Rat CSF 0.16  nmol/ml 71 
 Plasma 0.035 nmol/ml 71 
Squirrel  Brain 0.91-2.3 nmol/g 23 
Linoleamide 
(C18:2 cis,cis-9,12) 
Human Plasma 7.8 nmol/ml 5 
Eicosenoamide 
(C20:1cis-13) 
Rabbit Brain Trace  (<1.8nmol) 13 
Erucamide 
(C22:1cis-13) 
Human Meibomian secretiona Not reported 6 
Mouse Dorsal air sac Not reported 56 
Pig Plasma 0.011 nmol/g 55 
Lung 0.043 nmol/g 55 
Kidney 0.0089 nmol/g 55 
Liver 0.0036 nmol/g 55 
Brain 0.0018 nmol/g 55 
Rat Corneal micropocket Not reported 56 
aThe validity of this work is under debate. While the MS of meibomian secretions 
show several PFAMs in the Nichols paper, other commonly observed compounds, 
including cholesterol esters and wax esters, were not present.
7,72
 In addition, other 
studies examining the lipid content of meibomian gland secretions did not find 
PFAMs.
73
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activity,
25,31,32,49
 act as an analgesic,
49
 reduce anxiety,
49
 and stimulate Ca
2+
 release.
32
 One 
of its most potent effects is as a vasorelaxant, with an EC50 of 1.2 µM.
50
 
The targets on which oleamide act have been found to include depressant drug 
receptors,
35,37,49
 and it has been found to act as an allosteric activator for serotonin (5-HT) 
receptor subtypes (5-HT1A, 5-HT2A, 5-HT2C, and 5-HT7)
8,9,29,57,58
 and for the GABAA 
receptor.
34-36,49,59,60
 In addition to these neurotransmitter-type targets, oleamide has been 
shown to bind to CB1 cannabinoid receptors directly,
61
 indicating that its cannabinoid-
like actions may not be due to the “entourage effect” alone, as was initially 
hypothesized.
62
 The entourage effect arises when one compound increases the effect of 
another compound by inhibiting its inactivation (in this case, as a competitor for 
degradation by FAAH hydrolysis or cellular uptake against other cannabinoids such as 
anandamide). The exact meaning of these data is under debate, as the concentrations 
required for cannabinoid binding may not be in the physiological range.
43,63
 Regardless of 
its role as an endogenous cannabinoid, oleamide does appear to have cannabinomimetic 
effects by increasing the amount of available anandamide through the entourage 
effect.
64,65
 An investigation showed that both oleamide and anandamide impaired 
memory in FAAH knockout mice,
51
 indicating that oleamide acts independently of an 
effect on this enzyme. N-Oleoylglycine (NOG) was recently found to have oleamide-like 
effects without affecting the amount of oleamide in blood plasma levels of rats.
66
 The 
amount of NOG required to produce a maximum hypothermic response was half the 
amount of oleamide required to produce the same response. In addition, oleamide-
induced vasorelaxation was not affected by the presence of FAAH inhibitors.
67
 The 
implications of these findings are unclear. 
  Although oleamide has served as the model PFAM for analysis as a CNS 
signaling molecule and much has been uncovered about its physiological action, it is not 
necessarily the most abundant nor the most metabolically active PFAM. Many of the 
effects of other PFAM molecules have been found to be similar to those evoked by 
activation of the cannabinoid receptor systems, which include hypothermia, hypoactivity, 
analgesia, and catalepsy.
70
 The known function of PFAMs that have been isolated from 
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mammalian sources to date is summarized in Table 3-2, many of whose function(s) have 
mainly been studied in vitro. 
 
 A recent article by Nichols et al. indicated the presence of several PFAMs from 
human meibomian grand secretions.
6
 The validity of these findings is under debate. 
While the MS of meibomian secretions show several PFAMs in the Nichols paper, other 
commonly observed compounds, including cholesterol esters and wax esters, were not 
Table 3-2: Occurrence and Role of PFAMs in Mammals 
Compound Structure Organism Known Significance Ref 
Myristamide 
(C14:0)  
 
Human Unknown 6 
Palmitamide 
(C16:0) 
 
Human, 
Rabbit, 
Mousea, 
Sheepa 
Unknown, modestly attenuates 
seizures in mice, modest FAAH 
inhibitor 
5,6,11-
13 
Palmitoleamide  
(C16:1 cis-9) 
 
Human, 
Mousea, 
Sheepa 
Gap junction communication, 
serotonin receptor binding 
5,10 
Stearamide 
(C18:0) 
 
Human, 
Rabbit 
Unknown 6,13,25 
Elaidamide  
(C18:1 trans-9) 
 
Human Less active than oleamide, but 
induces sleep, inhibits epoxide 
hydrolase and phospholipase A2 
5,18,24,
26 
Oleamide 
(C18:1 cis -9) 
 
Human 
Mouse,  
Rabbit, 
Rat, 
Squirrel, 
Sheepa 
Sleep, memory, thermal and 
locomotor regulation, gap 
junction communication, Ca2+ 
flux, vasodilatation, hunger, 
anxiety, serotonin receptor 
binding, erg current inhibition 
5,6,13,1
5,17,18,
21-
23,25,27
-52 
Linoleamide  
(C18:2 cis,cis-
9,12)  
 
Human, 
Rabbit, 
Mousea, 
Sheepa 
Sleep and Ca2+ flux regulation, 
erg current inhibition, epoxide 
hydrolase and phospholipase A2 
inhibition, gap junction 
communication, FAAH 
substrate, serotonin receptor 
binding 
1,10,13-
15,20,24
,26,53 
Eicosenoamide  
(C20:1cis-13)  
Rabbit Unknown 13 
Erucamide  
(C22:1cis-13)  
 
Cat, Cow, 
Human, 
Rat, Pig, 
Mouse 
Fluid balance, angiogenesis 6,54-56 
aDemonstrated in this study for N18TG2 (mouse) or SCP (sheep) and not in previous studies. 
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present.
72
 In addition, other studies examining the lipid content of meibomian gland 
secretions did not find PFAMs.
73
 Although oleamide, erucamide and stearamide are 
known slip additives
74
 added to lubricate plastics during manufacturing, the other PFAMs 
found in this study have not been reported as plasticizers, one of which is myristamide 
(C14:0).
6
 This is the first report of myristamide from a mammalian source and its 
function, other than its potential to promote tear film stability and in maintaining a 
smooth refractive surface of the eye in meibomian secretions, is completely unknown. It 
does show some antibacterial properties
75
 and has been demonstrated as a substrate for 
fatty acid amide hydrolase (FAAH) in vitro.
2,14
 
 Palmitamide (C16:0) was also reported in human meibomian gland secretions,
6
 
but other studies confirm its presence as a mammalian PFAM in human leutal phase 
plasma in ten of sixteen female subjects
5
 and in rabbit brain and heart
13
 (see Table 3-1). 
Again, these are the only reports of palmitamide in mammals and its role is mostly 
speculative. Studies showed that palmitamide is a modest inhibitor of Fatty Acid Amide 
Hydrolase (FAAH) in vitro
2,7,12
 and modestly attenuates seizures in mice,
11
 but more 
work is necessary to explore its potential role as a mammalian signaling molecule. 
 Palmitoleamide (C16:1 cis-9) has only been reported in one study as an 
endogenous compound and its in vivo role remains mostly unexplored.
5
 An in vitro study 
showed that palmitoleamide is able to block gap junction communication in mouse glial 
cells as well as oleamide does,
15
 and can potentiate the 5-HT1A serotonin receptor after 
incubation with serotonin almost as well as can oleamide
10
 (Table 3-3). These roles are 
not surprising given the known function of oleamide in binding to 5-HT receptors and in 
blocking gap junction communication. Oleamide and palmitoleamide differ by only two 
carbons in acyl chain length, and further studies may demonstrate additional similarities 
in function. 
Elaidamide (C18:1 trans-9), while only different from oleamide as a trans- isomer 
at the double bond, does not have as much biological activity as oleamide. Because of its 
close structural relationship to oleamide, it has been used in many studies to demonstrate 
specificity of receptors and enzymes for the cis isomer oleamide, and an overview of 
oleamide activity as compared to other PFAMs (where numerical values were available) 
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is given in Table 3-3. Elaidamide does not attenuate gap junction communication in 
mouse glial cells as oleamide does,
15,27
 and elaidamide does not serve as an effective 
binder for 5-HT1A or 5-HT7 receptors as palmitoleamide (5-HT1A only), linoleamide, and 
oleamide do.
8-10
  Elaidamide does not modulate GABA-evoked current and is unable to 
modulate voltage-gated Na
+
 channels as oleamide does.
35
  
Two enzymatic studies have shown function for elaidamide: it was found to be a 
potent inhibitor of both human and rat microsomal epoxide hydrolase through 
simultaneous competitive and noncompetitive inhibition,
24
 and it is also an excellent 
inhibitor of phospholipase A2.
26
 Cravatt et.al. showed that elaidamide can induce sleep, 
but only half as long as was observed for oleamide (1 hour as opposed to 2 for a 10 mg 
dose in rat),
18
 even though elaidamide was not found to be an agonist for CB1 receptors 
transfected into HEK-293T cells.
76
 This action may be due to binding to GABA 
receptor(s). Elaidamide was found to inhibit binding to a voltage-gated Na
+
 channel of an 
agonist, but not nearly effectively as was oleamide.
37
 Similarly, elaidamide was found to 
inhibit repetitive firing of rat embryonic cultured cortical pyramidal cells, but oleamide 
was 3 times as effective at doing so.
35
 Elaidamide is biologically active but not nearly to 
the extent as is its cis isomer. Given the fact that the trans fatty acids are not naturally 
found except in some dairy products and in the meat of ruminants,
77
 the lowered 
biological activity of elaidamide is concomitant with the fact that the enzymes evolved 
alongside the cis isomer almost exclusively. There has been only one report of elaidamide 
as an endogenous mammalian PFAM, 
5
 and it is likely to have come from a dietary 
source.  
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Stearamide (octadecanamide, C18:0) has been found in human blood plasma
25
 and 
in rabbit brain and heart,
13
 but no true in vivo bioactivity has yet been identified; it has 
mostly been studied in tandem with oleamide to compare the alkyl chain with its 
unsaturated bioactive cousin much the way elaidamide has been studied as a trans isomer 
Table 3-3: Relative Activity of PFAMs on Various Targets 
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Ref 
5-HT potentiation  
      5-HT7  1 0.86      0.91  8 
      5-HT2C  1 6.67 -17.3       9 
      5-HT1A 1 0.2 0.32 0.96   0.88   10 
      5-HT2A 1 0 0 0.44   -0.16 0.32 0.16 10 
erg inhibition 1   1      24 
FAAH activity 1
c   1.54      1 
1d    0.33 0.14    2 
1e    0.93 0.47    7 
GABAA 
potentiation 
1 0        35 
Gap junction 
inhibition
a
 
1 0 0 1   1 0 0 15 
mEH 
inhibition 
1 0.98 0.063 1.56      24 
PLA2 
inhibition
b
 
1 0.5  0.5      26 
Sleep induction 
(time of sleep) 
1 0.5        18 
SRF inhibition 1 0.33        35 
Relative activity. Activity values for oleamide are set to 1 and activities of other compounds 
displayed as relative to oleamide activity. Negative values are for negative potentiation 
(receptor inhibition). 
Abbreviations: 5-HT, 5-hydroxytryptamine; erg, ether-à-go-go-related gene; mEH, 
microsomal epoxide hydrolase; PLA2, phospholipase A2; SRF, sustained repetitive firing 
(subsequent to a primary action potential) of pyramidal cells.  
aValues shown are for study with 50 µM PFAM. 20 and 100 µM studies were also done.15 
bValues shown are for porcine pancreatic PLA2. Several other species’ were also studied.
26 
cfrom mouse N18TG2 cells 
drat recombinant 
ehuman recombinant 
 
91 
 
 
 
of oleamide. Stearamide is not as active as oleamide on 5-HT receptors,
10
 and even shows 
the opposite effect on 5-HT2C receptors to decrease, rather than increase, the efficacy of 
receptor activation
9
 (Table 3-3). It also does not attenuate gap junction communication in 
mouse glial cells
15,27
 and is 15 times less effective than oleamide as a microsomal 
epoxide hydrolase inhibitor.
24,78
 Stearamide did not produce a decrease in core body 
temperature after intraperitoneal administration to rats as did oleamide and N-
oleoylglycine.
66
 The activity of stearamide relative to other PFAMs is also included in 
Table 3-3. Elaidamide is mildly biologically active, but stearamide even less so. 
Aside from oleamide, linoleamide (C18:2 cis,cis-9,12) is the most studied 
endogenous PFAM, and is found to have many of the same activities as oleamide (Table 
3-3). It inhibits microsomal epoxide hydrolase as well as oleamide does,
24
 and inhibits 
gap junction communication in glial cells almost as well as does oleamide.
15
 Linoleamide 
was found to induce calcium release from the endoplasmic reticulum of renal tubular 
cells.
20
 Both oleamide and linoleamide were found to block the erg (ether-à-go-go-
related gene) current equally well in rat pituitary cells.
53
 Linoleamide is an excellent 
competitive inhibitor for phospholipase A2, as is oleamide,
26
 but linoleamide is a better 
inhibitor and substrate for FAAH than is oleamide.
1,14
 It was found to potentiate the 5-
HT1A receptor nearly as well as oleamide, but for the 5-HT2A receptor it demonstrated 
only 44% of oleamide’s potentiation.10 It is interesting that one fewer double bond 
(stearamide) results in very little biological function, while one greater double bond 
(linoleamide) does not result in significant change in biological function compared to that 
of oleamide. 
The least well-known of the endogenously isolated PFAMs is eicosenoamide 
(C20:1 cis-13), which was observed in trace amounts in rabbit brain.13 Eicosenoamide 
has shown some potentiation of 5-HT receptors,
8,10
 but it does not inhibit gap junction 
communication by glial cells.
15
 Interestingly, the 11 isomer is an excellent inhibitor. 
Erucamide (C22:1cis-13)  does not have a significant effect on the binding affinity 
of 5-HT7 receptors to 5-hydroxytryptamine
8
 and does not inhibit gap junction 
communication as oleamide does.
15
 It does, however, have its own biological function 
and has been found in many places
55,56
 (Table 3-1),  including porcine blood plasma, 
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where it was found to regulate fluid volumes in various organs.55 The major bovine 
mesentery angiogenic lipid was identified as erucamide, and 2 µg was found to induce 
angiogenesis.
56
 Mitchell et al. showed that a sustained release of erucamide from a 
polymer matrix has a dose-dependent angiogenic effect on skeletal muscle regeneration 
after an injury,
54
 and it is speculated that this control of water content combined with 
repair of circulation may have a synergistic effect on the regenerative process.
55
   
Although many PFAMs have been known for two decades, little is known about 
their action in vivo except for oleamide. What is known, however, points to an interesting 
role for these molecules in signaling and demonstrates that PFAMs can belong to this 
class of bioactive molecules known as lipid messengers. 
The biosynthetic and catabolic mechanisms of these long-chain PFAMs are 
discussed briefly in Chapter 1 and at length in Chapter 4.  It has already been shown that 
N18TG2 cells contain oleamide
69
 and convert oleic acid to oleamide,
68,69
 results which 
were confirmed and expanded by quantifying over a time course in Chapter 2. These 
kinds of studies on PFAM metabolism have not been expanded to any of the other acyl 
groups beyond (18:1 cisΔ9). Since some of these PFAMs have been found in mammalian 
sources, it is likely that endogenous amounts of PFAMs other than oleamide could be 
found in N18TG2 cells. There are many additional questions that might be answered 
through studies of other PFAMs: are other FFAs converted to their corresponding 
amides? Can non-natural FFAs be converted to their amides? Do the cells secrete other 
PFAMs? Do the cells convert certain FFAs more quickly or in more abundance than 
others, and is there a recognizable trend in chain length, degree of unsaturation, or 
cis/trans isomers? Does the fingerprint of PFAM formation follow the enzyme substrate 
kinetics of the proposed biosynthetic and hydrolyzing enzymes? Are the related 
compounds, N-acylethanolamines (NAEs) converted to PFAMs? Is there a difference in 
any of these trends in different cell lines?  
In addition to N18TG2 cells, which are known to contain all the enzymatic 
machinery to convert oleic acid directly to oleamide,
68,69,Chapter 2
 the sheep choroid plexus 
(SCP) cells were chosen. SCP cells had approximately 45 times more endogenous 
oleamide than was found in the other two cell lines, N18TG2 and HEK-293. In addition, 
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after incubation with oleic acid, SCP cells still had at least 10 times as much oleamide as 
the other two cell lines.  
In this study, we examined the metabolism of a panel of fatty acids to their 
respective PFAMs in N18TG2 and SCP cells. The FFAs chosen correspond to 
endogenously found PFAMs: palmitic acid (PA), palmitoleic acid (POA) elaidic acid 
(EA), and linoleic acid (LOA). Data from the oleic acid (OA) incubations presented in 
Chapter 2 is included herein for discussion purposes. In addition, two non-natural PFAM 
precursors were studied: tridecanoic acid (TDA) and tridecanoylethanolamine (TDEA) 
(see Section 3.2) 
Some PFAMs, particularly oleamide and erucamide, have been found as slip 
additives in polyethylenes,
74,79,80
 plasticizers whose presence has brought under debate 
the finding of PFAMs in meibomian secretions.
72
 A recent article demonstrated the 
extraction of erucamide from pipette tips by DMSO.
79
 This must be taken into 
consideration when reviewing older literature and when preparing to perform PFAM 
extracts. Care has been taken to test for the presence of these slip additives in this study 
(see Section Error! Reference source not found.). 
3.2 Formation of PFAMs from Two Distinct Pathways: FFA and 
NAE 
 
The formation of PFAMs from an N-acylglycine (NAG) through the action of 
bifunctional peptidylglycine α-amidating monooxygenase (PAM) has been studied in 
vitro, with kinetic constants comparable to peptide precursor substrates.
4,81
 In addition, 
chemical inhibition of PAM by trans-4-phenyl-3-butenoic acid in N18TG2 cell culture 
resulted in the accumulation of N-oleoylglycine when these cells were grown in the 
presence of oleic acid
68
 (see also Chapter 5). 
The formation of the NAGs, however, is much more controversial. There have been 
two main pathways proposed, as seen in Figure 3-1. More details on the biosynthetic 
mechanism(s), including an in-depth discussion of potential enzymes, are discussed in 
Chapter 4. 
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 Activation of a fatty acid through the formation of a coenzyme A (CoA) 
intermediate is one obvious and much-hypothesized possibility for acyl chain activaction 
before glycination.
4,68,81,82
 There are several acyl-CoA synthetases known to perform this 
fundamental metabolic chemistry,
83,84
 and several candidates to perform glycination of an 
acyl-CoA, including acyl-CoA:glycine N-acyltransferase,
85,86
 bile acid-CoA:amino acid 
N-acyltransferase,
87
 and cytochrome c.
88,89
 The glycination pathway is shown in purple in 
Figure 3-1. 
 
 Figure 3-1: Formation of NAG and PFAM by Two Metabolic Pathways 
The purple arrows show one pathway with successive CoA-ylation and glycination of the FFA; 
the “glycination pathway.” The brown arrows show successive oxidation of an NAE to form 
the NAG; the “NAE oxidation pathway.” The NAG is converted to a PFAM  by PAM. The two 
pathways are joined by the action FAAH, which is able convert the NAE into a FFA. More 
details, including a discussion of potential metabolic enzymes, are in Chapter 4. 
Abbreviations: FFA, free fatty acid; FAAH, fatty acid amide hydrolase; NAE, N-
acylethanolamine; NAG, N-acylglycine; PAM, peptidylglycine α-amidating monooxygenase; 
PFAM, primary fatty acid amide 
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 Sequential oxidation of an N-acylethanolamine (NAE) is another hypothesized 
mechanism for NAG biosynthesis, and is indicated in brown in Figure 3-1. In cellulo 
work has demonstrated the oxidation of NAEs to NAGs in RAW 264.7, C6 glioma and 
Chang liver cells.
90,91
 Ivkovic et al. showed that an alcohol dehydrogenase, ADH3, is 
capable of oxidizing an NAE to its acylglycinal,
92
 which could then be oxidized to the 
NAG by an aldehyde dehydrogenase, and  Aneetha et al. showed that ADH7 is capable 
of oxidizing an NAE fully to a NAG in vitro.
93
 See Chapter 4 for more information on 
NAE oxidation to NAGs. 
These pathways are not mutually exclusive; Bradshaw et al. showed that an NAE 
could be converted to its corresponding NAG either through successive oxidation or 
through a glycine conjugation (both purple and brown pathways, Figure 3-1) in one cell 
line.
90
 In this study, we examined the metabolism of two exogenous acyl compounds, 
TDEA and TDA, to compare the rates of conversion to tridecanamide in both the SCP 
and N18TG2 cells and gain some kinetic insight into the competing metabolisms in these 
two cell lines. 
 
3.3 Materials and Methods 
3.3.1 Materials 
Elaidic and palmitoleic acids were from Fisher (Pittsburgh, PA). Linoleic and 
palmitic acids, 6-thioguanine and fatty acid-free BSA were from Sigma (St. Louis, MO). 
FBS was from Atlanta Biologicals (Lawrenceville, GA). Penicillin/streptomycin, EMEM 
and DMEM were from Mediatech Cellgro (Manassas, VA). BSTFA and silica were from 
Supelco (St. Louis, MO).  Mouse neuroblastoma N18TG2 cells were from DSMZ 
(Deutsche Sammlung von Mikrooganism und Zellkuturen GmBH). SCP cells were from 
American Type Culture Collection (Manassas, VA). Heptadecanoic acid, D33 was from 
C/D/N isotopes (Pointe-Claire, Quebec). 
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3.3.2 Standard Synthesis 
3.3.2.1 Acyl Chloride Synthesis 
The free fatty acid (FFA) and thionyl chloride were combined neat in a 1:2 molar 
ratio under nitrogen while stirring (Equation 3-1). The reaction was allowed to proceed 
under reflux at 50
o
C for 30 minutes. Excess unreacted thionyl chloride was removed by 
heating or under vacuum until the solution no longer produced gas. 
 
3.3.2.2 PFAM Synthesis 
For use as a standard, a series of PFAMs were synthesized. Commercially 
available acyl chlorides were used or, where not available, synthesized as above. The 
PFAM was prepared similar to Fong et. al.
94
 The undistilled acyl chloride was added 
dropwise to ice cold concentrated NH4OH (29% NH3) while stirring and in a ratio of 2.5 
ml acyl chloride:15 ml NH4OH (see Equation 3-2). Precipitation was allowed to go to 
completion. Excess NH4OH was removed by filtering with cold water. The sample was 
allowed to dry and stored at -20
o
C flushed under nitrogen. For GC-MS of synthesized 
PFAMs, see Appendix B.  
 
 
 
Equation 3-2: Synthesis of PFAM from Acyl Chloride 
 
 
 Equation 3-1: Synthesis of Acyl Chloride from a Fatty Acid 
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3.3.2.3 TDEA Synthesis 
 
Tridecanoyl chloride was synthesized as in Section 3.3.2.1. The N-
tridecanoylethanolamine (TDEA) was synthesized as shown in Equation 3-3 as follows: 
triethylamine base, acetonitrile, and ethanolamine were combined in a 1.5:1:1 ratio (vol), 
flushed under nitrogen, and left stirring under nitrogen at room temperature. The acyl 
chloride taken up in a small volume of acetonitrile and added dropwise to the 
ethanolamine mixture and left to stir overnight at room temperature.  
The N-acylethanolamine reaction was taken to a yellow solid in vacuuo, dissolved 
in a small volume warm ethanol, and recrystalized by adding cold H2O. The 
crystallization was allowed to continue on ice for approximately 30 min, then the solid 
was filtered in Buchner funnel and washed with ice cold H2O. The product was allowed 
to dry, flushed with nitrogen and stored at -20
o
C. For a GC-MS of the synthesized TDEA, 
see Appendix B. 
 
 
3.3.3 Fatty Acid-BSA Mixture 
Fatty acids were dissolved in ethanol and saponified with excess NaOH (~2x 
molar concentration), dried under vacuum and dissolved in phosphate-buffered saline 
(PBS) to make a 25 mM solution.  Sample was then heated in 49
o
C water bath for 5 
minutes

 before adding 2.5 mM BSA. Sample was stirred at room temperature for 4 
hours, sterile-filtered, and stored at -20
o
C. The fatty acids that were used are listed in 
                                                 
 

 BSA forms globules above 500C that make the solution impossible to sterile-filter through a 0.22 µm 
filter 
 
 Equation 3-3: Synthesis of 3-
13
C,
15
N-Oleoylethanolamine 
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Table 3-4. An N-acylethanolamine, tridecanoylethanolamine (TDEA) solution was made 
similarly, but an additional sonication step was added prior to addition of BSA. 
 
3.3.4 Cell Culture and Fatty Acid Incubation 
All cells were grown in 225 cm
2
 culture dishes. N18TG2 cells were grown in 
DMEM supplemented with 100 µM 6-thioguanine. SCP cells were grown in EMEM 
supplemented with 100 µM sodium pyruvate.  Both cell types were gown with 100 
I.U./ml penicillin, 1.0mg/ml streptomycin and 10% FBS at 37
o
C and 5% CO2. Cultures 
were grown to 75-90% confluency, culture medium removed and cells washed with PBS. 
After washing, the culture medium was replaced with media containing 0.5% FBS and 
10% fatty acid-BSA mixture for a final concentration of 2.5 mM fatty acid in 0.25 mM 
BSA. Three T-225 cm
2
 flasks were used for each time point, for a total of 12 flasks for 
each experiment. After 0, 12, 24, or 48 hour incubation, media was collected, cells 
washed with PBS and trypsonized. An aliquot was taken for counting on a 
hemacytometer with trypan blue. Cells were centrifuged and the pellet and conditioned 
media stored at -80
o
C. 
Zero hour samples were collected without addition of fatty acid-BSA mixture or 
0.5% FBS media but collected in 10% FBS media under normal growing conditions. 
These cells and the conditioned media were also stored at -80
o
C. Several controls were 
run with incubation for 48 hours in media containing 0.5% FBS and 0.25 mM BSA (see 
section Error! Reference source not found.). 
Table 3-4: Fatty Acids Used for Incubation 
Fatty Acid  
Tridecanoic Acid (TDA) C13:0 
Palmitic Acid (PA) C16:0  
Palmitoleic Acid (POA) C16:1 (cis-9)  
Linoleic Acid (LOA) C18:2 (cis,cis-9,12)  
Oleic Acid  (OA) C18:1 (cis-9)  
Elaidic Acid (EA) C18:1 (trans-9)  
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3.3.5 Metabolite Extraction 
Metabolites were extracted from cells similar to Sultana and Johnson (2006).
95
 4 
ml methanol was added to cell pellets and samples were sonicated for 15 minutes at room 
temperature. Samples were centrifuged at 5000 rpm for 10 min, and the supernatant 
separated from the pellet, dried under N2 in a warm water bath at 40-50
o
C. The pellet was 
re-extracted with 4 ml 1:1:0.1 (v/v/v) chloroform:methanol:water, sonicated for 10 min, 
vortexed 2 min and centrifuged 10 min at 5000 rpm. Supernatant from this step was 
added to the dried supernatant from the previous step and dried under N2 at 40-50
o
C. The 
pellet was re-extracted with 4.8 ml chloroform:methanol 2:1 (v/v) and 800 µl 0.5 M 
KCl/0.08 M H3PO4, sonicated 2 min, vortexed 2 min, and centrifuged 10 min at 5000 
rpm. The lower lipid phase was added to the dried supernatant from the previous steps 
and dried under N2 at 40-50
o
C.  
Metabolite extraction from conditioned media was similar. After spinning down 
to remove any cells, the entire volume of media collected from three flasks (~135 ml) 
was subjected to solvent extraction. The first two extractions were with 15 ml 
chloroform:methanol 2:1 and the second two extractions with 15 ml chloroform:methanol 
2:1 and 2.4 ml 0.5 M KCl/0.08 M H3PO4. No sonication was performed, and protein 
layers were condensed by centrifugation for 30-45 min at 10,000 rpm. Organic lipid 
phases were also combined and dried under N2 at 40-50
o
C or in vacuuo. 
3.3.6 Solid Phase Extraction 
Silica columns (0.5 g) were washed with n-hexane and run essentially as 
described by Sultana and Johnson.
95
 Lipid extracts were taken up in 100 µL n-hexane and 
added to washed silica columns. The mobile phase was run without positive pressure as 
follows: 4 ml n-hexane, 1 ml 99:1 hexane:acetic acid, 1 ml 90:10 hexane:ethyl acetate, 1 
ml 80:20 hexane:ethyl acetate, 1 ml 70:30 hexane:ethyl acetate, 1.5 ml 2:1 
chloroform:isopropanol, 0.5 ml methanol. The last two fractions were combined and 
dried down under N2 at 40-50
o
C. An internal standard, heptadecanoic acid, D33 (3 nmol), 
was added and dried before derivitization. 
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3.3.7 Sample Derivitization 
Trimethylsilylation was achieved using 100µL BSTFA (N,O-
bis(trimethylsilyl)trifluoroacetamide). Samples were flushed with dry N2, BSTFA added, 
flushed briefly again, and allowed to react at 55-60
o
C for 1 hour before running on GC-
MS. 
3.3.8 GC-MS 
All separations were performed using a Shimadzu QP-5000 GC-MS. Separations 
were achieved on a J & W Scientific (Folsom, CA) DB-5 column (0.25 mm x 30 m) in 
splitless mode. The GC temperature program was 55-150
o
C at 40
o
C/min, hold at 150
o
C 
for 3.6 min, ramp at 10
o
C/min to 300
o
C, and hold for 1 min. The transfer line was held at 
280
o
C and the injection port at 250
o
C throughout the separation.  Helium was used as the 
carrier gas, at a flow rate of 0.9 ml/min.  The mass range was 35-450 amu with a scan 
speed of 2000. The solvent cut time was set to 7 min. 
 Samples were injected twice; 33.3% of the sample volume, followed by 50% of 
the remaining sample volume, such that 1 nmol internal sample was in each sample run. 
After running a set of experimental samples through the GC-MS (0, 12, 24 and 48 hours, 
each injected twice), one of the 24 or 48 hour samples was dried down, spiked with the 
PFAM of interest, re-dried down, re-derivitized with BSTFA, and re-run on the GC-MS 
to validate sample retention times. Figure 3-2 shows an overlay of an experimental and a 
spiked sample. 
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3.3.9 Controls 
Solvents were run through all the same glassware and plasticware as cell and 
media samples and were subjected to sonication, solid phase extraction, and derivitization 
to test for contaminating plasticizers.
74
 Integration of the GC trace was taken over the 
same time integral as standard amides and for the same set of ions (Table 3-5). An 
averaged number of cells was used to calculate blank amount of amide per cell in the 
blank samples (see equation below). Unspent media was also subjected to extraction to 
check for existing amides. 
𝑎𝑚𝑖𝑑𝑒/𝑐𝑒𝑙𝑙 =
 amide extracted from cells −  (amide in blank)
# cells
 
In addition to unspent media and glass/plasticware, conditioned media and 
unspent media were incubated with various metabolites and tested to see if PFAMs 
accumulated over time without any cells present. Unspent media was incubated with 
either OA, NOG or NOE at 37
o
C for 48h. After incubation with N18TG2 cells for 48h 
(sans metabolites), conditioned media was sterile-filtered with a 0.45 µm filter to remove 
 
Figure 3-2: GC of experimental and spiked samples 
Panel A shows the GC over the entire time range for both the unspiked (black) and 
tridecanamide spiked (pink) sample. Panel B shows a TIC closeup of tridedcanamide-TMS. 
Panel C shows the same spectrum as B but with the experimental sample spiked with 5nmol 
tridecanamide overlaid in pink.  
102 
 
 
 
any cells. The conditioned media was then incubated with OA, NOG or NOE in BSA at 
37
o
C for an additional 48h. Extraction for PFAM analysis was carried out as normal. 
Finally, to test for the change in oleamide production over time without the 
presence of any metabolites (FFAs, NAEs or NAGs), SCP and N18TG2 cells were 
incubated for 48h with media containing 0.5% FBS and 0.25 mM BSA but no long chain 
fatty acyl metabolite. Cells and conditioned media were both collected and subjected to 
PFAM analysis as normal (Sections 3.3.5-3.3.8). 
3.3.10 Data Analysis 
Total ion chromatograms (TIC) were taken to more clearly determine the 
identities of species present in the sample. Post-run, a set of selected ions unique to the 
amides and nitriles under examination was overlaid and integrated so that effects of any 
co-eluting compounds could be minimized. These unique ion sets are based on electron-
impact (EI) fragmentation of the PFAMs and nitriles and can be found in Table 3-5. 
Fragmentations for nitriles (Figure 3-3) and PFAM-TMS (Figure 3-4) are also given 
below.  
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Table 3-5:  Selected ions for Integration of Amides and Nitriles 
Compound  Selected m/z’s  
Retention 
Time (min) 
Heptadecanoic 
Adic, D33 (HdA) 
119, 135, 149, 360, 375 15.1 
Tridecanonitrile  82, 97, 110, 124, 138, 147, 152, 166, 170, 188, 192, 195 9 
Tridecanamide  93, 100, 128, 131, 158, 170, 186, 200, 213, 270, 285 13.4 
Palmitoleonitrile  122, 136, 150, 164, 178, 192, 206, 235 12.66 
Palmitoleamide  59, 116, 128, 131, 144, 184, 198, 200, 240, 253, 310, 325 16.07 
Palmitonitrilea  69, 110, 124, 138, 152, 166, 180, 194, 208, 237 12.9 
Linoleonitrileb  95, 109, 120, 134, 148, 162, 176, 261 14.8 
Linoleamide  59, 67, 81, 91, 95, 109, 116, 119, 121, 128, 131, 135, 144, 
147, 149, 336, 352, 279 
15.98 
Oleo/elaido-nitrile  83, 97, 110, 122, 136, 150, 164, 190, 206, 220, 234, 263 14.9 
Ole/elaid-amide  59, 86, 112, 116, 122, 126, 128, 131, 136, 140, 144, 154, 
158, 170, 184, 186, 198, 200, 226, 238, 264, 281, 338, 353 
16.05 
The retention times listed here for each PFAM is the for the  –TMS derivative, as opposed to 
the underivitized amide. These retention times were all accurate for the GC-MS through 
February 2009, at which point some major repairs were done to the machine. After the 
repairs, all retention times were shifted about 2 minutes earlier. 
aPalmitamide-TMS was not integrated due to the coelution of large amounts of oleic acid-
TMS and octadecanoic acid-TMS that interfered with even the selected ion integration. 
Amounts of palmitamide were determined based on the palmitonitrile only, using standard 
curves of palmitonitrile only 
bLinoleamide-TMS was not integrated for a similar reason as for palmitamide-TMS, and only 
linoleonitrile was integrated, using standard curves of linoleonitrile only. 
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Figure 3-3: Fragmentation Patterns for Long Chain Acyl Nitriles 
Shown here are some of the most common fragments for electron impact ionization of the 
long chain acylnitriles that result from derivitization of a long chain PFAM with BSTFA. Not 
all the fragments from Table 3-5 are shown here. 
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Figure 3-4: Fragmentation Patterns of PFAM-TMS Compounds 
Shown here are some of the most common fragments for electron impact ionization of 
PFAM-TMS compounds. Not all the fragments from Table 3-5 are shown here. 
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Integration of samples was based on the summation of their selected ion 
chromatograms to reduce interference from any co-eluting contaminants. Figure 3-5 
shows how this analysis was performed. The examination of a specific multiple ion 
chromatogram (MIC) composed of a set of selected ions allows the accurate integration 
of compounds even with the presence of coeluting substances, and has literature 
precedence.
95
 There is a certain danger that isotopic peaks of coeluting compounds may 
contribute to the integration of the compound of interest, which is why care is taken to 
run blanks for all cell and media samples, both as solvents unexposed to any cell or 
media and media exposed to no cells. 
 
 
Figure 3-5: MIC Analysis of a GC Peak 
GC spectrum of tridecanamide-TMS in SCP cells. Panel A shows the TIC. Panel B shows the 
m/z 131 overlaid in pink on the TIC. Panel C shows the selected characteristic m/z ions for 
tridecanamide-TMS overlaid in colors over the TIC (black). Panel D shows the MIC, the 
summation of the individual selected ions. The horizontal red line indicates the integrated area. 
The y-axis is relative intensity and all graphs are plotted on the same scale. Note that in panel 
D the background peaks have diminished. 
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Heptadecanoic Acid, D33 (HdA), was added to each sample as an internal standard 
to test the performance of the instrument. The amides and nitriles of interest were 
integrated along with the HdA, both compared to their standard curves, and a correction 
factor determined based on the integration of HdA compared to its standard curve was 
used to adjust the amount of amide. Once the area under an amide peak was used to 
determine the number of nmol PFAM, it was divided by the number of cells worth of 
extract injected (i.e. if 1/3 of the sample was injected, the nmol amide was divided by 1/3 
the total number of cells counted for that sample). For media samples, the nmol amide 
was divided by the cell count from the cell sample taken from the same flasks rather than 
dividing by volume of media, so that the amount of amide secreted per cell could be 
estimated.  Each extraction sample was run on the GC-MS twice, and each incubation run 
at least twice to provide replicates. T-tests were run using GraphPad. 
3.4 Results 
3.4.1 GC-MS of FFA-Incubated Cells and Media 
 
All FFAs in both cell lines were found to be converted to the corresponding 
PFAM. For brevity, only a panel of GC-MS from cells incubated with linoleic acid is 
shown in this chapter (Figure 3-6 through Figure 3-9), with one representative time point 
for each sample. GC-MS for cells and conditioned media after incubation with each FFA 
and TDEA can be found in Appendix C. Due to a large amount of interfering background 
in the range of 17.5 – 20 minutes in the conditioned media containing linoleic acid, the 
amount of amide was calculated using the nitrile only, plotted against a standard curve of 
linoleonitrile from the linoleamide derivitization reaction. Similarly, oleic acid and 
octadecanoic acid co-eluted with palmitamide-TMS, so only palmitonitrile was integrated 
and compared to a standard curve of palmitonitrile only. 
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Figure 3-6: GC-MS of N18TG2 Incubated with LOA for 12 Hours, Showing 
Linoleonitrile 
GC-MS of N18TG2 cell extract after incubation with LOA for 12 hours, showing 
linoleonitrile. Panel A shows the whole GC and zoom in of the peak of interest. 
Panel B shows the MS of the indicated GC peak (linoleonitrile). Panel C shows the 
library database MS for linoleonitrile. Panel D shows the difference between panels 
B and C. The cells were extracted as described in the methods section. The cells had 
been incubated with 2.5 mM LOA in 0.25 mM BSA for 12 hours in this case before 
extraction 
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Figure 3-7: GC-MS of N18TG2 Conditioned Media Incubated with LOA for 48 Hours, 
Showing Linoleonitrile.  
GC-MS of N18TG2 media extract after incubation with LOA for 48 hours, showing 
linoleonitrile. Panel A shows the whole GC and zoom in of the peak of interest. Panel 
B shows the MS of the indicated GC peak (linoleonitrile). Panel C shows the library 
database MS for linoleonitrile. Panel D shows the difference between panels B and C. 
The cells were extracted as described in the methods section. The cells had been 
incubated with 2.5mM LOA in 0.25mM BSA for 48 hours in this case before 
extraction. 
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Figure 3-8:  GC-MS of SCP Cells Incubated with LOA for 48 Hours, Showing Linoleamide-TMS 
GC-MS of SCP cell extract after incubation with LOA for 48 hours, showing linoleamide-
TMS. Panel A shows the whole GC and zoom in of the peak of interest. Panel B shows the 
MS of the indicated GC peak (linoleamide-TMS). Panel C shows the library database MS for 
linoleamide-TMS. Panel D shows the difference between panels B and C. The cells were 
extracted as described in the methods section. The cells had been incubated with 2.5 mM LOA 
in 0.25 mM BSA for 48 hours in this case before extraction. 
 
111 
 
 
 
 
3.4.2 Quantitative Analysis of PFAMs in N18TG2 Cells 
 
Each PFAM, including the non-natural tridecanamide, was found in both N18TG2 
cells and conditioned media. In most cases, the amount of PFAM found in the 
conditioned media was very similar to the amount of PFAM found in the cells themselves 
(Figure 3-10). 
 
Figure 3-9: GC-MS of SCP Conditioned Media Incubated with LOA for 48 Hours, Showing 
Linoleamide-TMS 
GC-MS of SCP media extract after incubation with LOA for 48 hours, showing linoleamide-
TMS. Panel A shows the whole GC and zoom in of the peak of interest. Panel B shows the 
MS of the indicated GC peak (linoleamide-TMS). Panel C shows the library database MS for 
linoleamide-TMS. Panel D shows the difference between panels B and C. The cells were 
extracted as described in the methods section. The cells had been incubated with 2.5 mM 
LOA in 0.25 mM BSA for 48 hours in this case before extraction. 
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Figure 3-10: Quantification of PFAMs isolated from N18TG2 cells and media. Continued on the 
next page. 
 
 
0.E+00
5.E+02
1.E+03
2.E+03
2.E+03
0h 12h 24h 48h
p
m
o
l a
m
id
e
 p
e
r 
1
0
7
ce
lls
TDA
0.E+00
5.E+02
1.E+03
2.E+03
2.E+03
0h 12h 24h 48h
p
m
o
l a
m
id
e
 p
e
r 
1
0
7
ce
lls
TDEA
0.E+00
5.E+03
1.E+04
2.E+04
2.E+04
0h 12h 24h 48h
p
m
o
l a
m
id
e
 p
e
r 
1
0
7
ce
lls
POA
0.E+00
2.E+04
4.E+04
6.E+04
8.E+04
1.E+05
1.E+05
0h 12h 24h 48h
p
m
o
l a
m
id
e
 p
e
r 
1
0
7
ce
lls
PA
113 
 
 
 
 
 
 
 
 
Blanks showed little interference of PFAMs in unspent media and of slip 
additives in polyethylene. N18TG2 media blanks were approximately 1-22% of 
experimental amounts found in conditioned media, except for linoleamide, which was 
 
 
 
Figure 3-10: Quantification of PFAMs isolated from N18TG2 cells and media 
In each graph, cells are shown in blue, media in green, unspent media in pink and solvent blank 
in orange (left to right). Samples were incubated for 0, 12, 24 or 48 hours with corresponding 
fatty acid-BSA mixture. Error bars are ± standard deviation. 
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44%. Solvent blanks were even lower: between 0.5-8% of cell sample amounts, except 
for background interference in the region of tridecanamide, which gave background 
levels of 17-18% of experimental levels. 
  
 
 
 
Figure 3-12: Primary Fatty Acid Amides Produced in N18TG2 Cells Incubated with Various Fatty 
Acids 
Comparison of PFAMs found in N18TG2 cells after incubation with various FFAs and one 
NAE. Only cell data are shown here. Media data are available in Table 3-6 and Figure 3-10. 
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Figure 3-11: Endogenous PFAMs in N18TG2 Cells 
The amount of PFAMs found in normally growing N18TG2 cells without 
incubation with a FFA is shown here. Error bars are ± standard deviation. 
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Endogenous amides are quantified in Figure 3-11, and the amounts of amides 
found in N18TG2 cells and conditioned media after 0, 12, 24 or 48 hours incubation with 
the corresponding fatty acids are co-graphed in Figure 3-12 and in Table 3-6. In terms of 
endogenously found amides, palmitamide was by far the most abundant, followed by 
palmitoleamide, oleamide and linoleamide.  
Palmitamide was the most abundant PFAM after incubation with its 
corresponding FFA (0.25 mM) in N18TG2 cells. Aside from TDA, which is not a natural 
FFA and whose corresponding PFAM was found in very low amounts, PA was the only 
saturated FFA used for this experiment. Palmitoleamide was the next most abundant 
PFAM, followed by elaidamide, oleamide, linoleamide, and tridecanamide. Based on 
these findings, N18TG2 cells appear to convert 16-carbon chain FFAs to their PFAMs in 
greater abundance than 18-carbon chain or perhaps the hydrolysis of the 18-carbon 
PFAMs occurs preferentially. Elaidamide was found in greater abundance than oleamide, 
but only after 48 hours. Trans fatty acids are not normally found in appreciable amounts 
in nature.
77
 Most of the incubations revealed a linear increase in PFAM over time, but a 
much greater amount of elaidamide production was seen in the 48 compared to the 12 
and 24 hour samples. 
3.4.3 Quantitative Analysis of PFAMs in SCP Cells 
 
Each PFAM, including the non-natural tridecanamide, was found in both SCP 
cells and conditioned media. In most cases, the amount of PFAM found in the 
conditioned media was very similar to the amount of PFAM found in the cells themselves 
(Figure 3-13). 
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Figure 3-13: Quantification of PFAMs isolated from SCP cells and media, and blanks.  
Continued on the next page. 
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Controls showed even less interference of PFAMs in SCP samples than was found 
in N18TG2 samples. SCP media blanks were approximately 1-6% of experimental 
amounts found in conditioned media. Solvent blanks were between 1-4% of cell sample 
amounts, except for POA, which was 11% of the experimental value.    
 
 
 
Figure 3-13: Quantification of PFAMs isolated from SCP cells and media, and blanks  
In each graph, cells are shown in blue, media in green, unspent media in pink and solvent 
blank in orange (left to right). Samples were incubated for 0, 12, 24 or 48 hours with 
corresponding fatty acid-BSA mixture. Error bars are ± standard deviation. 
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  Endogenous PFAMs are quantified in Figure 3-14, and the amounts of amides 
found in SCP cells and conditioned media after 0, 12, 24 or 48 hours incubation with 
 
Figure 3-15: Primary Fatty Acid Amides Produced in SCP Cells Incubated with Various Fatty 
Acids 
Comparison graph of PFAMs found in SCP cells after incubation with various FFAs and one 
NAE. Note that only cell data are shown here. Media data are available in Table 3-6 and Figure 
3-13 
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Figure 3-14: Endogenous PFAMs in SCP Cells 
The amount of PFAMs found in normally growing SCP cells without 
incubation with a FFA is shown here. Error bars are ± standard deviation. 
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corresponding fatty acids are co-graphed in Figure 3-15 and in Table 3-6. SCP cells had a 
different profile of endogenously found amides than did N18TG2. Oleamide was much 
more abundant than any other endogenous PFAM, followed by palmitamide, 
palmitoleamide, and linoleamide. Again, there was a much greater abundance of PFAMs 
in SCP cells than in N18TG2 cells, as was found for oleamide in Chapter 2. 
In SCP cells, as in N18TG2, elaidamide was found in greater amounts than 
oleamide, but the punctuated result after 48 hours in N18TG2 is replaced here with a more 
gradual increase in PFAM. Palmitamide and linoleamide, however, show a more 
punctuated production with a significant increase in amount after 48 hours. Linoleamide 
was again the least abundant PFAM endogenously, and again tridecanamide was 
synthesized the least quickly.  
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Table 3-6: PFAMs in Cells and Media 
 
SCP cells SCP media 
SCP  
unspent 
media N18TG2 cells N18TG2 media 
N18TG2 
unspent 
media 
TDA       
12h 2033 ± 308 2239 ± 922 143 102 ± 10 284 ± 225 29 
24h 2653 ± 747 3228 ± 1245 211 261 ± 120 503± 162 48 
48h 2289 ±314 5132 ± 426 291 750 ± 317 1276 ± 367 134 
TDEA       
12h 1082 ± 277 2029 ± 1387  144 ± 68 256 ± 213  
24h 2680 ± 360 7529 ± 1601  283 ± 158 450 ± 37  
48h 6637 ± 1483 10301 ± 1074  573 ± 271 995 ± 488  
POA 407 ± 48 291 ± 96 0 342 ± 110 806 ± 573 3 
12h 2004 ± 363 3844 ± 348 0 1021 ± 769 1919 ± 1635 14 
24h 3076 ± 1837 5375 ± 2083 0 5847 8549 22 
48h 2926 ± 1580 7911 ± 759 0 8301 ± 1276 15136 63 
PA 1162 ± 208 857 ± 442 0 928 ± 253 5821 ± 136 0 
12h 3696 ± 792 5297 ± 1419 0 6150 ± 1779 2232 ± 1038 50 
24h 4533 ± 1637 6351 ± 739 0 8692 ± 3662 20585 ± 8187 80 
48h 33044 ± 3012 24699 ± 8429 0 21369 ± 6710 74273 ± 27305 225 
OA 6367 ± 2276 4087 ± 1852 85 119 ± 53 208 ± 156 27 
12h 6807 5699 ± 3735 179 823 ± 272 783 ± 320 93 
24h 9819 ± 2943 16579 ± 2054 265 2057 ± 709 1391 ± 203 151 
48h 9960 ± 5802 13170 ± 3873 352 2137 ± 424 1734 ± 134 423 
EA 6367 ± 2276  4087 ± 1852  119 ± 53 208 ± 156  
12h 12255 ± 3147 17458  735 ± 198 1656 ± 199  
24h 20944 51432 ± 18539  1401 ± 322 1915 ± 585  
48h 21251 ± 7156 126822 ± 19489  6686 ± 2194 10791 ± 736  
LOA 249 ± 180 151 ± 217 34 102 ± 60 34 ± 27 11 
12h 4024 ± 1341 6968 ± 1752 253 348 ± 161 391 ± 44 100 
24h 5208 ± 726 25559 ± 8107 394 298 ± 118 405 ± 105 162 
48h 29336 ±10433 53650 ± 29800 497 1258 ± 372 853 ± 268 454 
Amount of PFAMs found in cell and media samples endogenously and after incubation for 
12, 24 or 48 hours with the corresponding FFA.  Endogenous amount is listed without a time. 
Values are pmol/107 cells ± standard deviation. Samples have blanks subtracted from them: 
solvent blank for the cell samples, and unspent media blank for the media samples. The 
TDA/TDEA samples already have the 0h integration (negative control) subtracted from 
them. Endogenous 18:1Δ9 PFAM is assumed to be oleamide.
16
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3.4.4 Comparison of SCP and N18TG2 PFAM Production 
 
In every case except with palmitoleamide, more of the PFAM was found in SCP 
cells than in N18TG2 after incubation with FFA (Figure 3-16 and Figure 3-17), although 
nearly equal amounts of palmitamide were found in the two cell lines. In fact, there was 
23 times as much linoleamide in SCP than in N18TG2 cells after 48 hours incubation 
with LOA, but only 3 times as much elaidamide (Table 3-6), so the amount of variation 
was large and the two cell lines had distinct PFAM “fingerprints.” 
The much higher amount of endogenous oleamide in SCP cells (54 times 
compared to N18TG2 levels) that was discovered in Chapter 2 did not hold true for other 
endogenous PFAM levels (Figure 3-16). Other endogenous PFAMs ranged from just 1.2 
times higher (palmitoleamide) to 2.4 times higher (linoleamide) in the SCP as compared 
to N18TG2 cells. 
  
 
Figure 3-16: Endogenous PFAMs in SCP and N18TG2 Cells 
The amount of endogenous amides in N18TG2 (left) and SCP cells (right). Cells were 
grown in normal growth media with 10% FBS until 80-95% confluent, collected and 
extracted as described in the methods section. Quantification was done by GC-MS. 
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Figure 3-17: Comparison of PFAMs in SCP and N18TG2 Cells. Continued on the next page. 
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Figure 3-17: Comparison of PFAMs in SCP and N18TG2 Cells 
The amount of amides in SCP cells (brown) and media (blue), and in N18TG2 cells 
(purple) and media (green) plotted side by side here for comparison purposes. Cells 
were grown in media containing 0.5% FBS, 0.25 mM BSA and 2.5 mM FFA for 0, 12 
24 or 48 hours, collected and extracted as described in the methods section. 
Quantification was done by GC-MS. 
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3.5 Controls 
 
In addition to the solvent blanks and unspent media controls (see sections 3.4.2 and 
3.4.3), controls were run to test for the formation of PFAMs in unspent media and in 
spent media upon incubation with various metabolites. A recent report by Mueller and 
Driscoll
52
 identified oleamide-synthesizing activity in FBS, a component used in culture 
media in these experiments. In the Mueller and Driscoll experiments, incubation with 
oleoyl-CoA and ammonia or glycine and resulted in the formation of oleamide or N-
oleoylglycine, respectively.  
To test for oleamide-forming activity in the media used in these experiments, both 
conditioned and unspent media were incubated for 48 hours with various oleoyl 
metabolites. These results are summarized in Figure 3-18, and show no detectable 
difference between the amount of oleamide found in unspent media and media (spent or 
unspent) incubated with one of the metabolites. This shows that there is no PFAM-
forming metabolism occurring in the media with NOG, OA and NOE as precursors, and 
that the cells are not excreting enzymes capable of metabolizing these acyl amides. 
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 To test for the change in oleamide production in the cells without the presence of 
oleic acid or other oleoyl metabolites (but in the presence of all other components), both 
N18TG2 and SCP cells were incubated for 48h with media containing 0.5% FBS and 0.25 
mM BSA carrier. There was no detectable difference between the amount of oleamide 
found in the normally growing “0h” cells and those incubated for 48h with BSA and low 
serum media (Figure 3-19 Figure 3-20). This shows that the incubation conditions (0.5% 
FBS and 0.25 mM BSA) have no measurable effect on PFAM production in the absence 
of the FFA. 
 
Figure 3-18: N18TG2 Media Incubated with Metabolites with or without Previous Exposure to 
Cells. 
Media containing 0.5% FBS was incubated with OA, NOE or NOG for 48 hours. Half 
of the samples were conditioned media (48 hours of cell exposure) with any cells 
removed by sterile filtration. Each sample was repeated. Error bars are ± standard 
deviation. Conditioned media and extracted cells after 48 hours incubation with OA 
are also shown on the left for comparison. 
Abbreviations: NOE, N-oleoylethanolamine; NOG, N-oleoylglycine; OA, oleic acid  
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Figure 3-20: SCP Incubated with BSA and Normal Cells 
Amount of oleamide in cells and media extracted after incubation with BSA alone, under 
normal growing conditions (“0h”), and in unspent media and blank. Cells were incubated as 
normal for 48h and extracted as described in sections 3.3.5-3.3.8. 
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Figure 3-19: N18TG2 Incubated with BSA and Normal Cells 
Amount of oleamide in cells and media extracted after incubation with BSA alone, under 
normal growing conditions (“0h”), and in unspent media and solvent blank. Cells were 
incubated as normal for 48 hours and extracted as described in sections 3.3.5-3.3.8. 
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To test the robustness of this extraction method, cells and media were spiked with 
each PFAM and subjected to the standard extraction procedure. Percent recoveries ranged 
from 82-101% (Figure 3-21). 
 
 
3.6 Discussion  
 
This is the first known report of the conversion of FFAs other than oleic acid to 
their respective PFAM in N18TG2 cells. Although oleamide is the best studied PFAM, it 
is only one of many PFAMs that are known to be produced by this cell line and other 
tissue types. In addition, this is the first report of the PFAMs being found both 
endogenously and upon incubation with a FFA in SCP cells.  
 
Figure 3-21: Extraction Efficiency for PFAMs 
N18TG2 cells and media were spiked with 5 nmol of each amide and subjected to the normal 
solvent extraction, SPE, and derivitization for GC-MS. PFAM peaks were integrated using a 
set of characteristic ions as in Table 3-5 and compared to a standard curve. Error bars are ± 
standard deviation. 
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 In comparing the two cell lines, there are several obvious differences. Aside from 
the finding that SCP cells had more of each PFAM except palmitoleamide, the pattern of 
PFAM abundance differs between these two cell lines in terms of amount of each PFAM 
species. N18TG2 cells showed a higher turnover of 16-carbon fatty acids to primary 
amides than did SCP cells, and there was no discernable pattern of PFAM abundance in 
SCP cells relating to acyl chain length of degree of saturation. To qualify, the amount of 
corresponding PFAMs found in SCP cells was approximately PA ≥ LOA > EA > OA > 
POA > TDEA > TDA, whereas in N18TG2 it was PA > POA >EA > OA > LOA > TD ≥ 
TDEA after 48 hours of incubation time. Oleamide was the most abundant of the five 
PFAMs found in meibomian secretions,
6
 but still the unexpected findings that oleamide is 
far more abundant than the other SCP endogenous PFAMs, and that conversion of most 
FFAs to their corresponding PFAM occurs in much greater amounts in the SCP cells 
bodes further investigation. 
It was not possible to detect the difference between the cis/trans isomers oleamide 
and elaidamide due to the impurities in the complex cellular lipid extract, and the 
endogenous 18:1 amide found is reported here as oleamide because oleamide has been 
reported in N18TG2 cells and various other sources
43,68,69,96
 while elaidamide has only 
been found in human plasma to date.
5
 Trans fatty acids are not found in appreciable 
amounts in higher organisms, aside from some in dairy fat and in the meat of ruminants, 
whose stomachs contain bacterial isomerases capable of performing this conversion.
77
 
(The elaidamide found in human leutal phase plasma
5
 likely came from a dietary source, 
as do most trans-fatty acids.
16
) It is interesting, therefore, that both N18TG2 and SCP cells 
had greater amounts of elaidamide than oleamide after incubation with EA and OA, 
respectively. 
 The kinetic data for peptidylglycine α-amidating monooxygenase (PAM) with 
various NAGs as substrates is shown in Figure 3-22. The presence of low endogenous 
amounts of linoleamide may be partially accounted for by the lower Vmax/KM of the 
doubly unsaturated N-linoleoylglycine. However, once LOA incubation began, SCP cells 
showed a much higher amount of linoleamide. This may reflect a low availability of 
endogenous LOA. The N18TG2 cells, however, maintained a lower amount of linoleamide 
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per cell than other PFAMs after incubation with the corresponding FFA. This could 
reflect any number of possibilities: N18TG2 may express fewer FFA transport proteins 
that are specifically able to transport the doubly unsaturated FFA across cell membranes, 
LOA may be preferentially shuttled to a different metabolic route, or the different species 
may show different substrate specificities for any of the metabolic enzymes, including 
PAM, acyl CoA synthetase(s), cytochrome c, and FAAH.   
 
 
Although the degradative enzyme, FAAH, has been studied extensively,
97,98
 there 
is not a great deal known about substrate PFAMs with less than 18 carbons. Reported 
kinetic constants vary, but linoleamide is likely a better substrate than oleamide (Table 
3-8 Table 3-7). This helps explain why linoleamide was found in lower abundance in 
N18TG2 cells, since FAAH was not found to be expressed in SCP (see Chapter 4). Based 
on the other PFAM data in N18TG2 cells, 16-carbon PFAMs can be predicted to be worse 
substrates for FAAH than 18, since those 16-carbon PFAMs were found in greater 
abundance. Palmitamide was found to be a worse FAAH substrate than oleamide in 
vitro
2,7
 (see Table 3-7). Lower degrees of unsaturation may also be favorable against 
FAAH degradation because, in the N18TG2 trend, the unsaturated PFAM was most 
abundant, followed by the mono-unsaturated species and finally the bi-unsaturated 
linoleamide, which was found in lowest abundance. FAAH hydrolyzes NAEs more 
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Figure 3-22: Kinetic Data for PAM and Various 
N-Acylglycines 
Kinetic data for PFAMs as PAM substrates in 
tabular (left) and graphical (right) forms. 
Information is from Wilcox et.al.4 
Identification of each PFAM is noted below its 
point on the graph. These data are for rat 
PAM. 
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slowly with decreasing numbers of double bonds.
99
 It is interesting that oleamide is a 
better substrate for FAAH than is myristamide
2,7
 (Table 3-7) but tridecanamide is in far 
lower abundance than oleamide and any of the other PFAMs. 
 
No enzymatic assays have been done for FAAH with the substrate elaidamide to 
the author’s knowledge, but as the relative levels of PFAMs in N18TG2 thus far have 
completely mirrored FAAH substrate preference, one might predict that elaidamide is a 
poorer FAAH substrate than oleamide. This would explain why elaidamide was found in 
greater abundance than oleamide even though EA is not a naturally occurring FFA. 
In addition to testing for the conversion of endogenously found FFAs to their 
respective amides, a non-natural FFA and its corresponding NAE was also incubated 
with the cells to test for its conversion to a PFAM in an attempt to determine not only 
whether a non-natural acyl chain (aside from elaidic acid) could be converted to its 
primary amide, but also to gain some insight into the mode of formation of PFAMs (see 
Figure 3-1). This is the first report of conversion of an NAE to PFAM in these cell lines, 
as well as the first report of non-natural fatty acid and ethanolamines being converted to 
Table 3-8: Kinetic Data for FAAH 
Acyl Chain 
Km 
(µM) 
Vmax 
(µmol/min·
mg) 
V/K Source ref 
Linoleoyl 6.8 1448 213 N18TG2
ƚ
 1 
8.3 3317 400 Rat brain 3 
Oleoyl 9 941 105 N18TG2
ƚ 1 
14 340 243 N18TG2
ǂ 1 
ƚ
enzymatic activity is from a 10,000xg pellet 
ǂenzymatic activity is from the microsomal fraction 
Table 3-7: Relative Substrate Specificity of FAAH 
FAAH 
source: 
N18TG2
1 
Rat 
recombinant2 
Human 
recombinant7 
Anandamide 100 100 100 
Linoleamide 64   
Oleamide 42 73 70 
Palmitamide  10 33 
Myristamide  24 65 
The activity of anandamide is taken to be 100%, 
and the activity of the other substrates compared to 
anandamide. Data taken from14,15 
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their corresponding PFAM. Although both cell lines were able to perform this 
conversion, the rates of conversion were much lower than those found for natural FFAs 
(Figure 3-12 Figure 3-15), and the patterns of metabolic flow-through were not the same 
in the N18TG2 and SCP cells (Figure 3-23).  
 
 
  
 
N18TG2 cells metabolized TDA and TDEA with equal discrimination, whereas 
SCP cells preferred the TDEA substrate to the TDA. Bradshaw et al. found that 
incubation of labeled N-arachidonoyl-D4-ethanolamine produced labeled N-
aracyidonoylglycine in both RAW 264.7 and C6 glioma cells, indicating the oxidative 
formation of NAG. In addition, the unlabeled N-arachidonoylglycine was found in C6 
glioma cells, indicating they also hydrolyze the NAE to its FFA for glycination. Upon 
addition of a FAAH inhibitor, the NAG was no longer formed in the glioma cells, 
suggesting that the preferential mode of action of NAG formation is hydrolysis of the 
NAE to its FFA in the glioma, but not in the RAW 264.7 cells.
90
 The Bradshaw data and 
the findings herein demonstrate that not only is there more than one way to produce a 
 
Figure 3-23: Tridecanamide in SCP and N18TG2 Cells after TDA and TDEA Incubations. 
The rate of conversion of TDEA is steeper than the rate of conversion of TDA in SCP 
cells. In N18TG2 cells, however, there is no discernable difference in substrate 
conversion. 
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NAG, but that the mode of NAG production can vary from cell line to cell line (and 
likely tissue type to tissue type). This bodes further exploration to determine if there are 
differences in expression of the metabolizing enzymes in these cell lines, and in Chapter 
4 it is determined that FAAH is not expressed in SCP cells and an alcohol dehydrogenase 
was found in SCP, but not N18TG2, cells. These and other differences in enzyme 
expression have many implications for the metabolism of FFAs and NAEs in these cell 
lines (for more discussion see Chapter 4). 
3.7 Conclusion 
 
 The assay for PFAM quantification in cells and media that was developed in 
Chapter 2 was used here to show the conversion of a panel of long chain fatty acids to 
their corresponding amides in two model cell lines: SCP and N18TG2 cells. In addition to 
five endogenously found FFAs, two non-natural, odd-chain compounds were found to be 
converted to their corresponding PFAM in both cell lines and their respective conditioned 
media. 
 The amount of endogenous PFAMs was much higher in the SCP cells, 
particularly for oleamide. After incubation with a fatty acid, the profile of PFAMs was 
different between the two cell lines. The PFAM profile in N18TG2 cells mirrors the 
known substrate specificity for FAAH, with the PFAMs having the lowest Vmax/KM being 
in greatest abundance and those with the most favorable kinetic data being in least. 
 In addition to the differing profile of PFAMs after FFA incubation, SCP and 
N18TG2 cells showed different usage of TDA and TDEA. While N18TG2 cells used both 
at the same rate to form tridecanamide, SCP showed a preference for ethanolamine 
metabolism. Once again, the long chain fatty acid amide metabolism is shown to differ in 
different cell lines. These findings bode further exploration, and an investigation into 
their enzyme expression may yield some answers to these discrepancies. 
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4 Amide-Processing Enzyme Expression in Oleamide-Producing 
Cells 
 
4.1 Location and Biological Significance of Primary Fatty Acid 
Amides and N-Acylglycines 
 
Primary fatty acid amides (PFAMs) and N-acylglycines (NAGs) are important 
bioactive lipids found across many species.  PFAMs have been shown to be responsible 
for various effects in the central nervous system, including induction of sleep,
71-74
 
stimulation of Ca
2+
 release,
79,92
  inhibition of the erg current in pituitary cells,
93
 and 
activation of specific serotonin receptor subtypes
97-99
 and the GABAA receptor.
80-83
  (For 
a complete review of endogenous PFAMs see Chapter 3.)  
Less is known about the NAGs, but a recent surge of interest in these molecules 
and the development of better separations and more sensitive mass spectrometry 
instruments has allowed for the identification of many more N-acylamino acids than were 
known just a few years ago.
100-103
 N-Conjugation of long-chain fatty acids to glycine is a 
known method of detoxification and elimination, although recently N-oleoylglycine has 
been shown to have bioactivity as it serves in regulation of body temperature and 
locomotion.
104
 Other long-chain N-acylglycines have also been reported to have 
additional function. For example, N-arachidonoylglycine is an endogenous ligand for the 
orphan GPR18 receptor,
108
 is analgesic,
20
 inhibits FAAH
20
 and the GLYT2a glycine 
transporter.
109
 A summary of known mammalian long-chain PFAM and NAG 
metabolites can be found in Table 4-1. 
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Table 4-1: Occurrence and Role of Endogenous Long-Chain PFAMs and NAGs in Mammals 
Class Compound Organism Known Significance Ref 
PFAM Myristamide (C14:0) Human Unknown 56 
Palmitamide (C16:0) Human, 
Mouse 
Unknown, modestly attenuates 
seizures in mice, modest FAAH 
inhibitor 
56,58 (this 
dissertation) 
Palmitoleamide  
          (C16:1 cis-9) 
Human, 
Rabbit, 
Mouse 
Gap junction communication, 
serotonin receptor binding 
58,60(this 
dissertation) 
Stearamide (C18:0) Human, 
Rabbit 
Unknown 56,60 
Elaidamide (C18:1 trans-9) Human Less active than oleamide, but 
induces sleep, inhibits epoxide 
hydrolase and phospholipase A2 
58,70 
Oleamide (C18:1 cis-9) Human 
Mouse,  
Rabbit, 
Rat, 
Squirrel 
Sleep, memory, thermal and 
locomotor regulation, gap 
junction communication, Ca2+ 
flux, vasodilatation, hunger, 
anxiety, serotonin receptor 
binding, erg current inhibition 
23,58,71-87, 
58,60,88-
91(this 
dissertation) 
Linoleamide (C18:2 cis-9,12) Human, 
Rabbit, 
Mouse 
Sleep and Ca2+ flux regulation, 
erg current inhibition, epoxide 
hydrolase and phospholipase A2 
inhibition, gap junction 
communication, FAAH 
substrate, serotonin receptor 
binding 
92,93, 
56,60(this 
dissertation) 
Eicosenamide (C20:1 cis-13) Rabbit Unknown 28,60 
Erucamide (C22:1 cis-013) Cat, Cow, 
Human, 
Rat 
Fluid balance, angiogenesis 56,105-107 
NAG N-palmitoylglycine (C16:0) Rat Sensory neuronal signaling, 
antinociception, Ca2+ influx 
17,101 
N-stearoylglycine (C18:0) Mouse, 
Rat 
Unknown 102 
 
N-oleoylglycine 
         (C18: 1 cis-9) 
Mouse, 
Rat 
Temperature and locomotion 
control 
88,101,102,
104 (this 
dissertation) 
N-linoleoylglycine  
(18: 2 cis-9,12) 
Rat Anti-inflammatory 101,102,110 
N-arachidonylglycine  
(20:4 cis-5,8,11,14) 
Cow, Rat Antinociceptive and 
inflammatory suppression, 
control of T-cells proliferation, 
suppression of IL-1β secretion, 
reduction rectal carcinoma 
growth, Ca2+ and insulin 
release, GLYT2a inhibition 
3,110-114 
N-docosahexaenoylglycine  
         (22:6 cis-4,7,10,13,16,19) 
Rat Anti-inflammatory 102,110 
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4.2 PFAM and NAG Biosynthesis 
 
The pathway(s) for PFAM and NAG biosynthesis are currently under study in 
several laboratories, including the Bradshaw (formerly Walker), Merkler, and Mueller 
groups. The consensus is that there are two main routes to NAG biosynthesis, although 
the regulation of each route, the prevalence of each route in different cell and tissue 
types, and the exact enzymes involved are still under investigation. One of the proposed 
biosynthetic mechanisms is the activation of a long-chain free fatty acid (FFA) to an 
intermediate, the coenzyme A (CoA) thioester being a likely candidate, followed by 
glycination to form the NAG.
28
 A second proposed route for NAG biosynthesis involves 
sequential oxidation of an N-acylethanolamine (NAE) first to the N-acylglycinal and then 
to the NAG.
3,25
  
The route(s) to PFAM biosynthesis are better understood. The primary proposed 
mechanism of PFAM biosynthesis is by oxidative cleavage of the NAG by the 
bifunctional enzyme, peptidylglycine α-amidating monooxygenase (PAM).1,28 Another 
mechanism for which recent in vitro studies have given some evidence involves the direct 
amidation of an acyl-CoA with ammonia.
11,55
 The current proposed pathways for the 
synthesis and degradation of the NAGs and PFAMs is shown in Figure 4-1. 
 
140 
 
 
 
 
 
Considerable evidence has been gathered to support the action of peptidylglycine 
α-amidating monooxygenase (PAM, EC 1.14.17.3) in converting the NAGs to PFAMs. 
PAM is a bifunctional enzyme composed of peptidylglycine α-hydroxylating 
monooxygenase (PHM, EC 1.14.17.3) that catalyzes the stereospecific hydroxylation of 
the glycine α-carbon of glycine-extended substrates. The second functional unit of PAM 
 
Figure 4-1: Proposed Biosynthetic and Cataboic Pathways for NAGs and PFAMs 
The enzymes catalyzing the individual reactions are in the boxes and the fatty acyl group is 
represented by the bold blue „R‟. The reader is referred to Mueller and Driscoll 24  and Merkler 
et al.28,29 for recent reviews. Abbreviations: ACS, Acyl CoA-synthetase; ASC, ascorbic acid; 
ADH, alcohol dehydrogenase; AlDH, aldehyde dehydrogenase; CYP4F, cytochrome P450; Cyt 
c, cytochrome c; FFA, free fatty acid; lcACGNAT, a novel long-chain acyl-CoA:glycine N-
acyltransferase; NAE, N-acylethanolamine; NAG, N-acylglycine; PAM, peptidylglycine α-
amidating monooxygenase; PFAM, primary fatty acid amide; SDA, semidehydroascorbic acid. 
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is peptidyl-α-hydroxyglycine α-amidating lyase (PAL, EC 4.2.3.5), which releases 
glyoxylate from the α-hydroxylated acyl or peptidyl-glycine to form a PFAM or an 
amidated peptide (Equation 4-1). PAM is expressed in neuroendocrine tissues where it is 
known to amidate peptide messengers from their glycine-extended precursors.
48,115
 In 
vitro studies have shown that many non-peptides are PAM substrates, and that Vmax/KM 
for NAGs are comparable to those for peptide substrates.
1-8
 The equations for the 
stepwise transformation are shown below in Equation 4-1. 
. 
 
Chemical inhibition of PAM by trans-4-phenyl-3-butenoic acid in the PAM-
expressing N18TG2 cells
28,116
 resulted in the accumulation of N-oleoylglycine when these 
cells were grown in the presence of oleic acid.
28
 The main area of debate for this 
metabolic network has been in the formation of NAGs. Bradshaw et al. and Burnstein et 
al. demonstrated the conversion of NAEs to NAGs in three cell lines,
3,25
 and Merkler et 
al. demonstrated the conversion of 
14
C-oleic acid to a 
14
C-compound with the same 
retention time as N-oleoylglycine.
28
 These experiments demonstrate not only that NAGs 
are cellular metabolites but that they can be synthesized from two distinct precursors: 
 
 
Equation 4-1: Amidation of an N-Acylglycine by PAM 
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NAEs and FFAs. These two distinct metabolic precursors also indicate two distinct 
biosynthetic mechanisms: oxidation of an NAE and glycination of an activated 
intermediate, such as acyl-CoA.  
4.2.1 Anabolic Route to the NAGs I: Glycination of a Free Fatty Acid 
 
The ATP-dependent formation of acyl-CoA from fatty acids via acyl CoA ligase 
(ACS, a.k.a. acyl-CoA synthetase,  EC 6.2.1.x) is a well-established reaction that is found 
throughout the evolutionary tree, from Achaea to complex eukaryotes.
59,117,118
 
Overexpression in hepatic cells results in an increase in the amount of cellular long-chain 
acyl-CoAs.
119
 All the common fatty acyl-CoAs are known mammalian metabolites, 
including palmitoyl, palmitoleoyl, stearoyl, oleoyl, linoleoyl and arachidonoyl-
CoA.
120,121
This two-step reaction is diagrammed in Equation 4-2.  
 
Exactly which ACS isozyme is responsible for the CoA-ylation of particular 
FFAs in vivo has not been resolved completely, but much in vitro evidence has been 
amassed. The very long-chain ACSs, known both as ASCVLs and SLC27As (for solute 
carrier family 27A), metabolize fatty acids of 18-26 carbons in length, and the long chain 
ACSs, known as ACSLs, metabolize fatty acids of 12-22 carbons in length.
59,118
 Relative 
fatty acid preference for ACSL isoforms 1 and 3-6 is summarized in Table 4-2. (Isoform 
2 was found to be the same as isoform 1.) 
 
 
Equation 4-2: Fatty Acyl-CoA Lygase Reaction 
143 
 
 
 
Acyl CoA:glycine N-acyltransferase (ACGNAT, a.k.a. GAT, GLYAT, EC 
2.3.1.13) is one possible glycination enzyme found in the liver, kidney and brain.
13,122,123
 
There are two isoforms of this enzyme; isoform b is composed of the first 163 amino 
acids residues of isoform a, although kinetic studies have not been done to distinguish 
substrate preference between the two isomers. The ACGNAT reaction is shown in 
Equation 4-3, and proceeds via a ping pong mechanism.
124
 
 
  ACGNAT is known to form short-chain and branched-chain N-acylglycines 
from the corresponding acyl-CoA thioesters.
122,125
 However, ACGNAT is not likely to be 
the enzyme responsible for long-chain NAG formation because The Vmax/KM for acyl-
CoAs dramatically decreases as the length of the acyl chain increases.
40,122,126,127
 Long-
chain acyl-CoA thoesters are not ACGNAT substrates,
125
 with decanoyl-CoA being the 
longest acyl-CoA substrate accepted by mammalian ACGNAT.
128,129
 The Merkler 
laboratory verified these results using purified bovine liver ACGNAT. After a 4-hour 
incubation with high concentrations of ACGNAT, there was approximately 4% 
conversion of oleoyl-CoA to N-oleoylglycine (unpublished data), conditions under which 
benzoyl-CoA or butanoyl-CoA were completely converted to their respective NAG in 
less than 30 seconds. In addition, incubation of bovine liver ACGNAT PAM with 
 
 
Equation 4-3: Formation of N-Acylglycine by ACGNAT 
 
 
 
 
Table 4-2: In Vitro Substrate Preferences of Purified ACSL Isoforms 
Isoform Fatty acid preference 
ACSL1 16:0 ≈ 16:1 ≈ 18:1 ≈ 18:2 > 14:0 ≈ 18:0 ≈ 18:3 ≈ 20:4 > 20:5 >> 20:0 ≈ 22:0 ≈ 22:6 ≈ 24:0 
ACSL3 14:0 ≈ 20:4 ≈ 20:5 > 16:1 ≈ 18:1 ≈ 18:2 ≈18:3 > 16:0 ≈ 18:0 >> 20:0 ≈ 22:0 ≈ 22:6 
ACSL4 20:4 ≈ 20:5 >> 16:0 ≈ 18:0 ≈ 18:2 > 16:1 ≈ 18:3 ≈ 22:6 > 14:0 ≈ 18:1 ≈ 20:0 >> 22:2 
ACSL5 16:0 ≈ 16:1 ≈ 18:1 ≈ 18:2 ≈ 18:3 > 20:4 > 14:0 ≈ 18:0 >> 20:0 ≈ 22:0 ≈ 24:0 
ACSL6 16:0 ≈ 18:1 ≈ 20:4 ≈ 20:5 > 14:0 ≈ 22:6 > 16:1 ≈ 18:0 ≈ 18:2 ≈ 18:3 > 20:0 ≈ 22:0 ≈ 24:0 
This table is taken from Soupene and Kuypers (2008).59 
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octanoyl-CoA, glycine, and ascorbate, yielded the formation of octanamide and 
glyoxylate, but a similar experiment using oleoyl-CoA in place of octanoyl-CoA yielded 
neither oleamide nor glyoxylate.
126
 Based on these data from the Merkler lab combined 
with the previous literature, ACGNAT is very unlikely to be the in vivo enzyme 
responsible for long-chain NAG production. 
Two more enzymes that perform related chemistry have been proposed to transfer 
a glycine to an acyl-CoA: one that normally transfers myristoyl groups onto proteins and 
one that transfers amino acids to bile acids. N-Myristoyltransferase (NMT, EC 2.3.1.97) 
is responsible for the N-terminal acylation of proteins and has a strong preference for 
myristoyl-CoA and an absolute requirement for an N-terminal glycine residue (Equation 
4-4). Although palmitoyl-CoA is a reasonable inhibitor,
130
 free glycine and proteins with 
an N-terminal other than glycine are not substrates.
131
 
.  
Bile acid-CoA:amino acid N-acyltransferase (BAAT, a.k.a. BACAT, EC 2.3.1.65) 
catalyzes the conjugation of glycine or taurine to bile acid-CoA thioesters, and may also 
catalyze NAG biosynthesis in vivo. O‟Byrne et al. showed that BAAT could conjugate 
glycine to fatty acyl-CoA thioesters in vitro. However, Vmax/KM values were relatively 
low compared to the bile acid-CoA thioesters, with the values for the fatty acyl CoAs 
being only 20% of that reported for bile acids, and there was competing thioesterase 
activity that resulted in FFA formation even in the presence of glycine.
40
  While the in 
 
 
Equation 4-4: NMT Glycination Reaction 
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vitro data does support a role for BAAT in the biosynthesis of certain saturated long-
chain (C16-C20:0) and very long chain (C22-C26:0) NAGs, the specific activity of BAAT 
actually decreases for oleoyl-CoA when glycine is added as a co-substrate, and the 
specific activity for unsaturated acyl-CoAs was a fourth to a third of that for saturated 
acyl-CoAs.
90
 Therefore, if BAAT is an in vivo NAG biosynthesizing enzyme, it would 
likely function in limited capacity to form only the long-chain unsaturated NAGs. The 
BAAT glycination reaction is shown in Equation 4-5. 
 
The Mueller group has shown that cytochrome c (cyt c) is capable of glycine 
conjugation in vitro.
24,132
 A range of N-fatty acylamino acids have been synthesized from 
the cognate acyl-CoA thioesters and amino acids in the presence of H2O2, including N-
oleoylglycine, N-palmitoylglycine, N-stearoylglycine and N-arachidonylglycine.
10,132
  
The optimal pH for these cyt c reactions is 7.5, it displays Michaelis-Mentin 
kinetics with respect to oleoyl-CoA,
11
 and the KM values are reasonable (~50 µM for 
glycine, 200-900 µM for the other amino acids, 30 µM for oleoyl-CoA). Inhibition 
studies revealed a preference for acyl chains of 16 carbons or greater.
55,133
 This 
corresponds with previous studies that have demonstrated cyt c to have binding affinity 
for long-chain fatty acyl-CoA thioesters, although the acyl-CoAs bound less tightly than 
did FFAs.
134
 The colocalization of PAM and cyt c in secretory granules
48,50
 is also an 
interesting factor lending creed to the possibility of cyt c-mediated NAG biosynthesis 
(Table 4-3). The proposed reaction is shown in Equation 4-6. 
 
 
Equation 4-5: BAAT Glycination Reaction 
*Other amino acids are also used by this enzyme (see text). 
146 
 
 
 
The finding the cyt c will catalyze the conjugation of several other oleoylamino 
acids (and N-arachidonoylglycine) as well as anandamide and several PFAMs
11,55,132
 
could indicate that this chemistry is an artifact of the redox behavior of cyt c and that it 
may or may not be the in vivo enzyme regulating the biosynthesis of NAGs. The 
aminolysis of acyl-CoAs in the presence of ammonia occurs non-enzymatically at pH 9 
and above without H2O2. It is possible that H2O2 causes the reduction of Fe
3+ 
in cyt c, 
making it a better nucleophile to attack the carboxyl of acyl-CoA and increase the already 
high leaving potential of coenzyme A such that glycine or another nucleophile could 
more easily displace it to form the NAG. In fact, anandamide is formed spontaneously in 
the presence of arachidonoyl-CoA and ethanolamine, and the inclusion of H2O2 further 
increased the yield of anandamide. Addition of cyt c to this mixture actually reduced the 
amount of anandamide formed.
10
  
Heating of the cyt c-containing enzyme extract to 95
o
C was shown to increase the 
amount of product made.
11
 Incubation with different proteolytic enzymes, chymotrypsin, 
endoproteinase glu-C and elastase, did not decrease enzymatic activity. Incubation with 
trypsin and thermolysin was shown to increase enzymatic activity even after 30 minutes 
of incubation, although the commercially available cyt c also displayed resistance to 
proteolysis and heat denaturation.
11
  These treatments may be removing proteins that 
form inactivating complexes with cyt c or acyl-CoAs.  
Although the optimal pH for these reactions was shown to be 7.5, the other 
conditions under which these reactions were demonstrated are not biologically favorable. 
Optimal conditions were 100 µM oleoyl-CoA, 300 mM glycine and 2 mM H2O2,
24
 and 
 
 
Equation 4-6: Cyt C-Mediated Formation of N-Acylglycine 
*
Amino acids other than glycine are also substrates.
10
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even under these conditions the maximum percent conversion to N-oleoylglycine was 
<15%.
55
 Because of this requirement of such high concentrations of ammonia and 
hydrogen peroxide, and the fact that cyt c co-purifies with superoxide dismutase (SOD) 
and fatty acyl-CoA binding protein (ACBP), an oleamide “synthesome” was proposed 
(Figure 4-3 in Section 4.2.4) for the synthesis of PFAMs. This model may or may not be 
adaptable to the formation of NAGs if the amino transferase (AT) could also be a glycyl- 
or aminoacyl- transferase. More in vivo or in cellulo work is required to determine the 
exact significance of cyt c in terms of NAG formation. The subcellular localization of cyt 
c and other putative NAG biosynthetic enzymes is shown in Table 4-3. 
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Table 4-3: Subcellular Localization of Putative Biosynthetic Enzymes 
Enzyme  Reported Subcellular Localization Ref 
Acyl-CoA:glycine N-
acyltransferase (ACGNAT) 
cytoplasm 
mitochondrion 
13,14 
Long Chain Fatty Acyl-
CoA Ligasea  (ACSL, all 
isoforms) 
cytoplasm 
cytosol 
endoplasmic reticulum 
membrane (mitochondria-associated) 
mitochondrion 
peroxisome 
22,31
-33 
Bile Acid-CoA:amino acid 
N-acyltransferase  (BAAT) 
cytosol 
peroxisome 
40,41 
N-Myristoyltransferase 
(NMT)  
cytosol 
membrane (minor location) 
mitochondrion (minor location) 
42-
44 
Fatty acid amide hydrolase 
 (FAAH-1) b, c, d, e 
membrane 46,47 
Peptidylglycine α-
amidating monooxygenase 
(PAM)  
secretory granule 
cytoplasm 
membrane (integral) 
48,49 
Cytochrome C (Cyt c) mitochondrionf 
secretory granule 
50,51 
Alcohol dehydrogenase  
(ADH, all long-chain 
isoforms) g 
cytosol 
membrane (outer) 
52,53 
Aldehyde dehydrogenase 
(AlDH, all long-chain 
isoforms) h 
microsome
 
61 
Cytochrome P450 (CYP4F) 
microsome 66 
aSome studies show that different isoforms display different subcellular localizations.  For 
example, ACS1 was identified in endoplasmic reticulum, mitochondria-associated membrane 
and cytosol but not in mitochondria.22 In the same study, ACS4 was found primarily in the 
mitochondria-associated membrane and in the mitochondrial membrane but not the 
endoplasmic reticulum. 
bThere are reports of NMT in cytosol but these were done in Helicobacter pylori and 
Arabidopsis thaliana. 67,68 
CFAAH-2 was shown to be located extracellularly.69 
dNAAA was located in the peroxisome.46 
eAlthough both FAAH isoforms possess transmembrane domains, FAAH-1 has its catalytic 
domain facing the cytoplasm and FAAH-2 the luminal compartment.47 
fDuring apoptosis, cytochrome c leaves the mitochondria.51 
g Mus musculus lactate dehydrogenase was found extracellularly.94  
hStudies in various yeast isoforms reveal other subcellular localization, including membrane, 
microbody, microsome, mitochondrion and peroxisome.95,96 
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4.2.2 Anabolic Route II: N-Acylethanolamine Oxidation 
 
While it is clear that NAGs are produced in vivo (or in cellulo) from glycine and 
fatty acids or acyl-CoAs, it is also likely that there is more than one biosynthetic route to 
NAG formation, just as there is more than one biosynthetic route for the NAEs.
135
 In 
particular, a second metabolic pathway leading to the NAGs has been proposed: the 
oxidation of NAEs to NAGs by either an alcohol dehydrogenase alone or the sequential 
actions of an alcohol dehydrogenase and an aldehyde dehydrogenase (Equation 4-7). It is 
possible that both NAG biosynthetic pathways operate either in tandem, or one may be 
the favored biosynthetic route in specific cells, tissues, and disease states.  
 
The first evidence for the NAE-dependent pathway came in 2000 when Burstein 
et al. showed that anandamide is converted to N-arachidonoylglycine in cultured liver 
cells and conditioned media.
3
 More recently, Bradshaw et al. showed the conversion of 
deuterated anandamide to N-aracyidonoylglycine in both RAW 264.7 and C6 glioma 
cells
25
 (Figure 4-2, NAE oxidation pathway). These two cell lines seem to have different 
types of metabolisms. In addition to the labeled N-arachidonoylglycine, the unlabeled 
 
 
Equation 4-7: Sequential Oxidation of an N-Acylethanolamine by ADH or ADH 
and AlDH 
The first reaction would be done by an alcohol dehydrogenase. The second 
reaction would be done by either an alcohol dehydrogenase or an aldehyde 
dehydrogenase. 
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product was also found in the C6 glioma (but not RAW 264.7) cells, and upon addition of 
a FAAH inhibitor, URB 597, the unlabeled NAG was no longer formed in the glioma 
cells, suggesting that the glioma cells also hydrolyze NAE to its FFA for glycination 
(Figure 4-2, glycination pathway). This metabolism was not observed in the RAW 264.7 
cells, which only made the NAG through the oxidative pathway and generated the 
deuterated NAG, demonstrating that not only is there more than one way to make a NAG, 
but that different cell types show different metabolic profiles. 
 
The specific dehydrogenase enzymes responsible for these oxidations have not 
been determined. An alcohol dehydrogenase (ADH) would be responsible for the first 
oxidation of the NAE to an N-acylglycinal (top reaction, Equation 4-7). The second 
oxidation involving conversion of an N-acylglycinal to the NAG (bottom reaction, 
Equation 4-7), may either be catalyzed by an aldehyde dehydrogenase (AlDH), or and 
ADH, as some ADHs are known to oxidize NAEs and N-acylglycinals.
136
 Very recently, 
 
 
Figure 4-2: Two Pathways of Formation for NAGs 
Work of Bradshaw demonstrates both pathways are at work in C6 glioma cells. Both deuterated 
and undeuterated N-arachidonoylglycine were observed after incubation with D4NAE. Upon 
inhibition of FAAH, only D2NAG was observed.
25
  The glycination pathway is abbreviated here 
as an unknown. The authors suggest direct glycination of the FFA but their data does not rule out 
the activation of the FFA to a CoA or similar intermediate. 
Abreviations: ADH, alcohol dehydrogenase; AlDH, aldehyde dehydrogenase; D2/D4NAG, 
deuterated N-acylglycine; FAAH, fatty acid amide hydrolase; NAG, N-acylglycine 
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Aneetha et al. demonstrated the NAD
+
-dependent oxidation of N-
arachidonoylethanolamine (a.k.a. anandamide) with purified human ADH4 (a.k.a. ADH 
7, EC 1.1.1.1) in vitro, and showed that the unstable N-arachidonoylglycinal was then 
dismutated to the NAG.
137
 Another compelling reason to examine this isozyme is that 
ADH4 was found in the cornea,
138
 where PFAMs have been found in meibomian

 gland 
secretions.
56
 
Ivkovic et al. demonstrated that a panel of NAEs were substrates for bovine 
ADH3 with the Vmax/KM increasing as the acyl chain increased in length.
141
 Despite this 
trend, the best NAE substrates exhibited a Vmax/KM value that was >5% of the values 
obtained for alcohol substrates. This group determined that ADH3 did not catalyze 
aldehyde dismutation, meaning that the product was the N-acylglycinal, not the NAG. In 
sum, the work of Aneetha et al. and Ivkovic et al validate that the NAEs can serve as 
substrates for ADH, but it seems unlikely that either enzyme has a role in NAG 
biosynthesis in vivo, although solubility issues only allowed for study of NAEs up to 12 
carbons in length. 
A potential role for aldehyde dehydrogenase to catalyze reaction 2 in Equation 
4-7 remains unexplored. While enzymes involved in NAE oxidation in vivo remain to be 
definitively identified, work from Burstein and Bradshaw demonstrate that this chemistry 
does occur in cultured cells.
25,102
 The aldehyde dehydrogenases (AlDH) in this study 
were selected based on their affinity to bind long-chain substrates. AlDH3A1 (E.C. 
1.2.1.14) is selective for medium-to long-chain aldehydes.
142
 Additionally, AlDH3A1 is 
found in large abundance in the mammalian cornea (5-50% of water-soluble protein 
depending on species),
143
 alongside ADH4, and several PFAMs have been found in 
meibomian
1
 gland secretions.
56
 AlDH3A2 (E.C. 1.2.1.48) is known to have activity 
towards saturated and unsaturated aliphatic aldehydes ranging from 6-24 carbons in 
length, with NAD
+
 as a cofactor.
61
.   
 
                                                 

The validity of this work is under debate. While the MS of meibomian secretions show several PFAMs 
in the Nichols paper, other commonly observed compounds, including cholesterol esters and wax esters, 
were not present.  (139) Butovich, I. A. Prog Retin Eye Res 2009, 28, 483. In addition, other studies 
examining the lipid content of meibomian gland secretions did not find PFAMs. (140) Butovich, I. A.; 
Uchiyama, E.; Di Pascuale, M. A.; McCulley, J. P. Lipids 2007, 42, 765. 
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4.2.3 Degradation of Amides 
 
Fatty acid amide hydrolase (FAAH, EC 3.5.1.4), an integral membrane enzyme 
capable of hydrolyzing PFAMs, NAGs and NAEs, has been well characterized both in 
vivo and in vitro
15-21
 (see Figure 4-1, bottom right). Cravatt et.al. used an oleyl 
trifluoromethylketone column to perform affinity chromatography on rat liver 
homogenate. Once isolated, they cloned the cDNA for the enzyme, and expression in 
Chinese hamster ovary (CHO) cells resulted in high levels of hydrolysis, both of 
oleamide and anandamide, thus proving that this enzyme was responsible for their 
degradation in cellulo.
18
 Orthologs were soon identified for human,
15
 mouse,
15
 and pig.
144
 
In fact, a FAAH knockout study showed 50- to 100-fold reductions in the hydrolysis rates 
for anandamide and other fatty acid amides in mice, indicating that FAAH is the primary 
enzyme responsible for their hydrolysis in vivo.
21
 Pharmacological blockade of FAAH 
activity also led to highly elevated levels of endogenous PFAMs,
21,145-147
 leading to 
PFAM-associated analgesia,
21,145,148
 lowered anxiety,
145
 and decreased 
inflammation.
147,149
 This enzyme adds another dimension to the possible control and 
route to NAG and PFAM biosynthesis and degradation.  
There are two known isoforms of FAAH, FAAH-1 and FAAH-2, that show 
distinct expression patterns.
47
 Though the two human isoforms share only 20% sequence 
identity,
47
 the murid and human FAAH-1 orthologues share >80% sequence identity,
15
 
indicating that it is well-conserved. FAAH-1 and -2 show similar rates of hydrolysis for 
PFAMs and similar inhibitor sensitivity profiles, but FAAH-2 exhibits greater activity 
with NAEs and N-acyltaurines.
47
 The catalytic domain of FAAH-1 is predicted to reside 
on the cytoplasmic side, whereas that of FAAH-2 is predicted to be oriented in the 
luminal compartment of the cell by computer modeling and detergent sensitivity 
experiments.
47
 FAAH-2 has been identified in primates, marsupials, elephants, and more 
distantly related vertebrates but not in mouse, rat, sheep, dogs, cows or pigs, and it is 
believed that there may have been multiple independent losses of the ancient FAAH-2 
gene during mammalian evolution.
47
 Incidentally, the FAAH isoform for which we 
probed in N18TG2 and SCP cells in this study is FAAH-1.  
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In addition to degradation by FAAH, there are several other known possibilities to 
increase the hydrophilicity of these molecules for urinary excretion and other purposes. 
Cyclooxygenase-2 (COX-2, EC 1.14.99.1),
62,63
 lipoxygenase (LO, EC 1.13.11.12).
62
 A 
bacterial  cytochrome P450 (P450BM-3, a.k.a. CYP102A1) has recently been shown to 
monooxygenate the acyl chain of N-palmitoylglycine and other N-palmitoylamino 
acids.
65
  This enzyme is widely studied due to its similarity to mammalian  P450s, and the 
expression of mammalian cytochrome P450 (CYP4F, EC 1.14.13.30) was examined. 
NAGs contain a peptide bond, and therefore could be susceptible to proteolytic 
degradation as well.
54
 These degradative reactions are summarized in Table 4-4.   
  
4.2.4 Alternate Proposed Metabolism 
 
In addition to the metabolism described above, a number of less well supported 
hypotheses for PFAM b iosynthesis have been proposed (recently reviewed in references 
55,135), and are summarized in Table 4-5. 
The direct amidation of oleic acid by ammonia catalyzed by either FAAH 
working in reverse or by a glutamine synthetase-like enzyme has been proposed by more 
Table 4-4: Degradative Reactions for N-Acylglycines 
Enzyme Reaction ref 
PAM NAG + ASC + O2  PFAM + SDA + H2O + glyoxylate 1-8 
FAAH
a NAG/PFAM + H2O  FFA + glycine/NH3 15-21 
Protease NAG + H2O  FFA + glycine 54 
LO NAG + O2  HETE-Glys (oxidized NAGs) 62 
COX-2
b NAG + AH2 + 2O2  A + H2O  
+ PGH2-Gly and HETE-Gly (oxidized NAGs)  
62,63 
CYP4F
b,c NAG + AH2 + O2  A + H2O  
+ (ω-1, ω-2, and ω-3-monohydroxylated NAGs) 
65 
Degradative reactions for NAGs. 
aThis has only been shown for certain NAGs. 
bAH2 represents an electron acceptor such as NAD
+ 
cThe coenzyme used here is NADP+ because reactions were performed in vitro with bacterial 
CYP450BM-3 which used NADP+. This bacterial P450 is used as a model of mammalian 
flavoprotein-reductase-utilizing class II P450s, and the mammalian P450 would presumably 
use NAD+. 
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than one group.
23,57
 Monocarboxylates, like fatty acids, are not substrates for either 
glutamine synthetase
150
 or asparagine synthetase.
151
 The conversion of oleic acid to 
oleamide by rat brain microsomes is inhibited by both glutamine and ATP-Mg
2+
,
57
 data 
arguing against a glutamine synthetase-like synthesis of oleamide and the other PFAMs. 
The direct amidation of a FFA by the action of FAAH working in reverse was 
demonstrated in vitro.
16,57
 However, oleamide production in the N18TG2 cells increases 
upon the inhibition or inactivation of FAAH,
16,57
 and FAAH knockout mice were found 
to have increased levels of N-palmitoylglycine,
17
 providing evidence against a role for 
this enzyme for PFAM production in vivo. In addition, the conditions used to achieve 
these amidations were not biological: 50 mM ammonia and an optimal pH above 9.
16,57
 
Another proposed mechanism for oleamide biosynthesis is by aminolysis of 
phosopholipids
16
 or catabolism of sphingomyelin.
73
 There is no current evidence for 
sphingomyelin catabolism to a PFAM.
55
 Incubation of [
14
C]-oleic acid-containing 
phospholipids with NH4OH in the presence of N18TG2 cell homogenates did not result in 
the formation of [
14
C]-oleamide, arguing against phospholipid aminolysis as a route to 
the formation of intracellular oleamide.
16
  
 
Mueller and Driscoll (2009) recently reported oleamide synthesizing activity in 
fetal bovine serum (FBS).
55
 This “serum synthase” uses oleoyl-CoA and ammonia to 
form oleamide, or oleoyl-CoA and glycine to form N-oleoylglycine. The 65 kDa enzyme 
is reported to be inactivated by normal enzyme denaturing conditions (heat, solvent, 
Table 4-5: Proposed Alternate Paths for Primary Fatty Acid Amide Biosynthesis 
Proposed 
Amidation 
Reaction ref 
Cytochrome c Acyl-CoA + NH3 + H2O2 + 2H
+  PFAM + CoA-SH + 2H2O 11,12 
Gln Synthase FFA + ATP + Gln  PFAM + ADP + Pi + Glu 23 
FAAH (in reverse) FFA + NH3  PFAM + H2O  57 
Aminolysis Phospholipid + NH3  PFAM + Lyso-Phospholipid 
16,35,
36 
Catabolism 
 Sphingomyelin  PFAM + phosphosphingo 
-choline or -ethanolamine 
64 
Serum synthase Acyl-CoA + NH3 (or gly)  PFAM (or NAG)+ H2O 
55 
 
NAG synthase 
1. FFA + gly  NAG + H2O 
2. NAG  PFAM via PAM reaction 
25 
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trypsinization) and hydrogen peroxide, whereas cyt c is not inactivated under these 
conditions.
55
 
 Acyl-coenzyme A is not the only activated intermediate possible. Other possible 
activated fatty acids for attack by glycine could include a fatty acyl adenylate similar to 
the amino acid adenylates involved in charging tRNAs or in the biosynthesis of 
mycothiol.  Long-chain acyl adenylates are not known, but this does not rule out a 
potential role for them as activated intermediates. Another possibility could be a fatty 
acid thioester linked to a cysteine in a carrier protein, similar to intermediates observed in 
fatty acid biosynthesis.  
Bradshaw et al. recently proposed direct glycination of the fatty acid through a 
nucleophilic attack of the glycyl α-amino group at the carboxylate of the fatty acid by an 
unknown NAG synthase.
25
 Direct glycination seems chemically unreasonable at 
biological pH since the amino group would be protonated and, thus, would be a poor 
nucleophile to attack the carboxyl. One solution could be a decrease in the pKa of the  α-
amino group of the attacking glycine in the active site of the putative NAG synthetase. 
However, there is no direct evidence for such a novel NAG synthetase. Although the data 
presented from the Bradshaw group do not rule out such a unique chemistry, it also does 
not rule out the presence of an activated intermediate such as an acyl-CoA. 
Recent evidence has been given to show cyt c is responsible for the formation of 
oleamide as well as N-oleoylglycine from oleoyl-CoA in the presence of H2O2 in 
vitro.
11,24,132
 Cyt c was first identified as the oleamide-synthesizing enzyme in rat liver 
and kidney extracts.
11
 The cyt c reaction has a pH optimum of 7.5, and although it‟s 
stimulated greatly by the presence of H2O2, it can proceed at a low rate in the absence of  
H2O2 and has a KM of 21 µM for oleoyl-CoA with NH3. Radiolabel studies showed that 
other long-chain acyl CoAs could inhibit the formation of 
14
C-oleamide from 
14
C-oleoyl-
CoA, showing that other long-chain acyl CoAs could be substrates for cyt c.  
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However, the in vivo significance of these findings is unclear. Cells lacking both 
somatic and testicular forms of cyt c failed to upregulate oleamide biosynthesis during 
apoptosis as expected.
55
 Upon protein purification, the oleamide-synthesizing activity 
remained after heat denaturation and exposure to proteolytic enzymes, and maximal 
conversion under optimal conditions was only 39.5%. The turnover rate is also very slow: 
1 s
-1
 in optimal conditions.
11
 Neither ammonia nor H2O2 demonstrated saturating kinetics, 
and became inhibitory above their optimal concentrations.
11
 Again, the optimum amounts 
of H2O2 (2 mM) and ammonia (125 mM) are not in biological range, a finding that has 
prompted the proposal of an “oleamide synthesome”55 in which cyt c, SOD, ACBP and 
an AT would together act to house these high concentrations of substrates or keep them 
 
Figure 4-3: Hypothesized Oleamide Synthesome 
Conceptual diagram of oleamide synthesome proposed by Mueller and Driscoll.55 ACBP, 
Acyl-CoA binding protein; AT, amino transferase; cyt c, cytochrome c; SOD, superoxide 
dismutase. ACBP orients the acyl-CoA so that the thioester is in proximity to the oxidized 
Fe3+, which would then become reduced to Fe2+. AT would provide the amide nitrogen for 
nucleophilic attack at the acyl-CoA thioester. SOD provides H2O2 necessary to reoxidize 
the heme. Similar to the diagram in Mueller and Driscoll,55 but here curved arrows 
represent electron flow. 
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in a configuration to lower the optimal concentrations necessary (shown in Figure 4-3). 
Driscoll et al. has co-purified an ACBP and SOD with cyt c from rat kidney, providing 
support for such a synthesome.
11
 In this hypothetical oleamide synthesome SOD would 
produce H2O2, the ACBP would orient they acyl-CoA for action by cyt c, and the AT 
would generate the amide nitrogen, possibly from arginine or glutamine, although the 
amino transferase has not yet been identified.
55
 
The studies presented above provide for several hypotheses regarding the 
biosynthesis of NAGs and PFAMs. A summary of the evidence gathered in vivo and in 
vitro/in cellulo is shown in Figure 4-4. Most notably, there is likely more than one 
biosynthetic mechanism for the formation of NAGs in vivo: oxidation of an NAE and 
glycination of a FFA. Enzyme expression studies in NAG- and PFAM-producing cells 
should shed some light into which enzymes may be involved in their metabolism. In this 
study we examined the expression of putative NAG and PFAM biosynthetic enzymes, 
including ACGNAT, ACSL3-6, BAAT, NMT, FAAH-1, PAM, cyt c, ADH3-4, 
AlDH3A1-2 and CYP4F.  
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4.3 Model Cell Systems 
 
N18TG2 cells are an excellent model system for PFAM biosynthesis. When 
cultured with 
14
C-oleic acid, they produce 
14
C-oleamide and 
14
C-oleoylglycine.
28
 These 
cells must, therefore, contain all the necessary enzymatic machinery to produce PFAMs 
from FFAs. In order to gain a more thorough perspective about long-chain PFAM 
metabolism, two additional cell lines were examined: SCP and HEK-293 cells, both of 
 
Figure 4-4: In vitro and In Vivo Evidence for Amide Metabolism 
Summary of the current in vitro/in cellulo and in vitro evidence for NAG and PFAM 
metabolism. Where there was evidence both in vitro and in vivo/cellulo it is shown in green. 
For more details and specific references, see text. 
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which were shown to produce oleamide after incubation with oleic acid (Chapter 2). 
Several PFAMs have been found in the cerebrospinal fluid (CSF), 
72-74
  another reason to 
suggest that the CSF-producing choroid plexus cells are a good candidate for the study of 
PFAM biosynthesis. Glycination is a common method to facilitate urinary detoxification 
of acyl compounds
152-160
 (see also Chapters 1 and 2), explaining why these cells have 
been included in our studies. In addition, SCP and N18TG2 cells were shown to produce 
PFAMs from a variety of FFAs and from an NAE (Chapter 3), making them good 
candidates for analysis since they must both contain the enzymatic machinery for both 
the FFA  PFAM conversion and the NAE  PFAM conversion. 
In addition to the PFAM-producing cell lines, commercially available human 
cDNA was used for PCR analysis. Liver and kidney cells exhibit the highest expression 
levels of the short-and medium-chain acyl-CoA processing enzyme ACGNAT
161-166
 and 
were chosen not only to serve as positive control for expression of that enzyme but also 
for their potential to process long-chain acyl CoAs. Liver is also known to express 
BAAT.
40
 Since several PFAMs have been found in the cerebrospinal fluid (CSF), 
72-74
 
whole brain cDNA was also used as another positive control to find any proteins that may 
be expressed in SCP cells. 
4.4 Materials and Methods 
4.4.1 Materials 
 
Fetal bovine serum (FBS) was from Atlanta Biologicals (Lawrenceville, GA).  
Donor equine serum was from Thermo Scientific (Waltham, MA). DMEM, EMEM and 
penicillin/streptomycin were from Mediatech Cellgro (Manassas, VA). Mouse 
neuroblastoma N18TG2 cells were from DSMZ (Deutsche Sammlung von Mikrooganism 
und Zellkuturen GmBH). SCP and HEK-293 cells were from American Type Culture 
Collection (Manassas, VA). Primers were from Integrated DNA Technologies 
(Coralville, IA). MicroPoly(A) Pure mRNA purification kit and RETROscript Reverse 
Transcription kit were from Ambion (Austin, TX). First strand human cDNA was from 
Origene (Rockville, MD). QIA-Quick gel extraction kit was from Qiagen (Valencia, CA). 
PVDF membrane was from Millipore (Billerica, MA). Tween-20, protease inhibitor 
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cocktail (P8340) and Bradford reagent were from Sigma-Aldrich (St. Louis, MO). PAM 
(S-16) and FAAH (V-17) antibodes and their blocking peptides were from Santa Cruz 
Biotech, Inc. (Santa Cruz, CA). FACL5 (N-term), FACL3 (center), and FACL6 (center) 
antibodies (against ACSL proteins) and their corresponding blocking peptides were from 
Abgent (San Diego, CA). Goat anti-rabbit and donkey anti-goat secondary antibodies 
conjugated with horse radish peroxidase were from ICN Biomedical (Solon, OH).  The 
SuperSignal chemiluminescent detection system was from Pierce (Rockford, IL). All 
other reagents and cell culture supplies were of the highest quality available from 
commercial suppliers. 
4.4.2 Cell Culture  
 
All cells were grown in 225 cm
2
 culture dishes. N18TG2 cells were grown in 
DMEM supplemented with 100 µM 6-thioguanine. SCP and HEK-293 cells were grown 
in EMEM. All cell types were grown with 100 I.U./ml penicillin, 1.0 mg/ml streptomycin 
and 10% FBS (SCP and N18TG2) or horse serum (HEK-293) at 37
o
C and 5% CO2 
according to supplier instructions. Cultures were gown to 80% confluency, cells washed 
with PBS and trypsinized. Cells were collected by centrifugation, rinsed with PBS, and 
re-pelleted before removal of supernatant and lysis. 
4.4.3 Protein Sample Preparation 
 
Cell pellets were taken up in lysis buffer containing 20 mM Tris-HCl (pH 7.4), 2 
mM MgCl2, 1 mM EDTA, 1 mM EGTA, 150 mM NaCl, 1% (v/v) Triton X-100, and 1% 
(v/v) of a commercially available protease inhibitor cocktail.
After incubation at 4o for 
10 minutes, samples were sonicated on ice with a microprobe sonicator for 5 minutes. 
Samples were then centrifuged and the protein concentration of the supernatant was 
determined via a Bradford assay using BSA as the standard according to manufacturer‟s 
instructions. Samples were then diluted to 1-2 mg/ml with running buffer containing 5% 
β-mercaptoethanol and boiled for 5 minutes before storing at -20oC. 
                                                 

 From Sigma-Aldrich (P8340). Contained 4-(2-aminoethyl)benzenesulfonyl fluoride, pepstatin A, E-64, 
bestatin, leupeptin and aprotinin. 
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4.4.4 Western Blotting 
 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels 
were run with 10% (resolving) and 4% (stacking) acrylamide at 170 V until the dye front 
ran off the bottom of the gel (40-70 min). Gels were electroblotted to a PVDF membrane 
at 80 V for 1 hour, and membranes were soaked for 1 hour in a blocking solution (Tris-
buffered saline [TBS] containing 5% nonfat dry milk (NFDM) and 0.5% Tween-20 
(TBS-T)), and incubated overnight at 4
o
C in the presence of one of the following 
antibodies: PAM (S-16), FAAH (V-17), FACL5 (N-term), FACL3 (center), or FACL6 
(center) in TBS-T with 1% NFDM.  Antibodies were not commercially available for all 
enzymes of interest. Western blots were run for all available antibodies. 
After incubation, the membrane was washed 5 times with TBS-T, and then 
incubated for 1 hour with goat anti-rabbit or donkey anti-goat conjugated with horse 
radish peroxidase (diluted 1:10,000) in TBS-T with 3% NFDM at room temperature. A 
final set of 5 rinses was performed in TBS-T before visualizing antibody-antigen 
complexes using the SuperSignal chemiluminescent detection system on radiographic 
film. 
A molecular weight ladder was loaded to a lane on each SDS-PAGE gel. Initial 
studies were with an unlabeled ladder, Bio-Rad (Hercules, CA) prestained standards, cat# 
161-0318, and had to be drawn manually from the PVDF membrane to the film after 
exposure. Later studies utilized a commercial set of molecular weight standards 
(MagicMark
TM
 XP from Invitrogen, Carlsbad, CA) and contained an IgG binding site, 
allowing direct visualization with downstream immunodetection. Bands were measured 
from an origin to make a standard curve and the unknown molecular weight assigned 
based on that standard curve. One such example of a standard curve is shown in Figure 
4-14. 
 Blocking experiments were also performed with each antibody to verify that the 
proteins being detected were specific for the antibodies being used.  Antibodies were 
incubated with 50x molar excess of blocking peptide for 2.5 hours at 36
o
C with agitation, 
followed by 2-24 hours at 4
o
C in a total volume of 500 µl in PBS before continuing with 
normal Western blot procedure. For FACL5, several bands disappeared in the N18TG2 
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and SCP samples, leaving behind the bands of appropriate MW for ACSL5. This 
indicated the location of the true band for ACSL5 and showed that it was being expressed 
in the cells, as it outcompeted the blocking peptide for FACL5 antibody. The HEK-293 
cells did not show reduction of band number but had fewer bands after original 
incubation with FACL5 antibody. The bands disappeared for the remaining blocking 
experiments, but all previously detected bands had been the correct MW. 
4.4.5 RT-PCR and Sequencing 
 
Cell samples (N18TG2 and SCP) were isolated from culture (one T-75cm
2
 flask of 
~90% confluency), lysed, and their mRNA isolated using the MicroPoly(A) Pure
TM
 
mRNA purification kit. The mRNA sample was then reverse transcribed into cDNA 
using the RETROscript® Reverse Transcription kit. Human cDNA from liver, kidney 
and whole brain was used as commercially available. PCR primers were designed based 
on of available sequences from GenBank, and a list of primers used can be found in 
Appendix D. Typical PCR conditions were an initial 3 min denaturation at 95
o
C, 
followed by 25-45 cycles of denaturation at 95
o
C (1 min), annealing at 45
o
C (1 min) and 
elongation at 72
o
C (1 min) with a final elongation cycle of 7 min at 72
o
C.  The PCR 
product was gel-purified using a QIAQuick gel extraction kit, and the product sequenced 
on a Beckman sequencer or sent out for sequence verification at Moffitt Cancer Research 
Center.  
Primers were designed from the available sequences using the OligoPerfect
TM
 
primer designer from Invitrogen. Many sequences for sheep are unknown and primers 
were designed from multiple sequence alignments of other mammalian sequences from 
regions of high homology. Upon verifying sequenced results, Basic Local Alignment 
Search Tool (BLAST) results for multiple related species with a similarity score of ≥96% 
were considered positive results for sheep. 
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4.5 Results  
4.5.1 RT-PCR Gels 
 
The results of RT-PCR and PCR are shown below. For all of these samples, bands 
were subjected to sequencing for verification. BLAST hits of the sequencing results were 
used to confirm the identity of the putative mRNA sequence. A summary of these results 
can be found in Table 4-7 and Figure 4-20. 
 
 
 
 
 
 
 
        1                   2                 3                  4                5 
 
 
 
Figure 4-7: N18TG2 cDNA with Nested PAM primers 
Nested primers were used to detect the expression of PAM. No band was expected after the first 
round of PCR. 
 
Figure 4-6: N18TG2 RT-PCR for ACSL4 
Band on left shows N18TG2 cDNA with ACSL4 
primers (268 bp) 
 
     1         2        3   4        5         6        7         8  
 
Lane 1: neg control 
 2: ACGNAT (119 bp)* 
 3: ACSL3 (292 bp) 
 4: ACSL5,6 (205 bp) 
 5: BAAT (197 bp) 
 6: FAAH (334 bp) 
 7: PAM (194 bp) 
 8: MW ladder 
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200 
100 
 
300 
200 
 
Lanes  
1&2: PAM set 1  
   primers 
3: PAM set 2 primers  
   (nested) (431 bp) 
4: PAM set 2 primers,  
   negative control 
5. MW ladder  
 
600 
500 
400 
300 
200 
 
Figure 4-5: PCR in Human Kidney 
*Both ACGNAT bands were sequenced and both were 
matches to ACGNAT. There are two isomers of ACGNAT 
and the bands are expected to come from the two isomers. 
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Figure 4-10: SCP PCR for PAM 
SCP cDNA with PAM2 primer (nested) (431 bp) 
    1        2        3        4       5       6        7                 9       10      11     12      13      14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-9: PCR in Human Whole Brain and Liver cDNA 
*Note that band is wrong size in lane 13.  BLAST search of the sequencing results showed 
no significant similarity to database sequences 
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Figure 4-8: PCR for FAAH 
 
400 
300 
 
200 
 
Lane  1: SCP cDNA (no band) 
 2: human whole brain cDNA  
 3: human kidney cDNA 
 4. human liver cDNA  
 5: MW ladder 
All lanes with FAAH primers, and 
produce bands with 276 bp 
 
 Lane 1: brain + ACGNAT (119 bp) 
 2: brain + ACSL3 (292 bp) 
 3: brain + ACSL5,6 (205 bp) 
 4: brain + BAAT (197 bp) 
 5: brain + FAAH (334 bp) 
 6: brain + PAM (194 bp) 
 7: MW ladder (100-1000 bp) 
 9: liver + ACGNAT (119 bp) 
 10: liver + ACSL3 (292 bp) 
 11: liver + ACSL5,6 (205 bp) 
 12: liver + BAAT (197 bp) 
 13: liver + FAAH (334 bp)* 
 14: liver + PAM (194 bp) 
1000 
 
800 
700 
 
 
600 
500 
 
400 
300 
 
400 
300 
200 
100 
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 The PCR for ACGNAT in human kidney revealed two PCR bands (Figure 4-5), 
both of which were sequenced and both of which were positive matches to human 
ACGNAT after BLAST analysis. There are two isozymes of ACGNAT, consistent with 
the finding of two bands. No other ACGNAT PCR revealed two distinct bands. Another 
anomalous finding was that a band appeared as a product of PCR with human liver 
cDNA and FAAH primers that was smaller than the expected size (Figure 4-9). 
Sequencing and BLAST analysis revealed no significant similarity to database sequences. 
 No positive result could be obtained for FAAH in SCP cells. Four different primer 
sets were designed and tested, each with no positive results. PAM was found in every 
sample tested, as were each ACS isoform and cyt c, as would be expected. In cases where 
enzyme expression could not be found in the SCP and N18TG2 model cell lines, human 
cDNA acted as a means to test the efficacy of the system for detection of those enzymes. 
ACGNAT, BAAT and AlDH3A2 were all found in the human cDNA but not the model 
cell lines. CYP4F was not found in SCP cells which may reflect a low abundance or 
                    Human (157bp)                     SCP 
      Liver             Brain           Kidney                          N18TG2 (192bp)            (177bp) 
 
Figure 4-13: Cytochrome C PCR 
The expected band sizes are shown above in parentheses. 
 
Figure 4-12: SCP ADH3 PCR 
SCP with ADH3 primer (323 bp) 
        Kidney                   Brain                   Liver 
 
Figure 4-11: AlDH3A2 Human Brain, Liver and Kidney PCR 
Human DNA with AlDH3A2 primers (324 bp) 
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expression of a different isoform(s) in those cells, as there are many. There were three 
enzymes whose mRNA could not be detected in any samples: ADH4, AlDH3A1 and 
NMT (although NMT was only tested in SCP and N18TG2 cDNA). However, other 
isoforms of ADH and AlDH were detected. Table 4-7 provides a summary of PCR 
results. 
                         
4.5.2 Western Blots 
 
Sample Western blots are shown below. Not all enzymes had commercially 
available antibodies, and Western blots were performed for all available antibodies. A 
summary of these results can be found in Table 4-7 and Figure 4-20. A sample graph for 
determination of molecular weight from a protein ladder is shown in Figure 4-14. 
.  
 
  
 
Figure 4-14: Standard Curve for a MW Ladder in SDS-PAGE 
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    HEK-293                    N18TG2                                                    SCP 
        5µg                             5µg                                             5µg             10µg 
 Figure 4-17: FACL6 Western Blots 
Western blot for N18TG2, HEK-293 and SCP cells with FACL6 antibody 
against ACSL6. The amount of protein loaded is listed at the top of each well.  
Published MW for ACSL6 include 75 kDa (human K562 cells)30, 78 kDa 
(human erethrocytes)26,27 A cross-reacting protein around 55 kDa (PC12 cells) 
was also reported29 
                
     HEK-293                             N18TG2                                                             SCP                                  
         5µg                                    5µg                                                      5µg               10µg 
 
Figure 4-16: FACL5 Western Blots 
Western blot for N18TG2, HEK-293 and SCP cells with FACL5 antibody against 
ACSL5. The amount of protein loaded is listed at the top of each well. Published 
MW for ACSL5 include 73, 74.5 and 76 kDa (rat liver)22,37 
 
 
                        N18TG2                                     HEK-293                          N18TG2 
     22.5µg          5µg           15µg                   5µg            15µg                5µg          15µg 
       
 
Figure 4-15: FACL3 Western Blots 
Western blot for N18TG2 and HEK-293 cells with FACL3 antibody against ACSL3. 
The amount of protein loaded is listed at the top of each well. Published MW for 
ACSL3 include 79-80 kDa, 73kDa, and 64 kDa9 (from rat and mouse brain and 
human liver). The N18TG2 sample on the left was lysed with a protease inhibitor 
cocktail with dithiothreitol, PMSF, Na3VO4 and aproprotinin instead of the cocktail 
from Sigma. 
83 
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 The Western blot bands detected matched literature-reported molecular weights 
fairly well (see Table 4-6, and captions of Figure 4-15Figure 4-19). Although the 
molecular weights in this study that are displayed in Table 4-6 are derived from 
measuring the distance traveled over the length of the gel and plotting this ratio against a 
standard curve, inconsistencies in the gel and interference from overabundant protein in a 
single well can change the position of the band, as seen in Figure 4-15. In this case, the 
two different lanes containing HEK-293 proteins show different molecular weights due to 
loading a greater amount of protein in the “15µg” well. To help alleviate this, multiple 
wells were usually run with different amounts of protein from the same source.  In each 
Western blot sample, the molecular band patterns across the three species were very 
similar, with the exception of PAM. There are many splice variants of PAM, and 
                HEK-293                                N18TG2                                                     SCP 
       10ug            5ug       10ug        15ug         20ug        25ug                       10ug       15ug 
  
Figure 4-19: FAAH (V-17) Western Blot 
Western blot for N18TG2, HEK-293 and SCP cells with an antibody against FAAH. The 
amount of protein loaded is listed at the top of each well. FAAH (V-17) was the name of the 
antibody from Santa Cruz Biotech, Inc. Published MW for FAAH includes 60 kDa (mouse 
uterus, rat COS-7 cells)38,39 
These samples were lysed with a different protease inhibitor cocktail than listed in the 
methods. This cocktail contained dithiothreitol, PMSF, Na3VO4 and aproprotinin. 
 
                             SCP                                       N18TG2                   HEK-293 
              10µg         5µg                                  5µg                         5µg                               
 
 Figure 4-18: PAM (S-16) Western Blot 
Western blot for N18TG2, HEK-293 and SCP cells with PAM (S-16) antibody 
against PAM. The amount of protein loaded is listed at the top of each well. PAM 
(S-16) was the name of the antibody from Santa Cruz Biotech, Inc. Published 
MW for PAM include 80, 84-86 and 110 kDa (rat tissues)34-36 PAM-1 from 
mouse AtT-20 cells is 120 kDa.37 There are many splice variants of PAM.37,45 
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85 79 
57 
59 
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different tissues display different isoform expression.37,45 Expression data gathered 
through Western blotting matched that gathered via RT-PCR. 
  
 
 
4.5.3 Summary 
 
Using RT-PCR (or PCR) and DNA sequencing supplemented and verified by 
Western Blot analysis where possible, the expression of several purported PFAM 
biosynthetic enzymes was assayed in a series of cells and cDNA libraries, including the 
N18TG2, SCP and HEK-293 cells, and in cDNA libraries from human liver, kidney, and 
whole brain cDNA. These expression data for all DNA sources are summarized in Table 
4-7, and a visual representation of how these data fit with amide metabolism in N18TG2 
and SCP cells is shown in Figure 4-20. Not all enzymes had commercially available 
Table 4-6: Molecular Weights of Western Blot Bands: Detected and Published 
Enzyme MW detected Published 
MW 
Ref 
ACSL3 83 83 79 79 79 9 
74 74 73 73 73 
64 64  64 64 
ACSL5 
75 75 75 
76 
74.5 
22 
73 73 73 73 
ACSL6
a 
78
 
78 78
 
78
 26,27 
57 
57 57 55 
55
 
PAM 124 120 34-
36 85 84-86 
79 79 80 
FAAH 59 57 60 60 38,39 
Abbreviations: ACSL, long-chain acyl-CoA synthetase; FAAH, fatty acid 
amide hydrolase; MW, molecular weight; PAM, peptidylglycine α-amidating 
monooxygenase 
Color key: mouse; sheep; human; rat; monkey 
The tissue/cell source of each published MW is given in the caption below the 
corresponding Western blot figure. 
a
A cross-reacting 55kDa protein was reported to bind to anti-ACSL6 
antibodies 
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antibodies, and where it was possible to perform both a Western Blot and RT-PCR, the 
results were in good agreement with each other.  
 
 
 
Cyt c was found in all cell lines, as would be expected due to its important role in 
oxidative phosphorylation. The presence of ACSL(3-6), PAM, and FAAH, and not 
BAAT, ACGNAT or NMT in the oleamide-producing N18TG2 cells supports the 
hypothesis that cyt c or an enzyme yet to be discovered catalyzes N-fatty acylglycine 
Table 4-7: Summary of Expression Data 
 N18TG2 SCP HEK-293 Liver Brain 
Enzyme  PCR WB PCR WB PCR WB PCR PCR 
Acyl-CoA:glycine N-
acyltransferase (ACGNAT) P-  
P- 
 
P+ 
 
P+ P- 
Long Chain Fatty Acyl-CoA 
Ligase 3 (ACSL3)  
W+ 
 
W+ P+ W+ P+ P+ 
Long Chain Fatty Acyl-CoA 
Ligase 4 (ACSL4) P+  
P+ 
   
  
Long Chain Fatty Acyl-CoA 
Ligase 5 (ACSL5)  
W+ 
 
W+ P+ W+  P+ 
Long Chain Fatty Acyl-CoA 
Ligase 6 (ACSL6)  
W+ 
 
W+ P+ W+  P+ 
Bile Acid-CoA:amino acid N-
acyltransferase  (BAAT) P-  
P- 
 
P- 
 
P+ P- 
N-Myristoyltransferase 
(NMT)  P-  
P- 
   
  
Fatty acid amide hydrolase 
(FAAH-1) P+ W+ P- W- P+ W+ P+ P+ 
Peptidylglycine α-amidating 
monooxygenase (PAM)  P+ W+ P+ W+ P+ W+ P+ P+ 
Cytochrome C (Cyt c) 
P+ 
 
P+ 
 
P+ 
 
P+ P+ 
Alcohol dehydrogenase 4 
(ADH4)  P-  
P- 
 
P- 
 
P- P- 
Alcohol dehydrogenase 3 
(ADH3) P-  
P+ 
 
P+ 
 
P+ P+ 
Aldehyde dehydrogenase 3A1 
(AlDH3A1) P-  
P- 
 
P- 
 
P- P- 
Aldehyde dehydrogenase 3A2 
(AlDH3A2) P-  
P- 
 
P+ 
 
P+ P+ 
Cytochrome P450 (CYP4F) 
P+ 
 
P- 
 
P+ 
 
P+ P+ 
P+/-, expression was/was not found by (RT-)PCR; W+/-, expression was/was not found by Western 
Blot 
For human kidney samples, the cDNA was used for PCR and HEK-293 cells were used for Western 
blotting. PCR and Western blot results agree. At least one positive result was obtained for each enzyme 
except AlDH3A1 and NMT. 
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production by the proposed glycination route in vivo.  Control experiments showing the 
expression of ACGNAT and BAAT in liver and ACGNAT in kidney are consistent with 
literature reports,
40,125,128,129
 and demonstrate the ability to find those enzymes at least in 
those cells. The expression of metabolic processing enzymes as found in these studies 
may contribute to the small amounts of NAGs isolated throughout tissue and cell 
types,
17,101-103,111
 since any NAG formed would be quickly metabolized by PAM, FAAH 
or CYP4F, or any of the other processing enzymes not probed for in this study (Table 
4-4). No ADH4 expression was found in any cells, but those tissues probed are not 
known to contain ADH4, which is characteristically expressed in epithelial tissues of the 
aerodigestive tract and a few other tissues.
167
 The lack of expression of the specific ADH 
and AlDH enzymes for which we probed denotes that either other ADH and possibly 
AlDHs may be responsible for NAE oxidation in N18TG2 cells, or that glycination of the 
FFA is the only pathway for NAG formation in these cells (aside from possible direct 
amidation of acyl-CoA by cyt c, or some unknown possibility).  
172 
 
 
 
 
The expression of ADH3 alongside PAM, ACSL and cyt c in the SCP cells shows 
that there are multiple possible mechanisms to synthesize NAGs in these cells, and 
confirms that the metabolic network may be more complicated than a linear scheme 
(refer to Figure 4-1 Figure 4-20). SCP cells may be able to synthesize NAGs both 
through glycination of the FFA and oxidation of an NAE.  
FAAH had previously been found in N18TG2 cells,
168,169
 and those findings were 
confirmed in this report. FAAH-1 was also found in human liver, kidney and brain,
47,170
 
findings which were also replicated here. SCP cells had approximately 45 times as much 
endogenous oleamide and at least 10 times as much after incubation with oleic acid (see 
 
Figure 4-20: Metabolic Diagram of Expression Data for SCP and N18TG2 Cells 
Overview of expression data in SCP (pink) and N18TG2 (orange) expression data as it relates to 
the proposed metabolic pathways. 
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Chapters 2 and 3). The lack of detectable levels of FAAH expression in SCP cells is 
commensurate with the higher levels of PFAM that were detected in previous chapters, 
and makes sense given the known role of  choroid plexus in producing CSF
171
 where 
PFAMs have been found.
72-74,172
  
The literature precedence for FAAH expression is mixed. While there has been a 
noted lack of FAAH expression in mouse choroid plexus (CP),
173
 FAAH has been found 
in rat CP.
173
 Since oleamide has been found in rat plasma (35-56nM)
89,172
 and rat 
cerebrospinal fluid (156nM),
172
 enzymologic studies may reveal the affinity of rat FAAH 
for oleamide to be lower than other species‟ or for the active oleoyl amide in rats to be 
primarily N-oleoylglycine, since it can act independently of oleamide.
104
 The possibility 
that different mammalian FAAH shows different substrate specificity may have some 
precedence. Although human and rat FAAHs share 82% amino acid identity, they 
demonstrate distinguishable enzymological properties.
15
 Rat FAAH shows a much lower 
rate of hydrolysis of myristamide and palmitamide than does human FAAH; human 
FAAH hydrolyzes these substrates about three times faster.
15
 N-arachidonoylglycine is a 
much more potent inhibitor of rat FAAH than of human or mouse, and N-
arachidonoylalanine is a much more potent inhibitor of human and rat FAAH than of 
mouse.
20
 
The level of each PFAM found in Chapter 3 after incubation with the 
corresponding FFA in N18TG2 cells was inversely proportional to substrate preference for 
FAAH, but this pattern was not observed in SCP. With no FAAH to put pressure on the 
degradation of these PFAMs, the SCP cells showed a different profile. This difference in 
PFAM fingerprint, along with the large difference in PFAM amount in the two cell lines, 
demonstrates the importance of FAAH in determining endogenous levels of PFAMs.  
One of the central questions in NAG biosynthesis is that of the prevalence of the 
two competing pathways hypothesized: NAE oxidation of FFA glycination (Figure 4-2). 
In Chapter 3 it was shown that SCP and N18TG2 cells show different affinities for FFAs 
and NAEs in converting them to the PFAM. N18TG2 cells were indiscriminant with 
respect to the formation of tridecanamide from its two metabolic precursors: N-
tridecanoylethanolamine (TDEA) and tridecanoic acid (TDA). SCP cells, however, were 
able to convert TDEA to the corresponding PFAM at a higher rate than for the FFA. One 
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possibility is the differential expression of discriminating fatty acyl amide transport 
proteins in the two cell lines. The expression data presented here provides a hypothesis. 
N18TG2 cells lacked expression of all ADH and AlDH‟s examined. Thus, these cells 
likely metabolized TDEA to TDA by way of FAAH before conversion to tridecanamide. 
This may explain why TDA and TDEA were equal metabolic substrates in N18TG2 in 
terms of PFAM formation, as the acyl chains would all proceed through the same 
metabolic pathway, and the action of FAAH would not impede this metabolism due to its 
high turnover rate.
15
 Another NAE-hydrolyzing enzyme, N-acylethanolamine-
hydrolyzing acid amidase (NAAA) may also hydrolyze TDEA to its corresponding 
FFA.
46
 The expression of NAAA was not examined.  
SCP cells were shown to express ADH3. While ADH3 is not known to perform the 
N-acylglycinal  NAG reaction, it could be responsible for the synthesis of the aldehyde 
intermediate and an unidentified enzyme could finish the oxidation to an NAG. Studies 
have also shown that this dismutation of the relatively unstable long-chain aldehyde 
intermediate to its NAG can proceed at low rates non-enzymatically.
141
 Therefore, it is 
hypothesized that sequential oxidation of an NAE is the preferred metabolic route in SCP 
cells. 
HEK-293 cells were used for the Western blot expression studies, but 
commercially available human whole kidney cDNA was used for PCR. All the enzymes 
found in the whole human kidney cDNA were also found in HEK-293 cells even though 
HEK-293 contained only epithelial cells of the kidney. 
4.6 Conclusions 
The expression data presented here helps confirm several hypotheses diagrammed 
in Figure 4-1. Sequential oxidation of an NAE is a possible alternate route to the 
synthesis of N-acylglycines since dehydrogenases were found to be expressed in 
oleamide-producing SCP cells, cells that also showed a differential pattern of FFA and 
NAE conversion to PFAMs than N18TG2 cells. Perhaps the most significant finding was 
in regards to putative enzymes involved in the acyl-CoA  NAG reaction. Cyt c or a 
novel enzyme is likely to be involved in conversion from acyl-CoA to the NAG 
intermediate since no other CoA:glycine transferring candidate enzymes were found in 
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the N18TG2 cells (Figure 4-20 and Table 4-8). More analysis is required to determine the 
exact in vivo role of cyt c and regulatory mechanisms of this pathway. 
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5 Metabolic Elucidation of PFAM and NAG Biosynthetic 
Pathways 
 
5.1 Introduction 
 
The findings in Chapters 2-4 provide new information regarding the biosynthesis of 
NAGs and PFAMs in model cell lines. Both N-acylethanolamines (NAEs) and free fatty 
acids (FFA) can serve as precursors for the formation of primary fatty acid amides 
(PFAMs), and although the list of candidate enzymes involved in these pathways has 
been narrowed, their identities are still unclear. Enzyme expression assays provided no 
alcohol dehydrogenase (ADH) candidate in the N18TG2 cells, and the only putative 
glycination enzyme found was cytochrome c (cyt c), which one would expect to find in 
every cell line performing oxidative phosphorylation. 
Herein the role of cyt c in PFAM formation is investigated. We also examine the 
kinetics and mechanism of PFAM formation from NAE and FFA precursors using 
isotope labeling. In addition, we examine further the roles of fatty acid amide hydrolase 
(FAAH) in an additional model cell line, aortic endothelium, to further our understanding 
of not only the degradative enzyme but also the potential role of PFAMs in the 
cardiovascular system. Additionally, we explore the role of peptidylglycine α-amidating 
monooxygenase (PAM) with specific RNAi targeting combined with isotopic labeling to 
explicitly define its role in PFAM biosynthesis. 
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5.2 Primary Fatty Acid Amides and FAAH in Aortic Endothelial 
Cells 
 
Peptidylglycine α-amidating monooxygenase (PAM) is widely distributed 
throughout the body, and has been found in the cardiovascular system in cardiac 
ventricles,
5
 blood,
6
 atria,
5
 and aortic endothelium.
7
 Other α-amidating peptide 
biosynthetic enzymes, prohormone convertase 1 and 2 and carboxypeptidase E, are also 
found in the atria.
8-11
 These enzymes, including PAM, are known to play important roles 
in regulating amidated peptides in the cardiovascular system,
7,12,13
 but amidated acyl 
chains (PFAMs) have only been isolated from whole rabbit heart,
14
 so the individual 
tissue component(s) responsible for PFAM biosynthesis are unknown,
15
 although 
PFAMs have been found in human
16
 and rat
17,18
 plasma and rat cerebrospinal fluid.
17
 It 
has been suggested that these molecules are rapidly degraded by fatty acid amide 
hydrolase (FAAH), making their isolation difficult. 
FAAH has been established as the enzyme responsible for hydrolyzing oleamide 
and other primary fatty acid amides (PFAMs) and N-acylethanolamines (NAEs) in vitro 
and in other cell systems.
19
 FAAH has been well characterized in two endothelial cell 
lines: rat kidney
20
 and human umbilical vein.
21
 Although FAAH-2 has been found in 
primate heart, FAAH-2 is not a murid enzyme and to date there has been no evidence for 
PFAM hydrolysis via FAAH in the heart where PAM has been found.
15,22
  
Phenylmethylsulfonyl fluoride (PMSF) is a known FAAH inhibitor,
15
 and it has 
been used to prevent anandamide degradation in rat brain membrane samples.
23
 In this 
study, we attempt to determine whether oleamide can be isolated from human aortic 
endothelial cells (HAEC) endogenously, and whether FAAH is actively degrading 
oleamide in these cells to better understand the role of oleamide and other PFAMs in the 
cardiovascular system. Aortic endothelial cells were chosen because of their role in 
vasorelaxation,
24
 where anandamide-regulated vasodilation is endothelium-dependent.
25
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5.2.1 Materials and Methods 
5.2.1.1 Materials 
 
HAEC cells and endothelial cell basal medium with growth supplements were 
from Lonza (Walkersville, MD). Oleic acid (OA) was from Sigma-Aldrich (St. Louis, 
MO). BSTFA and silica were from Suppelco (St. Louis, MO). All other reagents and cell 
culture supplies were of the highest quality available from commercial suppliers. 
5.2.1.2 Cell Culture and Fatty Acid Incubation 
 
Cells were grown in 75 cm
2
 culture dishes at 37
o
C and 5% CO2 according to 
manufacturer’s instructions. Cultures were grown to 75-90% confluency and 200 µM 
oleic acid was added alone or in combination with either 1% dimethylsulfoxide (DMSO) 
or 100 µM phenylmethylsulfonyl fluoride (PMSF). Note that BSA was not used as a 
carrier protein for OA. PMSF (100 µM) was added to flasks containing OA for the last 
hour of incubation (except for the flask already containing PMSF). (For a sample list see 
Table 5-1). Cells were then collected by scraping, centrifuged, the conditioned media 
decanted, and the resulting cell pellet and conditioned media stored at -80
o
C. Cells were 
too small to count on the available microscopes so a cell volume was taken instead. Cell 
count was estimated based on the assumptions of cell density being 1 g/ml and the weight 
of a human cell being 10
-9
 g.
4
  
5.2.2 Metabolite Extraction 
Metabolites were extracted from cells using protocols similar to Sultana and 
Johnson.
26
 Methanol (10 ml) was added to the cell pellets and samples were sonicated for 
15 minutes at room temperature. Samples were centrifuged at 5000 rpm for 10 min and 
the supernatant decanted and dried under N2 in a warm water bath at 40-50
o
C. The pellet 
was re-extracted with 4 ml 1:1:0.1 (v/v/v) chloroform:methanol:water, sonicated for 10 
min, vortexed 2 min and centrifuged 10 min at 5000 rpm. The supernatant from this step 
was added to the supernatant from the previous step and continued drying under N2 at 40-
50
o
C. The pellet was re-extracted with 4.8 ml chloroform:methanol 2:1 (v/v) and 800 µL 
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0.5 M KCl/0.08 M H3PO4, sonicated 2 min, vortexed 2 min, and centrifuged 10 min at 
5000 rpm. The lower lipid phase was added to the supernatants from the previous steps 
and taken to dryness under N2 at 40-50
o
C.  
Metabolite extraction from conditioned media was carried out similarly.  The 
entire media contents of each experimental flask were centrifuged to pellet any cells and 
the supernatant submitted to solvent extraction. The first two extractions were with 15 ml 
chloroform:methanol 2:1 and the second two extractions with 15 ml chloroform:methanol 
2:1 and 2.4 ml 0.5 M KCl/0.08 M H3PO4. No sonication was performed, and protein 
layers were condensed by centrifugation for 30-45 min at 10,000 rpm. Organic lipid 
phases were also combined and dried under N2 at 40-50
o
C. 
5.2.3 Solid Phase Extraction 
Silica columns (0.5g) were washed with n-hexane and run essentially as described 
by Sultana and Johnson.
26
 Lipid extracts were taken up in 100 µL n-hexane and added to 
washed silica columns. The mobile phase was run without positive pressure as follows: 4 
ml n-hexane, 1 ml 99:1 hexane:acetic acid, 1 ml 90:10 hexane:ethyl acetate, 1 ml 80:20 
hexane:ethyl acetate, 1 ml 70:30 hexane:ethyl acetate, 1.5 ml 2:1 chloroform:isopropanol, 
0.5 ml methanol. The last two fractions were combined and dried down under N2 at 40-
50
o
C.   
5.2.4 Sample Derivitization 
Trimethylsilylation was achieved using 100 µL BSTFA (N,O-
bis(trimethylsilyl)trifluoroacetamide). Samples were flushed with dry N2, BSTFA added, 
flushed briefly again, and allowed to react at 55-60
o
C for 1 hour. More nitrogen was 
flushed to reduce the sample volume, and the entire sample was injected onto the GC-
MS. 
5.2.5 GC-MS 
All separations were performed using a Shimadzu QP-5000 GC-MS. Separations 
were achieved on a J & W Scientific DB-5 column (0.25 mm x 30 m) in splitless mode. 
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The GC temperature program was 55-150
o
C at 40
o
C/min, hold at 150
o
C for 3.6 min, 
ramp at 10
o
C/min to 300
o
C, and hold for 1 min. The transfer line was held at 280
o
C and 
the injection port at 250
o
C throughout the separation.  Helium was used as the carrier gas, 
at a flow rate of 0.9 ml/min.  The mass range was 35-750 amu with a scan speed of 2000. 
The solvent cut time was set to 5 min. 
5.2.6 Results 
 
The amount of oleamide in each HAEC cell and conditioned media sample was 
successfully determined and can be found in Table 5-1. The amount of oleamide found 
after 24 and 48 hours of incubation with OA (and no BSA vehicle) was approximately 
the same, but both values were much higher than that observed in the normal cell sample.  
An interesting note is that incubation for 48 hours with OA and a delivery vehicle, 
DMSO, resulted in an even greater amount of oleamide per cell than did inhibition of 
FAAH. 
 
 
Table 5-1: Oleamide in HAEC Cells 
Incubation Conditions Oleamide in 
Cells 
Oleamide in 
Media 
Total 
48h 1% DMSO + OA 11.6 215 227 
24h OA 11.2 52 63.2 
48h PMSF + OA 10.1 101 111 
48h OA 2.5 61 63.5 
normal 1.2 0 1.2 
Values are average pmol oleamide per 107 cells. Cell count was 
estimated based on cell volume and an estimated cell weight of 10-9g.4 
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Inhibition of FAAH by PMSF has resulted in a marked increase in oleamide 
production after 48 hours as compared to cells incubated with OA and no FAAH inhibitor 
(Figure 5-1), indicating that FAAH or another protease targeted by PMSF contributes to 
the degradation of oleamide or one of its precursors. Another possibility is that a protease 
that would normally hydrolyze N-oleoylglycine is being targeted by PMSF, although a 
protease responsible for this hydrolysis has not yet been identified (see Chapter 4). 
The finding of oleamide in endothelial cells is consistent with their function in 
control of vasodilatation, as oleamide is a potent vasorelaxant,
24
 and indicates that 
PFAMs may have a function in the cardiovascular system. Another function of 
endothelial cells is in angiogenesis, and erucamide is known to play a role in blood vessel 
growth.
27,28
 It would not be unexpected to find erucamide and other PFAMs in this tissue 
type. 
Although PMSF is a known FAAH inhibitor, it and many other chemical inhibitors 
are not necessarily specific to the enzymes of interest. The development of RNA 
interference (RNAi) allows for direct targeting of the enzyme of interest by taking 
advantage of the natural defense system of the cell against double-stranded bacterial 
 
Figure 5-1: Amount of Oleamide in HAEC Cells 
Oleamide extracted from HAEC cells after 
incubation with OA. Cell count was estimated 
based on cell volume and an estimated cell 
weight of 10-9g.4 
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RNA, and is used herein to explore the functions of two other potential PFAM-forming 
enzymes: PAM and cytochrome c. 
5.3 siRNA optimization 
 
When double stranded RNA (dsRNA) is detected in a eukaryotic cell containing 
this defense system, the enzyme Dicer cleaves long dsRNA into shorter fragments of 
dsRNA about 20-25 nucleotides in length. Many modern RNAi experiments start by 
incubating with these shorter dsRNA pieces delivered by some vehicle through the 
media. One of the strands of these small interfering RNA (siRNA) pieces is then bound to 
an endonuclease-containing RNA-induced silencing complex (RISC) to act as a template 
to search for complimentary mRNA within the cell. Once a complimentary mRNA 
sequence is detected by the RISC complex, it is cleaved by the Argonaute portion of the 
complex, preventing its translation and effectively knocking down expression of that 
gene. 
In order to use siRNA for gene silencing, experimental conditions had to be 
optimized for the N18TG2 cells. Typical methods of siRNA delivery include transfection 
reagents and, for more problematic samples, electroporation. Exact structures of 
transfection reagents are proprietary, but most are lipid- or amine-based. Electroporation 
is used in samples for which standard transfection methods are problematic.
29
 Two 
transfection reagents were used in this study. 
5.3.1 Materials and Methods 
 
5.3.1.1 Materials 
 
Transfection was done with Silencer® siRNA transfection II optimization kit 
from Ambion (Austin, TX) containing both siPORT
TM
 NeoFX
TM
 and siPORT
TM 
Amine 
transfection reagents, GAPDH siRNA and scrambled siRNA. DMEM and 
penicillin/streptomycin were from Mediatech Cellgro (Manassas, VA). Fetal bovine 
serum (FBS) was from Atlanta Biologicals (Lawrenceville, GA).  Mouse neuroblastoma 
N18TG2 cells were from DSMZ (Deutsche Sammlung von Mikrooganism und Zellkuturen 
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GmBH). PVDF membranes were from Millipore (Billerica, MA). Tween-20, protease 
inhibitor cocktail (P8340), and Bradford reagent were from Sigma-Aldrich (St. Louis, 
MO). GAPDH (FL-335) antibody was from Santa Cruz Biotechnology, Inc.  (Santa Cruz, 
CA) Goat anti-rabbit secondary antibody conjugated with horse radish peroxidase was 
from ICN Biomedical (Solon, OH). SuperSignal chemiluminescent detection system was 
from Pierce (Rockford, IL). All other reagents and cell culture supplies were of the 
highest quality available from commercial suppliers. 
5.3.2 Cell Culture  
 
During normal growth, N18TG2 cells were grown in DMEM supplemented with 100 
µM 6-thioguanine, 100 I.U./ml penicillin, 1.0 mg/ml streptomycin and 10% FBS at 37
o
C 
and 5% CO2 according to supplier instructions. During RNAi optimization experiments, 
2.5x10
4
 cells were incubated in each well of a 6-well plate; DMEM + pen/strep (normal 
media with no FBS) was used (instead of OPTI-MEM I media as suggested by the 
manufacturer. The concentration of each siRNA was used as suggested by the 
manufacturer, and two different delivery reagents: siPORT Amine and siPORT NeoFX, 
were used according to manufacturer’s instructions. After 72 hours incubation, cells were 
collected by scraping, centrifuged in a sterile 1.5 ml Eppendorf tube, rinsed with PBS, 
and re-pelleted before removal of supernatant and cell lysis. 
5.3.3 Protein Sample Preparation 
 
Cell samples were resuspended in lysis buffer containing 20 mM Tris-HCl (pH 
7.4), 2 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 150 mM NaCl, 1% Triton X-100, and 
1% of a commercially available protease inhibitor cocktail.

 After incubation at 4
o
 for 10 
minutes, samples were sonicated on ice with a microprobe sonicator for 5 minutes. 
Samples were then centrifuged, and the protein content of the supernatant determined by 
Bradford assay. The supernatant was diluted to 1-3 mg/ml with running buffer containing 
5% β-mercaptoethanol and boiled for 5 minutes before storing at -20oC. 
                                                 

 From Sigma-Aldrich (P8340). Contained 4-(2-aminoethyl)benzenesulfonyl fluoride, pepstatin A, E-64, 
bestatin, leupeptin and aprotinin. 
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5.3.4 Western Blotting 
 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels 
were run with  10% (resolving) and 4% (stacking) acrylamide at 170 V until the dye front 
ran off the bottom of the gel. Gels were electroblotted to a PVDF membrane at 80 V for 1 
hour, and membranes were soaked for 1 hour in a blocking solution (Tris-buffered saline, 
TBS, containing 5% nonfat dry milk (NFDM) and 0.5% Tween-20 (TBS-T)) and 
incubated overnight at 4
o
C in the presence of the antibody (diluted 1:500) in TBS-T with 
1% NFDM.   
After incubation, the membrane was washed 5 times with TBS-T, and then 
incubated for 1 hour with goat anti-rabbit conjugated with horse radish peroxidase 
(diluted 1:10,000) in TBS-T with 3% NFDM at room temperature. A final set of 5 rinses 
was performed in TBS-T before visualizing antibody-antigen complexes using the 
SuperSignal chemiluminescent detection system (Pierce, Rockford, IL) on radiographic 
film. 
 
5.3.5 Results 
 
 GAPDH knockdown was observed in N18TG2 cells incubated with siRNA in the 
siPORT
TM
 Amine, but not the siPORT
TM
 NeoFX
TM
, transfection reagent, as seen in 
Figure 5-2. Published MW for GAPDH (37 kDa) is similar to that found here.
1-3
 In 
addition to the successful demonstration of siPORT
TM
 Amine as a transfection reagent for 
N18TG2 cells, the demonstration that no knockdown occurred after incubation with 
scrambled siRNA indicates no off-target effects in this system. 
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5.4 PAM knockdown studies 
 
One of the criticisms of PFAM metabolic elucidation is that, while 
pharmacological inhibitors have been used to target PAM in vitro
30,31
 and in cellulo,
32
 
these inhibitors lack specificity and high efficacy.
33,34
 Inhibition of PAM by trans-4-
phenyl-3-butenoic acid (PBA) after injection was very short lived, with serum PHM 
activity being restored after just 24 hours.
34
 In addition to targeting PAM, 1 mM PBA 
was also shown to inhibit cyclooxygenase-2 activity by 82%,
35
 which may cause 
undesired off-target effects in cellulo. 
Although pharmacological inhibitors have been used to demonstrate the 
accumulation of  
14
C-N-Oleoylglycine after incubation with 
14
C-oleic acid,
32
 strongly 
suggesting that PAM is involved in converting N-oleoylglycine to oleamide, an 
experiment designed to specifically target PAM is required to determine the extent of its 
in celluo significance in this pathway. There are more specific and effective 
pharmacological inhibitors of PAM,
35
 but the most effective and specific inhibitor by 
modern standards is targeted siRNA. Another layer of specificity is added by the use of a 
labeled substrate: 
13
C18-oleic acid. Incubation with labeled OA and with successful PAM 
knockdown using the NAG assay method developed in Chapter 2 would represent 
          
Figure 5-2: RNAi Optimization with GAPDH 
Western blot of N18TG2 cells after GAPDH RNAi or nonsense RNAi (negative control) with 
two different transfection reagents: siPORT Amine or siPORT NeoFX. Published MW for 
GAPDH is similar to that found here.1-3 
 
 
36 kDa
 
 
 
193 
 
 
definitive proof of a role played by PAM in this biochemistry in cellulo if the 
corresponding labeled NAG could be isolated from the cells in appreciable amounts. 
 
5.4.1 Materials and Methods 
 
TriFECTa
TM
 RNAi kit containing three anti-PAM siRNA was a gift from 
Integrated DNA Technologies (Coralville, IA). The siPORT
TM
 Amine transfection agent 
was from Applied Biosystems (Foster City, CA). PAM (S-16) antibody was from Santa 
Cruz Biotechnologies, Inc (Santa Cruz, CA). Donkey anti-goat secondary antibodies 
conjugated with horse radish peroxidase was from ICN Biomedical (Solon, OH). BSTFA 
and silica were from Supelco (St. Louis, MO). Heptadecanoic acid, D33 was from C/D/N 
isotopes (Pointe-Claire, Quebec). Fatty acid-free bovine serum albumin (BSA) and 
13
C18-
oleic acid were from Sigma-Aldrich (St. Louis, MO). The remaining materials are as 
described in Section 5.3.1.1.  
The siRNA time course was run as described in Section 5.3.1 but with 24 and 48 
hour incubations to determine optimal siRNA incubation time. 
13
C18-N-Oleoylglycine and 
N-heptadecanoylglycine, D33, (HdG) were synthesized as described in Chapter 2, Section 
2.2.2.3. The fatty acid-BSA mixture was made as described in Chapter 3, Section 3.3.3. 
Based on time course study results, the cells were incubated for 56 hours with siRNA 
“A,” 48 of those hours with 2.5 mM 13C18-oleic acid in 0.25 mM BSA. Growing and 
collection conditions of N18TG2 cells are described in Chapter 2, Section 2.2.5. 
 After collection, cells were extracted as described in Section 2.2.6. An aliquot of 
cell extract was removed for oleamide analysis, and metabolites were separated via SPE 
as described in Section 2.2.7. The remaining sample was run on prep TLC as described in 
Section 2.2.8 for N-oleoylglycine analysis. Before prep-TLC and after solvent extraction, 
samples were spiked with 15 nmol HdG. GC-MS was run as described in Section 2.2.10, 
including running a spiked sample after two aliquots of the original sample were run. 
 
 
194 
 
 
5.4.2 Results 
 
Two of the siRNA tested in the timecourse study, “A” and “B,” showed good 
knockdown for PAM in the N18TG2 cells (Figure 5-3). siRNA “A” showed better lasting 
effects over 48 hours so it was used in subsequent experiments. The time course studies 
show that the siRNA-mediated knockdown for PAM lasts for at least 48 hours with this 
sequence, covering the entire time of the incubation with fatty acid. After 24 hours there 
is less PAM than there is after 48 hours with the siRNA, as the cell slowly returns to its 
normal metabolism. This means that any lingering PAM should interfere minimally with 
this experiment when OA is added to the culture medium (Figure 5-3). 
 
 
 Once it was determined which siRNA produced the best knockdown results, 
incubations were performed with siRNA “A” followed by 2.5 mM 13C18-oleic acid in 
0.25 mM BSA 8 hours later for a total incubation time of 56 hours. The average viability 
after 48 hours of PAM siRNA was 54%. An aliquot of each sample was removed for 
oleamide quantification, and the remaining sample used for N-oleoylglycine (NOG) 
quantification. Normal samples were run alongside as negative controls. The results of 
the prep-TLC isolation and GC/MS are shown in Figure 5-4, and the quantified amounts 
of N-oleoylglycine are shown in Figure 5-5. 
 
Figure 5-3: PAM Knockdown by siRNA in N18TG2 Cells 
The Western blot shows the amount of PAM in N18TG2 cells after incubation with 
various siRNA for 24 and 48 hours. 
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Figure 5-4: 
13
C18-N-Oleoylglycine in N18TG2 Cells Incubated with 
13
C18-Oleic Acid and PAM siRNA 
Panel A shows the GC of N18TG2 cell extract over the whole time scale (top) and a close-up of 
the 13C18-N-oleoylglycine-TMS (bottom). Panel B shows the MS of 
13C18-N-oleoylglycine-
TMS, and panel C shows the fragmentation of this molecule. 
Note that 13C18-N-Oleoylglycine is N-Oleoylglycine-
3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20-13C18. There are no 
13C on the glycine portion of 
the molecule. 
 
C 
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The amount of N-oleoylglycine found in the PAM-knockdown N18TG2 cells was 
higher than expected at 7510 (± 697) pmol/10
7
cells, compared to the normal cells with 50 
(± 29) pmol/10
7
cells (Figure 5-5).  This is the first quantitative measurement of 
endogenous N-oleoylglycine in N18TG2 cells. A prior experiment showed an 
accumulation of a peak with the same retention time as N-oleoylglycine with the addition 
of a PAM inhibitor, PBA,
32
 but that peak was neither verified nor quantified, and an 
endogenous amount was not determined. 
 
In comparing the amount of N-oleoylglycine (NOG) to oleamide found after 
incubation with oleic acid (OA), there is much more NOG than oleamide found when 
PAM expression is suppressed (Figure 5-6). The average amount of oleamide (both 
labeled and unlabeled) found in these cells after 56 hours of PAM siRNA and 48 hours of 
2.5 mM 
13
C18-OA incubation was 7.5 pmol/10
7
 cells, much smaller than the normal 
endogenous amount of 119 pmol/10
7
 cells in the absence of OA. These data explicitly 
define PAM as the in cellulo enzyme responsible for the oxidative cleavage of NOG to 
oleamide. 
The amount of oleamide found after 0, 12, 24, and 48 hour incubations with OA 
sans PAM siRNA from Chapter 2 is shown here in Figure 5-6 for comparison alongside 
the NOG quantification. The amount of NOG isolated after PAM knockdown and OA 
incubation (7510 pmol/10
7
 cells) is much higher than the amount of oleamide isolated 
 
Figure 5-5: Quantification of 
13
C18-N-Oleoylglycine 
in N18TG2 cells with and without RNAi for PAM 
The green bar shows NOG in normal cells, and 
the purple bar in PAM knockdown cells after 
incubation with 13C18-OA 
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after OA incubation (2250 pmol/10
7
 cells). This may indicate other fates of NOG beyond 
amidation by PAM. Indeed, a recent study revealed that NOG can function independently 
of oleamide; oleamide-like effects were observed after injection of NOG but serum levels 
of oleamide did not increase.
36
 Another possibility is that the greater amount of NOG 
may indicate simply that oleamide is a better substrate for FAAH than NOG. 
 
 Despite the higher level of NOG found after PAM knockdown and OA 
incubation, the endogenous amount of NOG found was lower than endogenous oleamide. 
The low levels of endogenous NOG reported here may partially explain the lack of 
literature in this field until more recently (see Chapter 2). The advent of more sensitive 
analytical techniques was required to identify compounds of such low abundance. In 
addition to quantifying NOG after PAM knockdown and OA incubation, the amount of 
oleamide was also quantified.  
  
Figure 5-6: Oleamide and N-Oleoylglycine in N18TG2 cells with and without PAM RNAi 
The left graph shows oleamide isolated from N18TG2 cells and media incubated with OA over 
a time course (red and blue). Co-graphed is labeled NOG and oleamide isolated after 56 hours 
incubation with anti-PAM siRNA (turquoise and orange), as well as the endogenous amount 
of NOG (light blue). The graph on the right is a close-up of endogenous levels of oleamide 
and NOG, as well as oleamide after knockdown of PAM and incubation with OA. 
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5.5 Cytochrome C Knockdown Studies 
 
Several recent articles by the Mueller group have implicated cytochrome c (cyt c) 
in the biosynthesis of oleamide. In vitro studies have shown the formation of oleamide 
and N-oleoylglycine upon incubation of oleoyl-CoA with cyt c and either ammonia or 
glycine, respectively.
37-39
 In addition, it was found to be expressed in oleamide-producing 
N18TG2 cells whereas other potential NAG-forming enzymes were not (Chapter 4). The 
potential role of cyt c in PFAM biosynthesis is elaborated in Figure 5-7. 
 
 
  
Due to its co-purification with a superoxide dismutase (SOD) and fatty acyl-CoA  
binding protein (ACBP), an oleamide “synthesome” was hypothesized in which the 
ACBP would orient an incoming acyl-CoA so that its thioester is proximal to the heme of 
cyt c. SOD would provide the H2O2 that was observed to increase catalytic activity. 
The oleamide- and N-oleoylglycine-forming activity of cyt c increases in the 
presence of H2O2, although some activity is observed without the peroxide. The reported 
optimal level of H2O2 for these reactions is very high (2 mM H2O2). Base levels of cyt c 
activity were explored sans H2O2 and found to be 5.4% conversion at best with 0.5 mg/ml 
cyt c, 5 mM NH3 and 1 mM oleoyl-CoA after 75 minutes of incubation time (see 
Appendix E). Other acyl-CoAs were not found to be cyt c substrates under these 
conditions (data in Appendix E). If cyt c is involved in PFAM biosynthesis it is likely to 
use H2O2 or some other means of reoxidizing its Fe
2+
.  
 
 Figure 5-7: Putative Role of Cyt C in PFAM Biosynthesis 
1 = Acyl CoA synthetase (ACS) 
2 = unknown enzyme or cytochrome c (cyt c) 
3 =  Peptidylglycine α-amidating monooxygenase (PAM) 
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To best study the role of cyt c in vivo/in cellulo, its removal by RNAi is the most 
targeted approach to isolate its role in PFAM biosynthesis. In these experiments, N18TG2 
cells were incubated with cyt c siRNA and oleic acid (OA) to determine the effect of cyt 
c knockdown on oleamide biosynthesis as compared to our standard incubation with OA 
from Chapter 2. 
5.5.1 Materials and Methods 
 
Silencer® Select Pre-designed siRNA against mouse somatic cytochrome c and 
siPORT
TM
 Amine transfection agent were from Applied Biosystems. Mouse anti-
cytochrome c and goat anti-mouse-HRP antibodies were from ZYMED® Laboratories 
(San Francisco, CA). BSTFA and silica were from Supelco (St. Louis, MO). 
Heptadecanoic acid, D33 was from C/D/N isotopes (Pointe-Claire, Quebec). Fatty acid-
free bovine serum albumin (BSA) and oleic acid were from Sigma-Aldrich (St. Louis, 
MO). The remaining materials are as described in Section 5.3.1.1.  
The siRNA timecourse was run as described in Section 5.4.1. The fatty acid-BSA 
mixture was made as described in Chapter 3, Section 3.3.3. The cells were incubated for 
56 hours with siRNA “A,” with 12, 24 or 48 of those hours with 2.5 mM OA in 0.25 mM 
BSA. Growing and collection conditions for N18TG2 cells are described in Chapter 2, 
Section 2.2.5. 
 After collection, cells were extracted as described in Section 2.2.6 and 
metabolites separated via SPE as described in Section 2.2.7. GC-MS was run as described 
in Section 2.2.10, including running a spiked sample after two aliquots of the original 
sample were run. Samples were analyzed as described in Chapter 3, Section 3.3.11. 
5.5.2 Results 
 
The results of cyt c knockdown studies are shown in Figure 5-8. Two different 
siRNA sequences were used, and both showed equal effectiveness at knocking down 
expression of cyt c. 
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The timecourse studies show that the siRNA-mediated knockdown of cyt c lasts 
for at least 48 hours, covering the entire time of the incubation with fatty acid. Before the 
48 hour time period, existing cyt c may still be present, and this may be reflected in the 
oleamide timecourse extraction, but the 48 hour samples show almost complete 
knockdown of the enzyme (Figure 5-8).  
One concern with using RNAi against cyt c is the toxicity to the cells, given its 
central role in oxidative phosphorylation. After 24 hours incubation with cyt c siRNA, 
the average viability of the N18TG2 cells was 88%. After 56 hours it was still 61%, 
comparable to what was observed in the PAM knockdown studies. 
To compare the amount of oleamide made in N18TG2 cells with and without cyt c 
knockdown, the same incubation was performed as in Chapter 2 in which the cells were 
incubated for 0, 12, 24 or 48 hours with 2.5 mM OA in 0.25 mM BSA under the same 
conditions, except that each flask was also incubated for 56 hours with cyt c siRNA, 
including the “0h” sample. The results of this incubation are shown in Figure 5-9 (top). 
For comparison, these results are plotted alongside the normal OA incubation results as 
well (Figure 5-9, bottom). 
 
 
Figure 5-8: Cytochrome C Knockdown by siRNA 
Western blot showing the successful knockdown of cyt c by two different 
siRNAs (“A” and “B”). For more details see text. 
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 There no significant difference between N18TG2 cell incubated with OA and cyt c 
siRNA and the same cells without cyt c siRNA (p = 0.6941, Figure 5-9). The 48 hour 
time point shows more oleamide per cell in the cyt c knockdown cells than in the normal 
cells. A recent publication by Mueller and Driscoll
40
 presents the concern of off-target 
oleamide knockdown that may be due to dramatic adaptive shifts in whole cell 
physiology caused by the knockdown of cyt c. However, experimental observations 
reveal more, not less, oleamide. 
These findings argue against the role of cyt c in oleamide biosynthesis in vivo, 
although it is possible that other cell lines show different metabolism and use cyt c as it 
has been shown in vitro,
40
 as has also been suggested by Mueller and co-workers. A 
 
 
Figure 5-9: N18TG2 Incubated with Oleic Acid and Cytochrome C siRNA 
Cells were incubated with OA for the times indicated and cyt c siRNA for 56 
hours (top). The bottom graph shows the normal cells incubated with OA and no 
cyt c knockdown co-graphed with the cyt c knockdown samples. 
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similar experiment on additional cell lines would determine whether cyt c plays this role 
in other cell lines. 
 
5.6 Interrogation of the N-Acylglycine Biosynthetic Pathways 
through Isotopically Labeled Precursors 
 
Two main pathways have been proposed for N-acylglycine (NAG) biosynthesis: 
sequential oxidation of an N-acylethanolamine (NAE) and glycination of the free fatty 
acid (FFA) through an activated intermediate (see the introduction to Chapter 4 for more 
details). Evidence presented in Chapter 3 has demonstrated that N18TG2 cells are capable 
of converting N-tridecanoylethanolamine (TDEA) into tridecanamide, but it is unknown 
whether the TDEA is oxidized to N-tridecanoylglycine or hydrolyzed to tridecanoic acid 
(TDA) before glycination. Strategic use of 
15
N
 
and 
13
C isotope labels would allow for the 
elucidation of these different biosynthetic possibilities, as outlined in Figure 5-10. The 
appearance of one or two isotopic labels in the final oleamide product would provide key 
insight into the mechanism of NAG formation. 
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Figure 5-10: Elucidation of the Biosynthesis of a PFAM  from Two Distinct Pathways 
Two competing pathways for N-acylglycine biosynthesis. Oxidation of N-
acylethanolamine is shown in brown and FFA glycination in purple. 13C is shown in 
green and 15N is shown in red. 
ASC, ascorbate; SDA, semihydroascorbate 
Enzymes: 1. Fatty acid amide hydrolase, 2. An alcohol dehydrogenase, 3. An aldehyde 
dehydrogenase, 4. Acyl-CoA synthetase, 5. Unknown, 6. Peptidylglycine α-amidating 
monooxygenase 
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5.6.1 Materials and Methods 
 Heptadecanoic acid, D33 and 1-
13
C-Potassium oleate were from C/D/N isotopes 
(Pointe-Claire, Quebec). Fatty acid-free bovine serum albumin (BSA), oleic acid and 
15
N-
Ethanolamine were from Sigma-Aldrich (St. Louis, MO). The remaining materials are as 
described in Section 5.3.1.1.  
The fatty acid-BSA mixture was made as described in Chapter 3, Section 3.3.3. 
The cells were incubated for 0, 12, 24 or 48 hours with 0.4 mM 3-
13
C,
15
N-
oleoylethanolamine in 0.4 mM BSA. Growing and collection conditions are described in 
Chapter 2, Section 2.2.5. 
 After collection, cells were extracted as described in Section 2.2.6 and 
metabolites separated via SPE as described in Section 2.2.7. GC-MS was run as described 
in Section 2.2.10, including running a spiked sample after two aliquots of the original 
sample were run. Samples were analyzed as described in Chapter 3, Section 3.3.11. 
5.6.1.1 Synthesis of Labeled N-Oleoylethanolamine 
1-
13
C-Oleoyl chloride was synthesized as shown in 
Equation 5-1 as follows: 2 g potassium oleate was 
suspended in approximately 50 ml dichloromethane as a 
slurry. Thionyl chloride (1.8 ml) was added dropwise under 
nitrogen while stirring at 50
o
C under reflux. The oleate 
dissolved upon addition of SOCl2. The solution was 
allowed to react under reflux at 50
o
C for 1 hour.  
TLC was performed after 60 minutes. The normal 
phase TLC was run in chloroform:methanol 98:2 and 
stained with potassium permanganate solution (Figure 
5-11).  
The acid chloride in DCM was added to a separatory funnel with approximately 
75 ml H2O to wash. After collecting the bottom organic layer, the pH of the aqueous 
layer was approximately 0.55. A second wash was performed with approximately 0.5 g 
sodium bicarbonate in the water. The pH of the aqueous layer was approximately 2.7. A 
 
 
 
 
 
 
 
Figure 5-11: TLC of 
Oleoyl Chloride Reaction 
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third wash was performed with approximately 0.5 g sodium bicarbonate again in the 
water, after which the aqueous layer had a pH of approximately 8.2. A fourth wash was 
performed without bicarbonate and the aqueous layer had a pH of 6.6. The organic DCM 
layer was then poured over MgSO4 to dry, decanted into a round-bottom flask and taken 
to a yellow oil in vacuuo. 
The N-oleoylethanolamine was synthesized as shown in Equation 5-1 (bottom) as 
follows: 15 ml triethylamine base, 10 ml acetonitrile, and 0.5 ml 
15
N-ethanolamine were 
combined in a 50 ml round-bottom flask, flushed with N2, and left stirring under N2 at 
room temperature. The volume of the acyl chloride was reduced to approximately 2 ml in 
vacuuo and then diluted to 10 ml with acetonitrile. This acyl chloride mixture was added 
dropwise to the ethanolamine mixture and left to stir overnight at room temperature.  
The resulting crude N-acylethanolamine was taken to a yellow solid in vacuuo, 
dissolved in approximately 25 ml warm ethanol, and recrystalized by adding cold H2O. 
The crystallization proceeded on ice for approximately 30 min, and the solid filtered in a 
Büchner funnel and washed with ice cold H2O. A white flaky, shiny solid (0.118 g) was 
obtained (5.8% yield) and was 94% pure by GC-MS analysis (Figure 5-12). 
 
 
 
 
 Equation 5-1: Synthesis of 3-
13
C,
15
N-Oleoylethanolamine 
The isotopic labels are shown in color (13C, green and 15N, red) 
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Figure 5-12: GC-MS of 3-
13
C1,
15
N-Oleoylethanolamine 
GC-MS of 3-13C,15N-oleoylethanolamine over entire timecourse (panel A) and zoom in of the 
appropriate peak (B). The MS of the indicated GC peak is shown in panel C. The peak at 15.3 
minutes is doubly-derivitized N-oleoylethanolamine-(TMS)2 (MS not shown). 
3-
13
C,
15
N-
Oleoylethanolamine
-TMS 
3-
13
C,
15
N-
Oleoyl-
ethanolamine
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5.6.2 Results 
 
The quantification of oleamide in the N18TG2 cells incubated with labeled NOE 
over time is shown in Figure 5-13 (top). For reference, the results of incubation with OA 
and with TDEA are also shown (Figure 5-13 bottom left and right, respectively). A 
sample GC-MS of one of the cell extractions is shown in Figure 5-14. 
 
 
 
 
Figure 5-13: Oleamide in N18TG2  Incubated with Labeled Oleoylethanolamine 
Oleamide isolated from N18TG2 cells after incubation with labeled N-oleoylethanolamine 
(top). These data are also plotted alongside oleamide isolated from conditioned N18TG2 media 
incubated with OA (bottom left) and cells incubated with TDEA (bottom right) for 
comparison. NOE, 13C,15N-oleoylethanolamine. 
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Figure 5-14: GC-MS of Labeled Oleonitrile from N18TG2 Cell Extract 
GC-MS of N18TG2 cell extract after incubation with 
13C,15N-oleoylethanolamine for 48 hours, 
showing oleonitrile. Panel A shows the whole GC (top) and zoom in of the oleonitrile peak 
(bottom). Panel B shows the MS of the indicated GC peak (oleonitrile). Panel C shows the 
library database MS for unlabeled oleonitrile. Panel D shows the difference between panels B 
and C. Note that in the cell-extracted oleonitrile, there are more isotopic peaks in the 
fragments containing the labeled carbon and/or nitrogen. 
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There was more oleamide isolated in the conditioned media than in the cells, 
something not observed in any of the incubations with FFAs and TDEA, as the amounts 
isolated in cells and conditioned media were very similar. The significance of this is 
unclear. The amount of oleamide found in the conditioned media after incubation with 
NOE is comparable to that found in the conditioned media after incubation with OA 
(Figure 5-13, bottom left). The amount of oleamide found in the cells after incubation 
with NOE is comparable with the amount of tridecanamide found in the cells after 
incubation with TDEA (Figure 5-13, bottom right). 
 Oleonitrile derived from the reaction of BSTFA with oleamide isolated from 
N18TG2 cells after incubation with 3-
13
C,
15
N-oleoylethanolamine is shown in Figure 5-14. 
The MS for the oleonitrile derived from cell-extracted oleamide (panel B) shows many 
more isotopic peaks than the library MS for unlabeled oleonitrile (panel C). Averaged 
spectra were taken over the time interval in which oleonitrile could be found, and 
averaged background spectra were subtracted from the oleonitrile spectra. Shown in 
Figure 5-15 is a set of the isotopic m/z’s that were examined for this study overlaid as 
selected ion traces in color. The oleonitrile peaks are shown with a vertical line through 
them, and the background spectra were taken from the left where no other significant 
peaks could be found. Much greater background noise was observed for m/z 123 in the 
conditioned media (Figure 5-15, panel A) than in the cell extract, making this subtraction 
necessary. Along with the 122, 123 and 124 set, two other isotopic sets were examined 
and are shown in Table 5-2. The relative intensity of each m/z peak for each unlabeled 
(122, 136 and 164), singly labeled (123, 137 and 165) and doubly labeled (124, 138 and 
166) were used in the ratios shown in Equation 5-2. A graphical representation of those 
ratios is shown in Figure 5-16. 
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Table 5-2: Fragments Used for Isotopic Ratio 
Assignment 
m/z structure 
122 
 123 
124 
136 
 136 
138 
164 
 165 
166 
 
𝐶˗𝑂𝑙𝑒𝑎𝑚𝑖𝑑𝑒.
13
𝐶˗𝑂𝑙𝑒𝑎𝑚𝑖𝑑𝑒.12
=
(𝑖123 + 𝑖137 + 𝑖165)
(𝑖122 + 𝑖136 + 𝑖164)
 
𝐶, 𝑁.
15 ˗𝑂𝑙𝑒𝑎𝑚𝑖𝑑𝑒.
13
𝐶˗𝑂𝑙𝑒𝑎𝑚𝑖𝑑𝑒.12
=
(𝑖124 + 𝑖138 + 𝑖166)
(𝑖122 + 𝑖136 + 𝑖164)
 
𝐶, 𝑁.
15 ˗𝑂𝑙𝑒𝑎𝑚𝑖𝑑𝑒.
13
𝐶˗𝑂𝑙𝑒𝑎𝑚𝑖𝑑𝑒.13
=
(𝑖124 + 𝑖138 + 𝑖166)
(𝑖123 + 𝑖137 + 𝑖165)
 
 
 
 
Equation 5-2: Calculations for the Ratios of Singly- and Doubly-Labeled Oleonitrile. 
Oleonitrile is a direct reaction product of derivitization of oleamide with BSTFA. 
The intensities (i) of each isotopic peak were added to obtain a relative intensity 
of each isotopic contributor. 
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Figure 5-15: Background Levels in N18TG2 Conditioned Media and Cell Samples 
GC of N18TG2 media (A) and cells (B) after incubation with 3-
13C,15N-oleoylethanolamine. 
The TIC is shown in black and m/z’s overlaid in different colors. 122 is a characteristic peak 
for unlabeled oleonitrile, 123 for a singly-labeled oleonitrile, and 124 for the doubly-labeled 
oleonitrile. The background is much higher for m/z 123  in the media sample, necessitating a 
subtraction of the background spectra from the oleonitrile spectra before assignment of 
isotopic ratios. 
212 
 
 
 
 The fact that there is much greater labeled product in the samples incubated with 
labeled NOE (turquoise and orange bars in Figure 5-16) indicates that the labeling comes 
from conversion of the labeled NOE to oleamide and not co-eluting contamination. In 
addition, the incorporation of the label seems to reach a saturation point between 0-12 
hours, as the ratio of labeled to unlabeled compound stays steady from 12-48 hours. 
 The ratio of doubly to singly labeled oleamide is approximately 0.99 ± 0.04 in the 
cells and 1.09 ± 0.09 in the media, indicating that there is an equal amount of singly- and 
doubly-labeled oleamide present. This implies that the ethanolamine has an equal 
likelihood of being oxidized to the NAG and being hydrolyzed to the FFA before 
glycination; that there is more than one biosynthetic mechanism for NAGs in the N18TG2 
cells and that they are likely to be acting at roughly equal rates.  
   
 
 
Figure 5-16: Isotope Ratios of Oleamide in N18TG2 after Incubation with Labeled N-
Oleoylethanolamine 
The purple bars represent the ratio of doubly-labeled oleamide to singly-labeled oleamide, 
and were calculated by taking the intensities of (124 + 138 + 166) divided by the intensities 
of (123 + 137 + 165), and the other two ratios calculated similarly. Turquoise bars represent 
the ratio of singly-labeled oleamide to unlabeled, and the orange bars represent the ratio of 
doubly-labeled oleamide to unlabeled. The error bars shown are 5% error. 
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5.7 Conclusions 
 
A PFAM, oleamide, has been isolated from human aortic endothelial cells. 
Incubation with a FAAH inhibitor results in a great increase in the amount of oleamide 
found after incubation with OA (Figure 5-1). Therefore, FAAH is likely at work in the 
cardiovascular system, or at least in endothelial cells. Although FAAH has been found in 
endothelial cells of other organs (kidney
20
 and umbilical vein
21
), there is no previous 
evidence for its action in the heart.
15,22
  The finding of PFAMs in these cells is the first 
report of its kind and suggests an important role in vasoregulation and angiogenesis is 
played by these molecules in the cardiovascular system. 
An overview of the findings detailed in this thesis regarding NAG and PFAM 
metabolism is summarized in Figure 5-17. The quantitative NAG assay described in 
Chapter 2 was successfully demonstrated here in N18TG2 cells to measure endogenous 
levels of NOG and labeled 
13
C18-NOG after incubation with 
13
C18-OA and PAM siRNA. 
This is explicit proof of the involvement of PAM in PFAM biosynthesis in cellulo, as the 
siRNA targets PAM specifically and its knockdown leads to large intercellular levels of 
NOG and very small levels of oleamide even when incubating with OA. Maintaining 
PAM levels at normal concentrations results in the finding of very low cellular NOG 
levels (Figure 5-5) In addition, incubation with PAM siRNA results in very low cellular 
oleamide levels (Figure 5-6). The amount of NOG produced upon PAM knockdown was 
lower than the amount of oleamide found with normal PAM levels. This could mean that 
NOG has other metabolic fates, or simply that it is a poor FAAH substrate relative to 
oleamide. 
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Figure 5-17: NAG and PFAM Biosynthesis in N18TG2 Cells 
Overview of what is now known about biosynthesis of NAGs and PFAMs in N18TG2 cells. 
Double arrows represent metabolic flow from one metabolite to another. Single arrows are 
known enzymatic reactions. The NAE to NAG double arrow is dashed because the NAG was not 
isolated itself but the corresponding PFAM was isolated. Isotopic labeling implies oxidation to 
the NAG before oxidative cleavage to the PFAM.  
Abbreviations: ACS, acyl-CoA synthetase; ADH, alcohol dehydrogenase; AlDH, aldehyde 
dehydrogenase; CYP4F, cytochrome P450; EA, elaidic acid; FAAH, fatty acid amide hydrolase; 
LOA, linoleic acid; NAE, N-acylethanolamine; NAG, N-acylglycine; NOE, N-
oleoylethanolamine, OA, oleic acid; PA, palmitic acid; PAM, peptidylglycine α-amidating 
monooxygenase; PFAM, primary fatty acid amide; POA, palmitoleic acid; TDA, tridecanoic 
acid; TDEA, N-tridecanoylethanolamine. 
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After incubation with 
13
C,
15
N-oleoylethanolamine, both 
13
C,
15
N-oleamide and 
13
C-oleamide were found in N18TG2 cells (Figure 5-13) in roughly equal proportion 
(Figure 5-16). This indicates that not only are both pathways at work to synthesize NOG 
(oxidation of NOE and glycination of OA), but that both pathways may be functioning 
with equal discrimination. This is in agreement with recent work by Bradshaw et al. who 
show that N-arachidonoylglycine is formed by two distinct pathways in C6 glimoa 
cells.
41
 In their case, however, hydrolysis of the NAE followed by glycination was the 
preferred mode of NAG biosynthesis as the amounts of unlabeled NAG produced were 
much higher (see Chapter 3 for more details of the Bradshaw experiments). Because 
oxidation of NOE is occurring and ADH3, ADH4, AlDH3A1 and AlDH3A2 were not 
found to be expressed in N18TG2 cells (Chapter 4), other ADH isoform(s) are likely 
responsible for NAE oxidation in vivo. Indeed, ADH3 and ADH4 did not have 
particularly favorable kinetics for formation of the acylaldehyde
42
 or NAG,
43
 although the 
in vitro nature of the studies did not allow for analysis of long chain NAEs in the aqueous 
solutions used. Further studies of ADH5 and ADH6 are required, as these two ADHs are 
poorly investigated to date. 
The levels of oleamide found after incubation with cyt c siRNA and OA were not 
significantly lower than that found in the absence of cyt siRNA (Figure 5-9). Although it 
is possible that other cells show a different mechanism for oleamide biosynthesis via cyt 
c, cyt c is not likely to play a role in direct PFAM biosynthesis in N18TG2 cells, either by 
glycination or amidation of oleoyl-CoA. Because there is no other candidate for NAG 
biosynthesis, as they have been ruled out by the expression studies in Chapter 4 and other 
enzymologic studies, and because the isotopic labeling studies indicate that both 
pathways are at work in the cells, it may be concluded that an unknown enzyme is 
responsible for in vivo NAG biosynthesis: an undiscovered long chain-specific glycine N-
acyltransferase. These findings do not rule out the activation of the FFAs to another 
intermediate, such as an acyl-adenylate similar to the amino acid adenylates involved in 
activating tRNAs, or a fatty acid thioester linked to a cysteine in a carrier protein, similar 
to intermediates observed in fatty acid biosynthesis. 
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Although there is now a much better understanding of how PFAMs are 
synthesized and in what amounts, there is much still to be explored. The activities of 
ADH5 and ADH6 need to be investigated for their ability to convert long-chain NAEs to 
aldehydes and potentially NAGs, as ADH4 is capable of doing for shorter chain NAEs.
43
 
If these are incapable of the dismutation, aldehyde dehydrogenases (AlDHs) should be 
investigated. Although the long-chain specific AlDHs were not found in N18TG2 cells 
(Chapter 4), other AlDHs could be candidates. Rabbit ADH was shown to oxidize 
dodecanal (KM = 20 µM) in the presence of NAD
+ 
and demonstrated a preference for 
longer-chain aldehydes.
44
 Rat liver mitochrondrial AlDH also oxidized dodecanal.
45
 
Longer-chain aldehydes have not been reported as AlDH substrates, either because they 
were not found to be substrates or, more likely, because of solubility issues preventing 
their analyses.
42
 
The existence of an unknown glycination enzyme poses the greatest challenge to 
elucidating this pathway. Initial attempts to locate this enzyme using bioinformatic tools 
to mine the mouse genome for ACGNAT, NMT and BAAT-like regions of DNA have 
yielded no novel expressed mRNA (data not shown). Several studies are underway in the 
Merkler laboratory to identify this enzyme, including a CoA-ylomics approach in which a 
biotinylated CoA was developed to probe for novel CoA-binding proteins. 
These long-chain amide signaling molecules show much potential for therapeutic 
targeting, as discussed in detail in Chapter 1. The diverse set of receptors which they 
target provide a broad spectrum for pharmacological treatment, and elucidating PFAM 
and NAG biosynthesis will provide excellent targets for a huge range of disorders, 
including anxiety, depression, sleep disorders, and many motor and neurodegenerative 
diseases. If a long chain-specific N-acyltransferase is identified, as the work in this 
dissertation would suggest, it could provide a specific target for regulating the 
metabolism of these molecules while avoiding broader effects seen by targeting enzymes 
such as FAAH or ACS’s. Finally, the revelation that NAGs and PFAMs are made by 
more than one biosynthetic scheme adds another dimension to the potential regulation 
and biosynthesis of these molecules. The field of lipidomics is a growing one that has 
broadened our view of the molecular world, and although the pharmacologic actions of 
oleamide have been appreciated for 15 years, most of these lipid signaling molecules 
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were unknown even 3-5 years ago. Evidence demonstrated in this dissertation represents 
a significant contribution to understanding the biosynthetic mechanisms of these unique 
and difficult molecules to which aqueous chemistry has been aspiring for 15 years. 
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Appendix A: Synthesis of a Novel N-Acylglycine Derivative 
 
Silylation is the most widely used derivitization for GC analysis, and N,O-
bis(trimethylsilyl)trifluoroacetamide (BSTFA) one of the more common silylating agents. 
Derivitization with BSTFA results in trimethylsilylation of reactive groups of compounds 
in the following preference: alcohol > phenol > carboxylic acid > amine > amide. Each 
active hydrogen is replaced with a trimethylsilyl (TMS) group (Equation A, top), where 
“active” hydrogens constitute those connected to an electronegative atom. In addition, the 
formation of a nitrile is observed when the compound being derivitized is a primary fatty 
acid amide (PFAM) (Equation A, bottom).  
 
Upon derivitization of an N-acylglycine (NAG), one would expect to see three 
products: NOG-TMS2, NOG (N-TMS), and NOG (O-TMS), the last two of which would 
 
 
Equation A: Derivitizations with BSTFA 
Formation of TMS derivative of a compound containing an activated hydrogen (top) and 
formation of a nitrile from a primary amide (bottom). Both are derivitizations with BSTFA. 
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co-elute. However, a fourth compound is observed under normal derivitization 
conditions, as shown in Figure A. From the MS, a structure was hypothesized to be an 
“enyliminoacetate.” Figure B Figure C show the fragmentation scheme for mono-and di-
TMS NAGs. Figure D shows the structure of the proposed N-oleoylglycine 
enyliminoacetate derivative and its fragmentation scheme. 
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Figure A: GC-MS of N-Oleoylglycine Derivitized with BSTFA 
Products of NOG derivitization with BSTFA. The “enyliminoacetate” is an unexpected 
product. Panel A shows the whole GC chromatogram (top) and closeup of NOG peaks 
(bottom). Panel B shows the MS spectrum for the enyliminoacetate derivative. Panel B shows 
the MS of NOG with two TMS groups attached. Panel D shows mono-derivitized NOG. 
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Figure B: Fragmentation Scheme for Di-TMS NAGs 
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 Figure C: Fragmentation Scheme for Mono-TMS NAGs 
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In order to verify the structure of this enyliminoacetate, a series of NAGs were 
synthesized and derivitized with BSTFA, including the linoleoyl-, palmitoyl-, 
palmitoleoyl- and deuterated heptadecanoyl (D33)- glycines. A detailed description of 
NAG synthesis can be found in Chapter 2, Section 2.2.2.3. GC-MS conditions can be 
found in Section 2.2.10. 
 
 Figure D: Fragmentation Scheme for Enyliminoacetate Derivatives of NAGs 
Appendix A: (Continued) 
 
226 
 
 
If the predicted structure is correct, the fragmentation of each additional NAG 
derivative could be predicted, as shown in Figure E. Figure F through Figure J show the 
resulting GC-MS of the synthesized NAGs, the MS of each enyliminoacetate derivative, 
and the fragmentation pattern that matches the predicted fragmentation pattern. (For MS 
of NAG-TMS and NAG-(TMS)2 derivatives, see Appendix B.) 
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Figure E: Fragmentation Patterns for Enyliminoacetate Derivatives of N-Acylglycines 
Fragmentation patterns predicted for enyliminoacetate derivatives of each NAG synthesized. 
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Figure F: GC-MS of Enyliminoacetate Derivative of NOG and Fragmentation 
GC of the enyliminoacetate derivative of N-Oleoylglycine (top), it MS (middle), and 
fragmentation (bottom) 
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 Figure G: GC-MS of Enyliminoacetate Derivative of NLG and Fragmentation 
GC of the enyliminoacetate derivative of N-linoleoylglycine (top), it MS (middle), and 
fragmentation (bottom). 
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Figure H: GC-MS of Enyliminoacetate Derivative of NPOG and Fragmentation 
 GC of the enyliminoacetate derivative of N-palmitoleoylglycine (top), it MS (middle), and 
fragmentation (bottom). 
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Figure I: GC-MS of Enyliminoacetate Derivative of NPG and Fragmentation 
GC of the enyliminoacetate derivative of N-palmitoylglycine (top), it MS (middle), and 
fragmentation (bottom). 
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A predicted reaction mechanism is given in Figure K and is based on the 
formation of a nitrile-like intermediate as has been seen for primary amides (Equation A). 
Of the reactive groups, the amide is the least reactive, and the additional steric hindrance 
of the glycine makes this reaction even slower than for a primary amide. The reaction 
 
 
Figure J: GC-MS of Enyliminoacetate Derivative of HdG and Fragmentation 
GC of the enyliminoacetate derivative of N-heptadecanoylglycine, D33 (top), it MS (middle), 
and fragmentation (bottom). 
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proceeds with a nucleophilic attack upon the silicon atom of the TMS donor, followed by 
the protonation of the derivitized oxygen from its neighboring amine or HCl available 
from the reaction mixture. The electrons are then drawn up towards the positively 
charged oxygen, forming a transient nitrile and causing the TMS group to leave. This 
mechanism is similar to one reported by Ichiyama involving a primary amide and L-
chloropropionic acid as the electrophile,
1
 and would mark the end of the reaction for a 
primary amide to form a nitrile. In this case, the nitrile formed is less stable because the 
nitrogen is also connected to glycine, leaving a positive charge on the nitrogen. The 
glycine α-hydrogen is highly acidic in this transition state and is readily abstracted, 
leaving behind electrons that then form a di-imino intermediate. The iminoacetate 
structure is finally formed with the abstraction of the hydrogen β to the nitrogen, forming 
the energetically favorable structure with resonance stabilization. The resonance 
structures are shown in Figure L. 
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 Figure K: Proposed Reaction Mechanism for the Formation of an Enyliminoacetate Derivative of 
NAGs 
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Figure L: Resonance of Enyliminoacetate Derivative of NAG 
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Appendix B: GC-MS of Synthesized Standards 
 
 Throughout these experiments standards had to be synthesized where not 
commercially available both for the formation of standard curves and for entry into the 
library database for compound verification in cell and media extracts. The GC-MS of 
these standards are shown below.  
GC-MS of PFAMs 
 
 Primary fatty acid amides (PFAMs) were synthesized as described in Chapter 2, 
Section 2.2.2.2. Where commercially available, acyl chlorides were used. Where they 
were not available, acyl chlorides were synthesized from fatty acids as described in 
Chapter 2, Section 2.2.2.1. The primary product of derivitization with BSTFA was an 
acyl nitrile, although the amide-TMS was also observed. 
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Figure M: GC-MS of 
13
C18-Oleamide 
Panel A shows the GC of U-13C18-oleamide. The nitrile spans from 14.5-15.3 minutes. The 
large peak from 16.1-17 is the fatty acid. The PFAM-TMS is around 18 minutes. Panel B shows 
the annotated MS of U-13C18-oleamide-TMS. Panel C shows the annotated MS of U-
13C18-
oleonitrile. 
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Figure N: GC-MS of Oleamide 
Panel A shows the GC of oleamide (top) with a close-up of oleonitrile and oleamide-TMS peaks 
(bottom). The unlabeled peak is underivitized oleamide. Panel B shows the annotated oleonitrile 
MS. Panel C shows the annotated oleamide-TMS MS. 
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Figure O: GC-MS of Tridecanamide 
Panel A shows the GC of tridecanamide. Overlaid on the tridecanamide-TMS close-up is the 
SIM for m/z 131, a characteristic m/z for PFAM-TMS resulting from a McLafferty 
rearrangement. The peak had been split into two but both had MS for tridecanamide-TMS. 
Contamination at the source caused the GC spectrum to show increased contaminants as the 
temperature increased (top right). Panel B shows the MS of tridecanamide-TMS 
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Figure P: GC-MS of Palmitamide 
GC-MS of synthesized palmitamide. Panel A shows the GC chromatogram over entire time 
period (top) and a close-up of the palmitonitrile peak (bottom). Palmitamide-TMS is at 
retention time 16.25 minutes. Panel B shows the MS of palmitonitrile. Panel C shows the MS 
of palmitamide-TMS 
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Figure Q: GC-MS of Palmitoleamide 
GC-MS of synthesized palmitoleamide. Panel A shows the GC chromatogram over entire time 
period (top) and a close-up of the palmitoleonitrile peak (bottom). Palmitoleamide-TMS is at 
retention time 16.1 minutes. Panel B shows the MS of palmitoleonitrile. Panel C shows the 
MS of palmitoleamide-TMS 
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Figure R: GC-MS of Elaidamide 
GC-MS of synthesized elaidamide. Panel A shows GC chromatogram over entire time period 
(top) and a close-up of the elaidonitrile peak (bottom). Elaidamide-TMS is at retention time 
17.8 minutes. Panel B shows the MS of elaidonitrile. Panel C shows the MS of elaidamide-
TMS. 
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Figure S: GC-MS of Linoleamide 
GC-MS of synthesized linoleamide. Panel A shows GC chromatogram over entire time period 
(top) and a close-up of the linoleonitrile peak (bottom). Linoleamide-TMS is at retention time 
17.7 minutes. Panel B shows the MS of linoleonitrile. Panel C shows the MS of linoleamide-
TMS. 
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GC-MS of NAGs 
 
N-acylglycines (NAGs) were synthesized as described in Chapter 2, Section 
2.2.2.3. Where commercially available, acyl chlorides were used. Where they were not 
available, acyl chlorides were synthesized from fatty acids as described in Chapter 2, 
Section 2.2.2.1. The primary product of derivitization with BSTFA under normal 
derivitization conditions (60 min 60
o
C) was the enyliminoacetate derivative, followed by 
NAG-TMS. If abundant enough NAG was present, the NAG-(TMS)2 was also observed. 
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Figure T: GC-MS of 
13
C18-N-Oleoylglycine 
Panel A shows the GC spectrum of 13C18-N-oleoylglycine. Left peak at 18.8min is the 
enyliminoacetate. Peak from 20-21 min is 13C18-N-oleoylglycine-TMS. There is less 
enyliminoacetate in this reaction mixture because the reaction was only allowed to proceed 15 
minutes instead of the normal 60. Panels B-D show MS from the large peak from 20-21 min 
with fragments annotated. 
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Figure U: GC-MS of N-Palmitoylglycine 
Panel A shows the GC of N-palmitoylglycine-TMS. The mono-derivitized NPG has a retention 
time of 20.6 minutes and its MS is shown in panel B. Panel C shows the MS for di-TMS NPG 
(retention time 20.2 minutes). Panel D shows the MS for the enyliminoacetate derivative of NPG 
(retention time 17.3 minutes). 
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Figure V: GC-MS of N-Palmitoleoylglycine 
Panel A shows the GC of N-palmitoleoylglycine-TMS. The mono-derivitized NPOG has a 
retention time of 19.2 minutes and its MS is shown in panel B. Panel C shows the MS for di-
TMS NPOG (retention time 18.85 minutes). Panel D shows the MS for the enyliminoacetate 
derivative of NPOG (retention time 17.2 minutes). 
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Figure W: GC-MS of N-Linoleoylglycine 
Panel A shows the GC of N-linoleoylglycine-TMS. The mono-derivitized NLG has a retention 
time of 19.3 minutes and its MS is shown in panel B. Panel C shows the MS for di-TMS NLG 
(retention time 19.05 minutes). Panel D shows the MS for the enyliminoacetate derivative of 
NLG (retention time 17.4 minutes). 
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GC-MS of NAEs 
 
N-acylethanolamines (NAEs) were synthesized as described in Chapter 3, Section 
3.3.2.3. The primary product of derivitization with BSTFA was a mono-TMS derivative, 
but di-TMS product was also observed. 
 
Figure X: GC-MS of N-Elaidoylglycine 
Panel A shows the GC of N-elaidoylglycine-TMS. The mono-derivitized NEG has a retention 
time of 20.6 minutes and its MS is shown in panel B. Panel C shows the MS for the 
enyliminoacetate derivative of NEG (retention time 18.8 minutes). 
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Figure Y: GC-MS of N-Tridecanoylethanolamine 
Panel A shows the GC of N-tridecanoylethanolamine (TDEA). The peak indicated with a 
vertical line is for mono-derivitized TDEA and its MS is shown in panel B. The peak at 15.9 
minutes is for bi-derivitized TDEA and its MS is shown in panel C. 
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Appendix C: GC-MS of Mammalian Cells 
  
 The results of incubations of each fatty acid and N-tridecanoylethanolamine in 
SCP and N18TG2 cells and media are shown below. For brevity, only one timepoint 
example from each cell and media incubated with each fatty acid or TDEA is shown. 
Many of the MS shown below are the TICs (full range of m/z), but for integration 
purposes only the select ions specific to each acyl nitrile and/or PFAM-TMS were used 
(see Chapter 3, Section 3.3.10 for more information). Both nitriles and PFAM-TMS were 
observed products, and both samples showing nitriles and PFAM-TMSs are shown 
below. 
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GC-MS of Palmitoleic Acid-Incubated Cells Over Time 
 
 
 
 
Figure Z: GC-MS of N18TG2 Cell Extract after Incubation with POA for 12h, Showing 
Palmitoleamide-TMS 
GC-MS of N18TG2 cell extract after incubation with POA for 12h. Panel A shows the whole 
GC and zoom in of the peak of interest. Panel B shows the MS of the indicated GC peak 
(palmitoleamide-TMS). Panel C shows the library database MS for palmitoleamide-TMS. 
Panel D shows the difference between panels B and C. The cells were extracted as described 
in the methods section in Chapter 3. The cells had been incubated with 2.5mM POA in 
0.25mM BSA for 12 hours in this case before extraction. 
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Figure AA: GC-MS of N18TG2 Media Extract after Incubation with POA for 12h, Showing 
Palmitoleamide-TMS and Interference from OA 
GC-MS of N18TG2 media extract after incubation with POA for 12h. Panel A shows the whole 
GC and zoom in of the peak of interest. The palmitoleamide-TMS peak is buried within the 
OA peak. Panel B shows the MS of the indicated GC peak (palmitoleamide-TMS). Panel C 
shows the library database MS for palmitoleamide-TMS. Panel D shows the difference 
between panels B and C. The cells were extracted as described in the methods section in 
Chapter 3. The cells had been incubated with 2.5mM OA in 0.25mM BSA for 12 hours in this 
case before extraction. 
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Figure BB: GC-MS of SCP Cell Extract after Incubation with POA for 48h, Showing 
Palmitoleamide-TMS 
GC-MS of SCP cell extract after incubation with POA for 48h. Panel A shows the whole GC 
and zoom in of the peak of interest. Panel B shows the MS of the indicated GC peak 
(palmitoleamide-TMS). Panel C shows the library database MS for palmitoleamide-TMS. 
Panel D shows the difference between panels B and C. The cells were extracted as described 
in the methods section in Chapter 3. The cells had been incubated with 2.5mM POA in 
0.25mM BSA for 48 hours in this case before extraction. 
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Figure CC: GC-MS of SCP Media Extract after Incubation with POA for 48h, Showing 
Palmitoleonitrile  
GC-MS of SCP media extract after incubation with POA for 48h. Panel A shows the whole GC 
and zoom in of the peak of interest. Panel B shows the MS of the indicated GC peak 
(palmitoleonitrile). Panel C shows the library database MS for palmitoleonitrile. Panel D shows 
the difference between panels B and C. The cells were extracted as described in the methods 
section in Chapter 3. The cells had been incubated with 2.5mM POA in 0.25mM BSA for 48 
hours in this case before extraction. 
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GC-MS of Palmitic Acid-Incubated Cells Over Time 
 
For data analysis, only the palmitonitrile was integrated and plotted against a 
corresponding standard curve in which only the palmitonitrile was integrated. This was 
due to the interference of oleic acid and octadecanoic acid -TMS esters co-eluting with 
palmitamide-TMS in both cell and media samples. One sample is shown with 
palmitamide-TMS where resolution was slightly better (Figure ). 
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Figure DD: GC-MS of N18TG2 Cell Extract after Incubation with PA for 24h, Showing 
Palmitonitrile 
GC-MS of N18TG2 cell extract after incubation with PA for 24h. Panel A shows the whole 
GC and zoom in of the peak of interest. Panel B shows the MS of the indicated GC peak 
(palmitonitrile). Panel C shows the library database MS for palmitonitrile. Panel D shows the 
difference between panels B and C. The cells were extracted as described in the methods 
section in Chapter 3. The cells had been incubated with 2.5mM PA in 0.25mM BSA for 24 
hours in this case before extraction.  
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Figure EE: GC-MS of N18TG2 Media Extract after Incubation with PA for 48h, Showing 
Palmitoleamide-TMS  
GC-MS of N18TG2 media extract after incubation with PA for 48h. Panel A shows the whole 
GC and zoom in of the peak of interest. The single ion trace m/z 131, characteristic for 
derivitized amides, is shown overlaid in red. Panel B shows the MS of the indicated GC peak 
(palmitamide-TMS). Panel C shows the library database MS for palmitamide-TMS. Panel D 
shows the difference between panels B and C. The cells were extracted as described in the 
methods section in Chapter 3. The cells had been incubated with 2.5mM PA in 0.25mM BSA 
for 48 hours in this case before extraction.  
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Figure FF: GC-MS of SCP Cell Extract after Incubation with PA for 48h, Showing Palmitonitrile 
GC-MS of SCP cell extract after incubation with PA for 48h. Panel A shows the whole GC and 
zoom in of the peak of interest. Panel B shows the MS of the indicated GC peak 
(palmitonitrile). Panel C shows the library database MS for palmitonitrile. Panel D shows the 
difference between panels B and C. The cells were extracted as described in the methods 
section in Chapter 3. The cells had been incubated with 2.5mM PA in 0.25mM BSA for 48 
hours in this case before extraction. 
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GC-MS of Elaidic Acid-Incubated Cells Over Time 
 
Unambiguous assignment of unsaturated acyl chains can pose a problem in some 
samples. Separation of cis/trans isomers is not ideal on a nonpolar matrix such as the 
 
Figure GG: GC-MS of SCP Media Extract after Incubation with PA for 24h, Showing 
Palmitonitrile 
GC-MS of SCP media extract after incubation with PA for 24h. Panel A shows the whole GC 
and zoom in of the peak of interest. Panel B shows the MS of the indicated GC peak 
(palmitonitrile). Panel C shows the library database MS for palmitonitrile. Panel D shows the 
difference between panels B and C. The cells were extracted as described in the methods 
section in Chapter 3. The cells had been incubated with 2.5mM PA in 0.25mM BSA for 24 
hours in this case before extraction.  
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dimethylpolysiloxane GC column that is commonly used for lipid analysis.
1
  A highly 
polar bis(cyanopropyl) polysiloxane phase has been shown to provide this separation but 
was not available for these analyses to determine whether the complex lipid extract 
would be separable on such a column. The assumption is made that any 18:1 fatty acid 
amide found after incubation with elaidic acid is elaidamide.  
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Figure HH: GC-MS of N18TG2 Cell Extract after Incubation with EA for 48h, Showing 
Elaidamide-TMS  
GC-MS of N18TG2 cell extract after incubation with EA for 48h. Panel A shows the whole GC 
and zoom in of the peak of interest. Panel B shows the MS of the indicated GC peak 
(elaidamide-TMS). Panel C shows the library database MS for elaidamide-TMS. Panel D 
shows the difference between panels B and C. The cells were extracted as described in the 
methods section in Chapter 3. The cells had been incubated with 2.5mM EA in 0.25mM BSA 
for 48 hours in this case before extraction.  
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Figure II: GC-MS of N18TG2 Media Extract after Incubation with EA for 48h, Showing 
Elaidonitrile 
GC-MS of N18TG2 media extract after incubation with EA for 48h. Panel A shows the whole 
GC and zoom in of the peak of interest. Panel B shows the MS of the indicated GC peak 
(elaidonitrile). Panel C shows the library database MS for elaidonitrile. Panel D shows the 
difference between panels B and C. The cells were extracted as described in the methods 
section in Chapter 3. The cells had been incubated with 2.5mM EA in 0.25mM BSA for 48 
hours in this case before extraction.  
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Figure JJ: GC-MS of SCP Cell Extract after Incubation with EA for 24h, Showing Elaidamide-
TMS 
GC-MS of SCP cell extract after incubation with EA for 24h. Panel A shows the whole GC and 
zoom in of the peak of interest. Panel B shows the MS of the indicated GC peak (elaidamide-
TMS). Panel C shows the library database MS for elaidamide-TMS. Panel D shows the 
difference between panels B and C. The cells were extracted as described in the methods section 
in Chapter 3. The cells had been incubated with 2.5mM EA in 0.25mM BSA for 48 hours in this 
case before extraction.  
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Figure KK: GC-MS of SCP Media Extract after Incubation with EA for 24h, Showing Elaidonitrile 
GC-MS of SCP media extract after incubation with EA for 24h. Panel A shows the whole GC 
and zoom in of the peak of interest. Panel B shows the MS of the indicated GC peak 
(elaidonitrile). Panel C shows the library database MS for elaidonitrile. Panel D shows the 
difference between panels B and C. The cells were extracted as described in the methods section 
in Chapter 3. The cells had been incubated with 2.5mM EA in 0.25mM BSA for 24 hours in this 
case before extraction.  
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GC-MS of Tidecanoic Acid-Incubated Cells Over Time 
  
 
 
Figure LL: GC-MS of N18TG2 Cell Extract after Incubation with TDA for 48h, Showing 
Tridecanamide-TMS 
GC-MS of N18TG2 cell extract after incubation with TDA for 48h. Panel A shows the whole 
GC and zoom in of the peak of interest. Panel B shows the MS of the indicated GC peak 
(tridecanamide-TMS). Panel C shows the library database MS for tridecanamide-TMS. Panel 
D shows the difference between panels B and C. The cells were extracted as described in the 
methods section in Chapter 3. The cells had been incubated with 2.5mM TDA in 0.25mM 
BSA for 48 hours in this case before extraction.  
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Figure MM: GC-MS of N18TG2 Media Extract after Incubation with TDA for 48h, Showing 
Tridecanamide-TMS  
GC-MS of N18TG2 media extract after incubation with TDA for 48h. Panel A shows the whole GC 
and zoom in of the peak of interest. Panel B shows the MS of the indicated GC peak 
(tridecanamide-TMS). Panel C shows the library database MS for tridecanamide-TMS. Panel D 
shows the difference between panels B and C. The cells were extracted as described in the 
methods section in Chapter 3. The cells had been incubated with 2.5mM TDA in 0.25mM BSA for 
48 hours in this case before extraction.  
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Figure NN: GC-MS of SCP Cell Extract after Incubation with TDA for 12h, Showing 
Tridecanamide-TMS  
GC-MS of SCP cell extract after incubation with TDA for 12h. Panel A shows the whole GC 
and zoom in of the peak of interest. Panel B shows the MS of the indicated GC peak 
(tridecanamide-TMS). Panel C shows the library database MS for tridecanamide-TMS. Panel 
D shows the difference between panels B and C. The cells were extracted as described in the 
methods section in Chapter 3. The cells had been incubated with 2.5mM TDA in 0.25mM 
BSA for 12 hours in this case before extraction.  
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Figure OO: GC-MS of SCP Media Extract after Incubation with TDA for 24h, Showing 
Tridecanamide-TMS 
GC-MS of SCP media extract after incubation with TDA for 24h. Panel A shows the whole 
GC and zoom in of the peak of interest. Panel B shows the MS of the indicated GC peak 
(tridecanamide-TMS). Panel C shows the library database MS for tridecanamide-TMS. Panel 
D shows the difference between panels B and C. The cells were extracted as described in the 
methods section in Chapter 3. The cells had been incubated with 2.5mM TDA in 0.25mM 
BSA for 24 hours in this case before extraction. 
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GC-MS of Tidecanoylethanolamine-Incubated Cells Over 
Time 
 
  
 
 
Figure PP: GC-MS of N18TG2 Cell Extract after Incubation with TDEA for 48h, Showing 
Tridecanamide-TMS 
GC-MS of N18TG2 cell extract after incubation with TDEA for 48h. Panel A shows the whole 
GC and zoom in of the peak of interest. Panel B shows the MS of the indicated GC peak 
(tridecanamide-TMS). Panel C shows the library database MS for tridecanamide-TMS. Panel 
D shows the difference between panels B and C. The cells were extracted as described in the 
methods section in Chapter 3. The cells had been incubated with 2.5mM TDEA in 0.25mM 
BSA for 48 hours in this case before extraction.  
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Figure QQ: GC-MS of N18TG2 Media Extract after Incubation with TDEA for 12h, Showing 
Tridecanamide-TMS 
GC-MS of N18TG2 media extract after incubation with TDEA for 12h. Panel A shows the 
whole GC and zoom in of the peak of interest. Panel B shows the MS of the indicated GC peak 
(tridecanamide-TMS). Panel C shows the library database MS for tridecanamide-TMS. Panel 
D shows the difference between panels B and C. The cells were extracted as described in the 
methods section in Chapter 3. The cells had been incubated with 2.5mM TDEA in 0.25mM 
BSA for 12 hours in this case before extraction.  
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Figure RR: GC-MS of SCP Cell Extract after Incubation with TDEA for 24h, Showing 
Tridecanamide-TMS  
GC-MS of SCP cell extract after incubation with TDEA for 24h. Panel A shows the whole 
GC and zoom in of the peak of interest. Panel B shows the MS of the indicated GC peak 
(tridecanamide-TMS). Panel C shows the library database MS for tridecanamide-TMS. Panel 
D shows the difference between panels B and C. The cells were extracted as described in the 
methods section in Chapter 3. The cells had been incubated with 2.5mM TDEA in 0.25mM 
BSA for 24 hours in this case before extraction.  
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 (1) Sanchez-Avila, N.; Mata-Granados, J. M.; Ruiz-Jimenez, J.; Luque de 
Castro, M. D. J Chromatogr A 2009, 1216, 6864. 
 
 
Figure SS: GC-MS of SCP Media Extract after Incubation with TDEA for 48h, Showing 
Tridecanamide-TMS 
GC-MS of SCP media extract after incubation with TDEA for 48h. Panel A shows the whole 
GC and zoom in of the peak of interest. Panel B shows the MS of the indicated GC peak 
(tridecanamide-TMS). Panel C shows the library database MS for tridecanamide-TMS. Panel 
D shows the difference between panels B and C. The cells were extracted as described in the 
methods section in Chapter 3. The cells had been incubated with 2.5mM TDEA in 0.25mM 
BSA for 48 hours in this case before extraction.  
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Appendix D: Primer Sequences 
 
 The primers used in Chapter 4 for RT-PCR expression studies are shown in Table 
A. Not all sequences were known for sheep and so those primers are based on multiple 
sequence alignments of those from closely related species. The FAAH isoforms probed 
were all FAAH-1, as that is the only isoform expressed in mice and sheep.
1
 
 
Table A: Primer List, Predicted Fragment Size, and Successful PCR Experiments 
Primer target sequence 
Expected 
fragment 
size (bp) Target DNA 
ACGNAT: sense GTGGACAAGTGGCCTGATTT    
ACGNAT: antisense CAGTTTTGGGGATCTTTGGA 119 human kidney, liver 
acyl-CoA synthetase 4: sense CACCATTGCCATTTTCTGTG    
acyl-CoA synthetase 4: antisense GCCTTCAGTTTGCTTTCCAG 268 N18TG2, SCP 
acyl CoA synthetase 3: sense TGTGCGACAGCTTTGTTTTC    
h acyl CoA synthetase 3: 
antisense CTGGGGTGTGGCTTATCAGT 
292 human brain, 
kidney, liver 
acyl CoA synthetase 5 and 6: 
sense TTCGAAGAAGCCCTGAAAGA 
   
h acyl CoA synthetase 5 and 6: 
antisense AGAAATCAGCCACCACGTTC 
205 human brain, 
kidney 
BAAT: sense TGGCCTTGGCTTACCATAAC    
BAAT: antisense CGTGGCTGTGACTTGCTTTA 197 human liver 
FAAH: sense CATGTCACTCTCCTGCTCCA    
FAAH: antisense AGCCAGGGCTACACAGAGAA 230 N18TG2 
FAAH: sense AAGCAACATACCCCATGCTC    
FAAH: antisense 
GTTTTGCGGTACACCTCGAT 
276 human brain, 
kidney 
FAAH: sense GCAGCGCTTCCGGCT    
FAAH: antisense 
TAGAGCAGGCCCTGCC 
228 human brain, 
kidney, liver 
PAM1: sense CACTGGATATTCGCATGC    
PAM1: antisense ACTAGATGTGCCGCCGAT (nested)   
PAM2: sense GACACTGTCCACCATATG    
PAM2: antisense CCTAAATGGTGAGTATG 431 N18TG2, SCP 
PAM: sense TTGCTCTTTGCAGTGAATGG    
PAM: antisense 
CACACGGTGTTGGTATGAGC 
194 human brain, 
kidney, liver 
Cytochrome c: sense GTCAGGCCCCTGGATACTCT   
Cytochrome c: antisense 
TCTGCCCTTTCTTCCTTCTTC 
157 Human brain, 
kidney,  liver 
Cytochrome c: sense CCAAATCTCCACGGTCTGTT   
Cytochrome c: antisense GTCTGCCCTTTCTCCCTTCT 192 N18TG2 
Cytochrome c: sense 2 CCAAACCTCCATGGTCT   
Cytochrome c: antisense 2 CTTCTTCTTAATGCC 177 SCP 
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ADH3: sense TGATGGCACCACCAGATTTA   
ADH3: antisense 
ACAGCCCATGATGACTGACA 
262 Human brain, 
kidney, liver 
ADH3: sense AGTTGGGGTTGTGGAGAGTG   
ADH3: antisense AAAATCCACAGCCGATCAAG 320 N18TG2 
ADH3: sense 2 GCTGCTGTTAAAACTG   
ADH3: antisense 2 CTGGTCCCATAGTTCAT 323 SCP 
ALDH 3A2: sense GGGAGGGAAAAGTCCATGTT   
ALDH 3A2: antisense 
GTTGGGGCTATGTAGCGTGT 
324 Human brain, 
kidney, liver 
CYP4F12: sense GGAGCTCAGTGCCCTTGTAG   
CYP4F12: antisense 
GCCTCCAAACATGAAGGTGT 
310 Human brain, 
kidney, liver 
CYP4F17: sense ACCAGCCCTTCCTGTACCTT   
CYP4F17: antisense GCCTCCAAACATGAAGGTGT 278 N18TG2 
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